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(q) RT-PCR  quantitative Real Time- Polymerase Chain Reaction 
ADC    Arginine Decarboxylase 
APC   Antigen Presenting Cell 
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BMM   Bone Marrow Derived Macrophages 
cAMP   cyclic Adenosine monophosphate 
CAT   Cationic Amino-acid Transporter 
CD   Cluster of Differentiation 
d.p.i   days post infection 
DFMO  α-difluoromethylornithine 
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Folr2   Folate Receptor-2 
GM-CSF  Granulocyte and Monocyte Colony Stimulating Factor 
IFNγ   Interferon gamma 
Ig   Immunoglobulin 
IL   Interleukin 
iNOS   inducible Nitric Oxide Synthase 
L-NMMA  NG-monomethyl-L-arginine 
LPS   Lipopolysaccharide 
Mgl2   Macrophage galactose N-acetyl-galactosamine specific lectin 2 
MHC   Major Histocompatibility Complex 
Mmr   Macrophage mannose receptor  
mPGES-1  microsomal Prostaglandin E2 synthase-1 
MSC   Myeloid Suppressor Cell 
NK   Natural Killer 
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ODC   Ornithine Decarboxylase 
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SUMMARY 
 
 
 In Chagas disease, caused by Trypanosoma cruzi, macrophages and 
cardiomyocytes are the main targets of infection. On the other hand, macrophages can 
be activated in different ways by Th1 or Th2 cytokines leading to classic or alternative 
activation, which results in different functional outcomes. Those different ways are 
often differentiated by the expression of enzymes involved in L-arginine metabolism. 
Thus, we studied the expression of such enzymes in heart tissue during in vivo infection 
of BALB/c and C57BL/6 mice. We found that expression of inducible nitric oxide 
synthase (iNOS), arginase I and II as well as ornithine decarboxylase, were much higher 
in BALB/c compared to C57BL/6 mice and related to parasite burden in heart tissue. 
Th1 and Th2 cytokines were expressed in heart tissue in both infected mouse strains, 
but the Th1/Th2 balance was predominantly Th1 in C57BL/6 mice and Th2 in BALB/c 
mice at the peak of parasite infection. By using mice strains genetically deficient in 
various cytokines or their receptors, we found that IL-13, probably in cooperation with 
IL-4, IL-10 and prostaglandin E2, induces arginase I expression. Inducible nitric oxide 
synthase and arginase II were expressed by cardiomyocytes. Interestingly, heart 
infiltrated CD68+ macrophages were the major cell type expressing arginase I. When 
purified, CD11b+ heart infiltrating cells expressing both arginase I and iNOS did not 
present a clear M1/M2 polarization but showed a myeloid suppressor cell phenotype. In 
addition, these CD11b+ cells modulated T cell proliferation in vitro. Thus, arginase I 
expression may influence parasite cell survival, and might be also regulating the 
inflammatory T cell response in heart during infection.  
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INTRODUCTION 
 
 
I. Chagas Disease.  
 
I.1. General aspects and Life cycle. 
 
 American trypanosomiasis, or Chagas disease, is a multisystemic disorder that, 
according to the latest report from the WHO, affects approximately 18 million people, 
with 120 million at risk. This is an endemic disease in Latin America where it is spread 
through 18 countries from the southern cone of the continent (Fig. 1), up to Mexico 
(WHO, 2002). 
 Transmission of the disease to humans mainly occurs by three different ways:  
By the insect vector, by blood transfer of infected blood and by vertical transmission. 
 
                          
 
 
                        
 
  
 Trypanosoma cruzi, a flagellated protozoa of the Kinetoplastidae family, was 
first identified by Carlos Chagas in 1909 as the causal agent of the disease which was 
named after him. This parasite has a complex life cycle (Fig. 2) involving several stages 
in both vertebrates and insect vectors. T. cruzi has three main different morphologies: 
epimastigote, which replicates in the blood-sucking triatomine insect vector; 
trypomastigote, which infects the vertebrate host´s cells, and amastigote, which 
replicates intracellularly inside the host´s cells (Burleigh and Andrews, 1998; Tanowitz 
et al., 1992). Transmission of T. cruzi to humans occurs when feces released by the 
triatomine bug, while it sucks blood from the vertebrate, containing infective metacyclic 
trypomastigotes, break through the skin into the bloodstream. There, the flagellated 
forms of the parasite infect a wide variety of host cells (mainly macrophages and 
Figure 1. Distribution of Chagas disease.  In purple, is shown Chagas disease distribution from the southern cone of the 
American continent up to Mexico. From (Morel and Lazdins, 2003) 
                                                                         12 
cardiomyocytes). Once inside the cells, trypomastigote forms transform into 
amastigotes, which multiply intracellularly. After this, amastigotes break out the cell 
and give place again to trypomastigotes, which are released into the bloodstream where 
they spread and infect new cells again. Then, parasites can be sucked from the 
bloodstream by a triatomine bug while taking a blood meal. Once in the gut of the bug, 
trypomastigotes transform to epimastigotes, and multiply through the digestive track 
until they reach the intestines where are transformed into metacyclic trypomastigotes 
and released with the feces when the bug takes blood from a vertebrate host. 
 
 
 
 
 
 
Individuals residing in rural areas of Latin America are at highest risk of 
infection, because the bugs live in these dwellings and feed constantly on the 
inhabitants during the night. The WHO has conducted several programs for the 
elimination of the insect vector, and for comprehensive health education with marked 
success in the southern cone where the incidence has fallen by over 70% since 1985. 
Also blood screening to prevent transmission through transfusion needs to be performed 
Figure 2. Life cycle of Trypanosoma cruzi. Triatomine bug bites the vertebrate host and releases with the feces metacyclic parasites 
that enter the host, infect cells, multiply as amastigotes and break out the cell to the bloodstream. When triatome bug bites an 
infected host, tripomastigotes in the blood are sucked up by the bug and turn into epimastigotes in the insect’s gut where they 
multiply. In the intestine epimastigotes differentiate back to metacyclic trypomastigotes that are released with the feces when the bug 
feeds on the host. 
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to prevent and control the disease. Two drugs (benznidazol and nifurtimox) are 
available for the treatment of the acute phase of the disease but, besides having a high 
percentage of side effects, are not useful for the chronic phase. Moreover, to date, an 
effective immunotherapy or vaccine is still lacking. 
 
I.2. Clinical findings. 
 
 Two phases, acute and chronic, can be differentiated in Chagas disease 
(Kirchhoff, 1993; Prata, 2001; Tanowitz et al., 1992). In the acute phase, few days after 
infection, a local inflammatory lesion appears at the site of infection where the 
metacyclic trypomastigotes infect and undergo their first rounds of multiplication. Then, 
parasite dissemination through the body occurs, and circulating blood trypomastigotes 
can be easily observed (parasitemia); a small number of patients develop symptoms of 
cardiac affection, reflecting an underlying severe myocarditis. This might lead to heart 
failure, which is responsible for the few deaths in the acute Chagas disease. 
Meningoencephalitis also may occur, especially in some immunosuppressed patients 
(Hoff et al., 1978). However, the acute phase mainly remains undiagnosed without 
severe clinical symptoms. In contrast, the common manifestations and most severe 
pathology of the disease appear many years (10 to 30) after infection with T. cruzi in 
approximately 30% of the infected people, in what has been named chronic phase of the 
disease. During this phase, circulating parasites cannot be detected in blood, but 
progressive damage occurs involving esophagus, colon and heart. In the chronic phase, 
the heart is the most commonly affected organ; cardiomyopathy frequently develops, 
being congestive heart failure the most common cause of death in these patients.  
 
I.3. Experimental model for Chagas disease: the mouse. 
 
The mouse, because of its small size and easy maintenance, has been the 
preferred animal for a great number of experiments. Mice are susceptible to T. cruzi 
infection and develop acute and chronic phase somewhat similar to the pathology 
described in humans. 
However, both mouse and parasite strains, as well as inoculation procedure, 
determine susceptibility and pathogenesis of Chagas disease in the mouse model, but, 
despite the differences found among them, mice show an acute phase when blood-form 
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parasites can be detected in blood by microscopic techniques spanning from 7 to 30 
days. After this period, chronic phase begins to develop; no parasites can be detected in 
blood, and chagasic cardiomyopathy can be observed in histopathological studies of 
hearts from infected mice. 
 
II. Immune response in Chagas disease. 
 
 T. cruzi infection triggers a complex immune response. As an intracellular 
pathogen, involves an intricate, and not yet well understood, crosstalk of many cellular 
and humoral mechanisms from the innate and adaptive immunity. 
 
II.1. Innate immunity 
  
 As part of the first barrier that the parasite encounters after entering the host, 
molecules and effector cells from the innate immunity play a very important role in 
immune response against T. cruzi. 
After breaking the skin barrier, the parasite enters the blood and tissues, and 
triggers the early response of complement and acute phase proteins (C-reactive protein, 
serum amyloid P component). These molecules, bind to T. cruzi and mediate its 
receptor-mediated endocytosis. Also, macrophages and dendritic cells express in their 
surface mannose receptor, which recognizes carbohydrates with molecular patterns not 
found in host cells.  
T. cruzi is also able to actively enter in a variety of cell types, especially 
macrophages, triggering a diversity of molecular interactions that mobilize the innate 
immune response of the host (Fig. 3). Macrophages secrete IL-12 that activates natural 
killer (NK) cells to produce interferonγ (IFNγ) (Aliberti et al., 1996), this cytokine acts 
reciprocally in macrophages which release tumor necrosis factor (TNF) to act 
synergistically with IL-12 and IFNγ to induce the production of nitric oxide (NO) by 
these cells (Abrahamsohn and Coffman, 1996; Munoz-Fernandez et al., 1992). 
However, there are several evidences supporting the fact that inflammatory response is 
self-regulated and macrophage activation and NO production is reduced by the so-called 
anti-inflammatory cytokines. It has been found that IL-10 is required to prevent an 
excessive pro-inflammatory response during T. cruzi infection (Gazzinelli et al., 1992; 
Hunter et al., 1997; Reed et al., 1994), and something similar occurs with tumor growth 
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factor (TGF)β (Silva et al., 1991) although this cytokine might have other functions 
besides immune regulation (Hall and Pereira, 2000; Ming et al., 1995). It has been 
proposed that IL-4 is also downregulating IFNγ and inflammation when cooperating 
with IL-10 (Abrahamsohn et al., 2000), but some other reports showed that this 
cytokine has similar effects to those of IFNγ as trypanocidal activity (Golden and 
Tarleton, 1991; Wirth et al., 1989). Although the role of IL-13 is not clear yet, it has 
been documented that this cytokine might also be involved in the regulation of IFNγ 
release (Antunez and Cardoni, 2001).  
 
 
 
Macrophages exposed to IFNγ become very effective as antigen presenting cells 
(APCs) and interact and present T. cruzi peptides to T lymphocytes. Also, TNF is 
capable of inducing mature dendritic cells and their migration from the skin and mucosa 
to the lymphoid organs to start and activate the expansion of lymphocytes specific for 
Figure 3. Scheme of innate response to Trypanosoma cruzi. 
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microbial antigens (Fearon and Locksley, 1996). But not only professional APCs are 
able to present parasite peptides, the ability of T. cruzi to invade a high number of 
mammalian cell types involves them into the inflammatory and immune responses. 
Cardiomyocytes have been shown to respond to the infection releasing NO, cytokines 
and chemokines (Fichera et al., 2004; Machado et al., 2000). 
 
II.2. Adaptive immunity 
 
Immune response against T. cruzi also involves activation of the humoral and 
cellular components of the adaptive response (Fig. 4). Acute experimental T. cruzi 
infection in the murine model triggers an intense and polyclonal activation of B 
lymphocytes, which implies an overproduction of immunoglobulins (Ig). The response 
against parasite antigens in this phase represents only a very small fraction of the total 
Ig produced (Minoprio et al., 1989). This polyclonal response is widely dependent on 
CD4+ helper T cells (Minoprio et al., 1989).  
The importance of the two main subpopulations of T lymphocytes, CD4+ and 
CD8+ cells, in controlling infection has been widely established. T. cruzi is able to infect 
almost any type of cell in the host tissues (Lenzi et al., 1996); after escaping the 
parasitophore vacuole in the cytoplasm (Nogueira and Cohn, 1976), parasite antigens 
will be processed and presented in the context of MHC class I molecules which will be 
recognized by effector T CD8+ cells. On the other side, dead parasites, soluble parasite 
antigens, or parasites that did not escape the parasitophore vacuole (McCabe et al., 
1984), will be presented only by professional APCs through MHC class II to the CD4+ 
T cells, which will cooperate with B cells to induce antibodies. Moreover, despite the 
fact that B cell deficient mice succumb to infection (Kumar and Tarleton, 1998), the 
protective immune response seems to mostly depend on CD8+ cells that produce IFNγ. 
Cytotoxic CD8+ T cells can control infection through perforin/granzyme mediated 
killing of infected cells and/or FAS-mediated apoptosis (Kumar and Tarleton, 1998). 
However, there are reports indicating that CD8+ T cells cannot completely control 
infection because they become unresponsive (Martin and Tarleton, 2004).  
Cytokines play a key role in regulating both the induction and the type of 
immune response, but no clear polarization into Th1 versus Th2 was seen when 
studying mice susceptible or resistant to T. cruzi challenge (Powell et al., 1998; Zhang 
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and Tarleton, 1996a, 1996b). Thus, the role of Th1/Th2 cytokines during infection is not 
yet clearly established.  
 
 
 
 
 
Also, a variety of chemokines, have been suggested to play a key role in the 
influx of the immune cells to target tissues during infection, reviewed in (Silva et al., 
1991; Teixeira et al., 2002). CCR5 and its ligands play a central role on T cell migration 
to the heart (Machado et al., 2005) and parasite proliferation (Hardison et al., 2006a), 
CXCL9 and CXCL10 do not affect leukocyte migration but when blocked with 
neutralizing antibodies resulted in a decrease in parasite load in the heart (Hardison et 
al., 2006b). Also chemokines as CXCL12 and CCL4 have been implicated in thymocyte 
migration and development (Mendes-da-Cruz et al., 2006). Overall, there is a complex 
network in which specific chemokines play different roles in the pathophysiology of the 
disease. 
 
Figure 4. Scheme of adaptive response to Trypanosoma cruzi 
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II.3. Autoimmunity and immunomodulation. 
  
Among the possible mechanisms responsible for the pathogenesis of chronic 
Chagas disease, autoimmunity is the one that has received more experimental support 
but also elicited more controversy (Girones et al., 2005; Girones and Fresno, 2003; 
Kierszenbaum, 1986, 1999; Levin, 1996; Soares et al., 2001; Tarleton, 2001, 2003). On 
the other hand, there are studies suggesting that parasite persistence in host tissue is 
the key in the pathogenesis of the chronic form of the disease since anti-parasite 
treatment decrease disease severity (Tarleton, 2001). 
Several mechanisms might explain how an infectious pathogen can break 
immunological self-tolerance. Among them, molecular mimicry, bystander activation, 
and polyclonal lymphocyte activation have been widely documented in Chagas disease  
(Girones et al., 2005; Kierszenbaum, 2003) . However, none of these three mechanisms 
is exclusive and any combination of them or the three could be taking place. 
An important issue, usually not taken into account, is the role of regulatory T 
cells (Tregs), which have been described to suppress autoimmune responses. In addition 
to the classical Tregs that leave the thymus, there are others, Tr1 and Th3, which 
acquire regulatory capacity on the periphery (Battaglia et al., 2002). Thus, a definition 
of the role of Tregs during T. cruzi infection, may contribute to shed some light to the 
mechanisms that control the pathogenesis observed in chronic Chagas disease. 
 
III. Regulation of immune responses by L-arginine metabolism 
 
L-arginine can be metabolized inside the cells by two main enzymes (Fig. 5), 
arginase and nitric oxide synthase (NOS) to give urea and L-ornithine, and L-citrulline 
and NO, respectively.  
L-arginine in cells can also be metabolized through a less known pathway by 
Arginine Decarboxylase (ADC) that produces Agmatine, which can regulate both NO 
production and polyamine synthesis (Satriano, 2004). 
The cationic amino-acid transporters CAT-1, CAT-2 and CAT-3 are a family 
of transmembrane proteins that transfer L-arginine (among other cationic amino-acids) 
from the extracellular, to the intracellular compartment to compensate the degradation 
produced by the arginase and inducible NOS (iNOS) enzymes. Expression of CAT-3 is 
restricted to the brain (Verrey et al., 2004) but CAT-1 and CAT-2 are present in 
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macrophages and in some cases have been shown to play an important role in regulating 
macrophage activation in response to parasites (Wanasen et al., 2007; Yeramian et al., 
2006). 
 
III.1. Arginase 
  
 To date, two arginase isoforms have been described in mammals. These 
isoforms are encoded by different genes and have different subcellular location 
(Jenkinson et al., 1996). 
 Arginase I, also known as hepatic arginase, is located in the cytoplasm, and is 
highly expressed in liver, but also, in a restricted way, in other cell types, as 
macrophages. This isoform is mainly induced by Th2 cytokines (IL-4, IL-13) (Corraliza 
et al., 1995; Munder et al., 1998), and also IL-10, TGFβ, granulocyte and macrophage 
colony stimulation factor (GM-CSF) and prostaglandin E2 (PGE2) (Boutard et al., 1995; 
Corraliza et al., 1995; Jost et al., 2003). 
Arginase II is located in the mitochondria; it is expressed in a wide variety of 
tissues and cell types, mainly in kidney (Levillain et al., 2005), but also prostate, small 
intestine (Gotoh et al., 1997), and cardiomyocytes (Aoki et al., 2004). This isozyme is 
mainly induced by LPS and dibutyryl cAMP (Gotoh et al., 1996). 
Both arginase isoforms catalyze the same reaction, and no clear distinct function 
has been described for each of them although this is still debated (Cederbaum et al., 
2004). 
 Arginase is involved in the Urea cycle catalyzing the conversion of L-arginine 
into L-ornithine and urea. Further on, L-ornithine can be metabolized by Ornithine 
aminotransferase to increase L-proline, which is required for collagen synthesis. On the 
other hand Ornithine Decarboxylase (ODC), is the key enzyme of the polyamine 
pathway; it enhances the production of polyamines, needed for proliferation of all 
eucaryotic cells. ODC is a highly regulated eukaryotic enzyme, with one of the lowest 
half lives known in mammals, mainly due to the binding of the antizyme (AZ) that 
directs ODC degradation by the 26 S proteasome (Pegg, 2006). 
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III.2 iNOS 
  
 Together with the other NOS isoforms (nNOS in neuronal tissue, and eNOS in 
endothelial cells), iNOS catalyzes the oxidation of L-arginine to L-citrulline and NO, 
with the intermediate formation of Nω-hydroxy-L-Arginine (NOHA). 
 iNOS isoform is found in a diversity of cell types in the immune system (Wu 
and Morris, 1998) and also in cardiomyocytes (Tsujino et al., 1994). The most common 
inducer for iNOS is IFNγ combined with LPS, but also other Th1 cytokines as IL-12, 
IL-1, and TNF. 
 iNOS generates both NO and superoxide ion (O2- ) which leads to peroxynitrite 
(ONOO-) formation (Xia and Zweier, 1997). However, very low L-arginine 
concentrations result in low NO formation and high generation of superoxide, that is 
very unstable and is converted to hydrogen peroxide (H2O2) and oxygen (Kusmartsev et 
al., 2004).   
NO, reactive nitrogen-oxide species (RNOS) as ONOO- and reactive oxygen 
species (ROS) as O2- and H2O2, produced by NOS are known as very efficient 
mechanisms to fight against pathogens, but they also have high autotoxicity and, when 
excessive, can result in pathology. 
  
III.3 Arginase and iNOS balance.  
 
There is an important cross-regulation between iNOS and arginase products. 
NOHA, an intermediate form in the NO synthesis, has been shown to inhibit arginase 
(Daghigh et al., 1994) and it has been reported that polyamines can affect iNOS 
expression (Mossner et al., 2001; Sonoki et al., 1997); also arginase has been implicated 
in downregulating iNOS by depleting L-arginine, since decreased availability of this 
amino acid blocks iNOS protein synthesis and stability (El-Gayar et al., 2003; Lee et al., 
2003). It is noteworthy that iNOS and arginase enzymes share L-arginine as a substrate 
and, although the affinity constant of iNOS for L-arginine is 1000-fold higher that of 
arginase, the Vmax of arginase is more than 1000-fold faster than that of iNOS which 
results in a similar utilization of L-arginine by both enzymes (Wu and Morris, 1998).  
Due to the substrate sharing, these enzymes have been involved in the regulation 
of the Th1/Th2 balance during immune processes, and have been used as markers for 
macrophage activation (Mills et al., 2000).  
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III.4 L-arginine metabolism in parasitic diseases. 
 
Several infections by intracellular bacteria can have their outcome modified by 
the modulation of the routes mentioned above; this is the case of Helicobacter pylori 
(Gobert et al., 2002; Gobert et al., 2001), Chlamydia sp. (Huang et al., 2002).  
The arginase-iNOS balance also modifies several protozoan infections; 
Macrophage arginase during Trypanosoma brucei infection has been shown to deplete 
concentrations of L-arginine, and by doing so, avoid NO dependent killing of the 
parasite (Gobert et al., 2000); also in Trypanosoma congolense infection, arginase and 
alternative activation of macrophages have been described to play a crucial role in the 
development of a chronic infection (Noel et al., 2002). During Leishmania sp. in vitro 
(Iniesta et al., 2001; Iniesta et al., 2002) and L. major in vivo infection (Iniesta et al., 
Figure 5. Scheme of different pathways for L-arginine metabolism 
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2005; Kropf et al., 2005) it is clear that arginase inhibitors reduce pathology by 
lowering parasite replication inside macrophages. 
T. cruzi triggers cytokines and chemokines in infected cardiomyocytes 
(Machado et al., 2000) and macrophages (Bergeron and Olivier, 2006) that induce 
potent nitric-oxide dependent trypanocidal activity (Gazzinelli et al., 1992; Metz et al., 
1993; Munoz-Fernandez et al., 1992; Pakianathan and Kuhn, 1994; Plasman et al., 
1994), but results in infected mice are still unclear (Cummings and Tarleton, 2004; 
Girones et al., 2006; Holscher et al., 1998). Moreover, when excessive, NO can also 
have a cytotoxic effect in the host and lead to immune suppression of T cells (Goni et 
al., 2002).   
On the other side, peripheral blood monocytes showed decreased nitric oxide 
production during acute Chagas disease in rats, due to the increase of arginase activity 
(Fabrino et al., 2004). In addition, macrophages infected in vitro (and macrophages 
from infected mice), by interaction with apoptotic cells through the vitronectin receptor, 
increase TGF-β and PGE2 release which enhance ODC activity in macrophages, 
promoting parasite proliferation (Freire-de-Lima et al., 2000; Lopes et al., 2000). Also, 
cruzipain, a T. cruzi antigen, up-regulates arginase activity in macrophages and 
promotes intracellular growth of the parasite (Giordanengo et al., 2002; Stempin et al., 
2002; Stempin et al., 2004). In addition, it promotes arginase II induction in 
cardiomyocytes acting as a survival factor because it is able to rescue them from 
apoptosis (Aoki et al., 2004). 
It’s worth mentioning that in other trypanosomatids, as Trypanosoma brucei and 
Leishmania donovani, replication is controlled by the polyamine synthesis inhibitor α-
difluoromethylornithine (DFMO) through inactivation of parasite ODC. However, T. 
cruzi lacks arginase (Camargo et al., 1978) and ODC, and DFMO treatment has been 
shown to be ineffective. The parasite relies on external source of polyamines for 
growth, probably from the host. Alternatively, T. cruzi could synthesize polyamines 
from L-arginine via agmatine (Persson, 2007). Also, during T. cruzi infection in mouse 
macrophages and rat myoblasts, pharmacological inhibition of ODC reduced invasion 
and intracellular proliferation and these effects were reverted by the exogenous addition 
of agmatine or putrescine (Kierszenbaum et al., 1987). 
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IV. L-Arginine metabolism in mononuclear phagocytic cells. Regulation of 
immune responses 
 
IV.1 Monocyte-Macrophage activation: M1 & M2 macrophages. 
  
 Cells from the monocyte-macrophage lineage are known to be a very 
heterogeneous cell type depending on the differentiation and activation state, site and 
tissue distribution.   
 Traditionally, activation of macrophages was considered when they exerted 
cytotoxic response against intracellular pathogens and also when soluble mediators of 
the immune response were released. Nowadays, the capacity of macrophages to 
eliminate intracellular pathogens is known to be mediated by NO (Hibbs, 2002), RNOS 
and ROS (Kusmartsev et al., 2004; Xia and Zweier, 1997), and to be induced by Th1 
cytokines (as IFNγ and TNF) alone or with microbial products. These macrophages also 
show capacity to produce high levels of IL-12 (in humans IL-23 too), IL-1, TNF, IL-6, 
and low levels of IL-10 (reviewed in (Mosser, 2003)). Such an activation state leads the 
scientific community to call these cells classically activated macrophages or M1 
macrophages (in analogy to Th1). 
 In opposition to the type of activation mentioned above, mononuclear 
phagocytes, which do not show cytotoxic properties and release high levels of IL-10 
instead of IL-12, are named alternatively activated macrophages.  This terminology 
was conceived for those macrophages that are activated by IL-4/IL-13 cytokines and 
expressed high arginase I levels, which some authors named M2 in analogy to the M1 
type, but also to those ones that show “deactivation” state in presence of IL-10. Other 
authors also distinguish amongst the alternative activation what they call type II 
activated macrophages (Anderson and Mosser, 2002), mononuclear phagocytes exposed 
to immune complexes and LPS; these cells secrete high IL-10 and low IL-12 levels, and 
trigger Th2-like responses in T lymphocytes (Anderson et al., 2002).  
 Due to the fact that some consensus is needed to establish a common 
nomenclature for these mononuclear phagocytic cells, Mantovani et al. (Mantovani et 
al., 2004) propose the following (Fig. 6): 
 M1 corresponds to the classic activation described above. The generic term M2 
is used to define macrophage activation other than M1 based in common functional 
properties (low IL-12 secretion and involvement in Th2 responses, immunoregulation 
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and tissue remodeling). Also the three well defined forms of M2 will be referred to as 
M2a, induced by IL-4/IL-13; M2b, induced by immune complexes and agonists of Toll-
like receptors (TLRs) or IL-1R; and M2c induced by IL-10 and glucocorticoid 
hormones. 
 
 
 
 
 
 
Ghassabeh et al. (Ghassabeh et al., 2006) identified a common gene signature for 
generic M2 cells elicited in different pathological conditions analyzing several genes 
grouped in specific functional clusters (anti-inflammation, wound healing, angiogenesis, 
cell-cycle regulation, and others). 
 
IV.2. Myeloid suppressor cells     
 
 Back in the 1970s and early 1980s researchers described what they called natural 
suppressor cells; non-lymphocyte cells, capable of suppressing lymphocyte response to 
immunogens and mitogens in an MHC-independent manner (Strober, 1984). Nowadays, 
it is known that these cells are a subset of myelomonocytic cells called Myeloid 
Suppressor Cells (MSCs), which accumulate during acute and chronic immune 
responses to pathogens, immune stress (after exposure with super antigen and 
Figure 6. Different subpopulations for polarized monocyte/macrophage cells according to their 
functional properties. 
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subsequent extensive T-cell activation), tumor growth and development, and others. 
MSCs are equipped with extremely efficient mechanisms for destroying invading 
pathogens, and are also highly efficient in suppressing activated T-cells. Reviewed in 
(Bronte and Zanovello, 2005). 
These cells are commonly identified in mice by the expression of CD11b and 
Gr-1 surface markers; in addition to these markers MSCs might also express a wide 
variety of myeloid-cell differentiation markers as Ly-6C, CD31 (Bronte et al., 2000); 
also, there are important differences in the phenotype depending on the anatomical site 
where they are located or in the pathological conditions. A rigid cell-surface-marker 
classification for MSCs is not available at present moment; it would need to separate the 
continuum that is myeloid differentiation into discrete steps. (Bronte and Zanovello, 
2005) 
 
T-cell suppression and L-arginine metabolism 
 
 Arginase and iNOS, either separately or in combination, are used by MSCs to 
inhibit T-cell responses. (Fig.7) 
Arginase: Loss of CD3ζ chain is the only mechanism, to date, that has been 
described and proven to have an effect on T-cell function. When MSCs were isolated 
from tumors, arginase I activity caused depletion of L-arginine amino acid in the extra 
cellular microenvironment. This inhibited re-expression of the ζ-chain of CD3 after its 
TCR signaling-induced internalization by antigen stimulated T-cells, thereby impairing 
the function of these cells (Baniyash, 2004; Rodriguez et al., 2004). 
iNOS: NO, does not impair the early events triggered by the TCR, but acts 
instead at the level of IL-2 receptor signaling, blocking the phosphorylation and 
activation of signaling molecules (Bingisser et al., 1998; Mazzoni et al., 2002). 
Arginase and iNOS: When both enzymes are induced, depletion of extra 
cellular L-arginine occurs. This leads the iNOS enzyme to switch his NO producing 
effect to mostly superoxide ion production, and subsequently ROS and RNOS. These 
species can have multiple inhibitory effects on T cells. Combined activity of arginase 
and iNOS enzymes was shown to be important in MSCs from mice with tumors, but 
also in chronic infections with helminthes (Bronte et al., 2003; Brys et al., 2005). This 
indicates that co-expression of iNOS and arginase might be a molecular marker for 
MSCs (Bronte and Zanovello, 2005). It is important to consider in this issue, that some 
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authors describe a mechanism of down regulation for iNOS mRNA when levels of L-
arginine are low; what will result in a decreased iNOS protein stability (El-Gayar et al., 
2003). 
 
  
 
 
 
MSCs in parasitic infections 
 
 There are several evidences of the role of MSCs in parasitic diseases. Human T 
cells stimulated in the presence of a crude extract of H.pylori had reduced proliferation 
and this correlated with decreased CD3ζ expression (Zabaleta et al., 2004). Also, results 
from experimental infections with Schistosoma spp. (Terrazas et al., 2001), Candida 
albicans (Mencacci et al., 2002), and T. cruzi (Abrahamsohn and Coffman, 1995; Goni 
et al., 2002) illustrate the existence of an IFNγ induced, NO dependent mechanism of 
immunosuppression, mediated by MSCs that colonize the spleen during the acute phase 
of the disease.  
 
  
   
 
 
  
Figure 7. Arginase and iNOS inhibit T cell response in different ways. a) MSCs expressing iNOS, 
b) MSCs expressing arginase, c) MSCs expressing both arginase and iNOS enzymes  
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OBJECTIVES 
 
 
 
 
 
 
 
1. Analyze the expression of arginase and other L-arginine metabolic enzymes in 
hearts of susceptible and resistant strains of mice infected with T. cruzi.  
 
2. Determine the agents responsible for arginase I induction in hearts of T. cruzi 
infected mice. 
 
3. Study the role of arginase I in hearts of T.cruzi infected mice. 
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MATERIALS AND METHODS 
 
I. Parasites and mice 
 
Work was performed with two different T. cruzi strains: Y and Tulahuen 
(obtained from Dr. John David, Department of medicine, Harvard Medical School, 
Boston, Massachusetts, U.S.A.). Blood trypomastigotes of the two T. cruzi strains were 
routinely maintained by infecting mice and purifying them from their blood. Young 
adult (6 to 8-week-old) BALB/c and C57BL/6 mice were purchased from Harlan, 
Interfauna Iberica. iNOS deficient mice (NOS2tm1 Lau), TNF deficient mice (B6;129S6-
Tnftm1Gkl), hybrid B6129SF2/J (wild-type, control mice for TNF deficient mice), IL-10 
deficient mice (129-Il10tm1Cgn/J), 129Sv, control mice (129S1/SvImJ, wild type for IL-
10, and IFNγ-R deficient mice), all purchased from The Jackson Laboratory, Bar 
Harbor, ME. IL-4 deficient 129Sv mice (Kopf et al., 1993) and IFNγ receptor-deficient 
129Sv mice (Huang et al., 1993) were a gift from Manfred Kopf, (Max-Planck-Intitute 
for Immunobiology, Freiburg), and IL-4R deficient BALB/c mice (Mohrs et al., 1999) 
were a gift from Dr. Beschin (VUB, Brussels) All mice were maintained under 
pathogen-free conditions in the animal facility at the Centro de Biología Molecular, 
Universidad Autónoma de Madrid (Spain). 
 Groups of 3-5 mice were infected with 2x103 typomastigotes per mice (unless 
stated different) by intraperitoneal injection. At different days post infection (d.p.i.), 
mice were euthanized in a CO2 chamber and blood and various tissues were collected. 
Samples were processed for RNA and protein expression, enzymatic activity, 
immunohistochemistry, confocal immunofluorescence analyses and magnetic cell 
sorting. 
For in vitro infections, Y strain parasites were co-cultured with Vero cells (CCL-
81, ATCC) and trypomastigotes were purified from supernatant. 
 
II. Real time PCR for parasite detection  
 
Hearts were minced into small pieces and DNA was isolated with High Pure 
PCR Template preparation Kit, Roche. For T. cruzi detection, we followed the PCR 
assay described by (Piron et al., 2007). Different amounts of DNA purified from Y 
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strain epimastigotes were used to generate the standard curve. Experimental heart tissue 
PCR reactions contained 100 ng genomic DNA. 
 
III. mRNA analysis by quantitative RT-PCR 
 
 Total RNA was extracted from heart tissue mechanical disruption in TRIzol 
reagent (Invitrogen) as indicated by the manufacturer. For quantitative real time (q) RT-
PCR analysis, reverse transcription of total RNA was performed using the components 
of the High Capacity cDNA Archive Kit (Applied Biosystems) and amplification of 
different genes (arginase I, arginase II, iNOS, CAT-1, CAT-2, ODC, IFN-γ, TNF-α, IL-
4, IL-10, IL-13, TGF-β, mPGES-1 and Ribosomal 18S) was performed using TaqMan 
MGB probes and the TaqMan Universal PCR Master Mix (Applied Biosystems) on an 
ABI PRISM 7900 HT instrument (Applied Biosystems). All samples were ran in 
triplicate. Quantification of gene expression by real-time PCR was calculated by the 
comparative threshold cycle (CT) method following the manufacturer’s instructions. All 
quantifications were normalized to the ribosomal 18S control to account for the 
variability in the initial concentration of RNA and in the conversion efficiency of the 
reverse transcription reaction. RQ= 2-ΔΔCT 
 (q)RT-PCR of CD11b+ purified cells was performed as follows: Total RNA was 
extracted with TRIzol reagent following manufacturer instructions. Reverse 
transcription was carried out by using 1-2 µg total RNA, 0,5 µg oligo(dT) and 200 units 
Superscript II reverse transcriptase (all from Invitrogen) in a total volume of 20 µl 
following the manufacturer recommendations. (q) PCR was performed using a total 
volume of 25 µl, containing Bio-Rad iQ SYBR Green Supermix, 4µl of (1/25) diluted 
cDNA reaction as template and 0,2 µM of each primer, in a Bio-rad iCycler (Bio-Rad 
Hercules, CA). Each PCR cycle consisted of 1 min denaturation at 94ºC, 45 sec 
annealing at 55ºC and 1 min extension at 72ºC. PCR primer sequences were described 
in (Ghassabeh et al., 2006). For (q) PCR analysis, the values were normalized against 
the house-keeping gene S12.  
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IV. Protein expression analyses 
 
Protein extracts from heart tissue were prepared by mechanical disruption of the 
tissue in phosphate buffered saline (PBS) containing 0,1% Triton X-100 (Merck), 100 
µg/ml of pepstatin, 100 µg/ml of aprotinin and 100 µg/ml of antipain (all protease 
inhibitors from Sigma-Aldrich) utilizing a PT 1300 D homogenizer (Polytron). Protein 
concentration was determined by the bicinchonic acid method (Pierce). Western blot 
analyses were performed as follows: 15 µg of tissue extract were fractionated on SDS-
10% polyacrylamide gel and transferred to a Nitrocellulose membrane Hybond-ECL 
(Amersham Biosciences).  Primary antibodies were diluted as follows: Goat anti-mouse 
Arginase I (V-20, Santa Cruz Biotechnology) 1:1000, Purified anti-mouse iNOS (BD 
Transduction) 1:500, mouse monoclonal anti-mouse ODC (clone ODC-29, Sigma) 
1:500, goat anti-mouse Actin (I-19, Santa Cruz Biotechnology) 1:1000. Then, the 
membranes were incubated with horseradish peroxidase (HPO) conjugated rabbit anti-
goat (Sigma) 1:10000, or goat anti-mouse (Pierce) 1:1000 as secondary antibodies. 
Detection was carried out with Supersignal detection reagent (Pierce) and photographic 
film exposure. For cell-cultured cells, samples were treated as mentioned above except 
for the mechanical disruption. 
 
V. Measurement of arginase activity 
 
Arginase activity was measured in cell and tissue lysates as previously described 
(Corraliza et al., 1994). Briefly, the mixture of 50 µl of 10 mM MnCl2 and 50 mM Tris-
HCl, pH 7.5, plus 50 µl of heart tissue or cell extract were heated at 55°C for 10 min to 
activate the enzyme. Arginine hydrolysis was carried out by the addition of 50 µl of 0.5 
M arginine, pH 9.7, to a 50 µl of the lysate. Incubation was performed at 37°C for 60 
min, and the reaction was stopped by the addition of 400 µl of an acid mixture 
containing H2SO4 (96%), H3PO4 (85%), and H2O (1:3:7, vol/vol/vol). After adding 25 
µl of 9% µ-isonitrosopropiophenone (ISPF; Sigma) and heating at 100°C for 45 min, 
the formed urea was colorimetrically quantified at 540 nm. A calibration curve was 
prepared with increasing amounts of urea solution. 
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VI. Immunohistochemistry  
 
Hearts from mice infected with 104 T. cruzi trypomastigotes (T strain) were 
removed at different times, fixed in 10% neutral buffered paraformaldehyde and 
embedded in paraffin. Four micrometer-thick sections were mounted on gelatine coated 
glass slides. Samples were deparaffinized and rehydrated. Endogenous peroxidase 
activity was blocked by incubation with 3% hydrogen peroxide in PBS for 10 min. 
Slices were permeabilized with 1% Triton X-100 in PBS for 10 min. The sections were 
then washed and non-specific binding prevented by incubating with 2% bovine serum 
albumine (BSA) for 30 min. Samples were incubated with anti-arginase II, or anti-iNOS 
antibodies, or isotypic antibodies (all purchased from Santa Cruz Biotechnology, Inc.) 
diluted 1:100. After washing with PBS, the samples were incubated with anti-rabbit 
HPO (Sigma Aldrich) diluted 1:250. The antigen-antibody complexes were visualized 
by the diaminobenzidine/hydrogen peroxide technique and counterstained with 
hematoxylin. The slides were observed under a light microscope (Carl Zeiss, Germany) 
and photographed (Axiocam HRc).  
 
VII. Confocal immunofluorescence  
 
Organs were removed from mice at different times post infection, fixed in a 4% 
paraformaldehyde solution and after 1h placed in a 30% sucrose solution over night. 
Hearts were then embedded in Tissue-Tek (Sakura) and frozen. 10-15 µm sections were 
cut using a cryostat. Slides were fixed in acetone for 10 min at room temperature, and 
incubated 10 min with NH4Cl to avoid autofluorescence; then were washed and 
incubated over night at 4ºC with the following primary antibodies diluted to 10 µg/ml in 
100mM Tris-HCl pH 8.0, 300mM NaCl, 0,1% Triton X-100, 5% normal mouse serum: 
goat anti-mouse arginase I (V-20, Santa Cruz Biotechnology), rat anti-mouse CD68 
(clone FA-11, Serotec), rat anti-mouse CD11c (clone N418, e-Bioscience), rat anti-
mouse F4/80 (clone BM8, e-Bioscience). Rat IgG2a (clone R35-95, BD Pharmingen), 
and ChromPure Goat IgG (Jackson Immunoresearch) were used as isotypic controls. 
Secondary antibodies were used at the following dilutions: F(ab´)2 Goat anti-rat IgG 
fluorescein isothiocyanate (FITC; Serotec)1:100, Cy 5-conjugated Donkey anti-goat 
IgG (Jackson Immunoresearch) 1:50. Stained slides were subjected to confocal 
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microscopy using a LSM510 META confocal laser coupled to an Axiovert 200 (Zeiss) 
microscope. 
 
VIII. Neonatal mouse primary cardiomyocyte culture 
 
Neonatal cardiomyocytes were obtained following a procedure previously 
described (Wang et al., 1999). For this, one to three-day-old neonatal mice were 
euthanized, hearts were removed aseptically and kept in Hanks’ balanced salt solution 
without Ca2+ and Mg2+ (HBSS) (in g/l: 0.4 KCl, 0.06 KH2PO4, 8.0 NaCl, and 0.05 
Na2HPO4, pH 7.4) on ice. The tissues were washed three times and minced into small 
fragments. The remaining pieces were dissociated with trypsin (0.25% wt/vol in HBSS) 
at 37°C. The cells released after the first digestion were discarded, whereas the cells 
from subsequent digestions were added to an equal volume of cold HBSS with Ca2+ and 
Mg2+ plus 10% fetal bovine serum (FBS; Biowittaker) (in g/l: HBSS plus 0.14 CaCl2, 
0.047 MgCl2, 0.049 MgSO4, 0.35 NaHCO3, and 1.0 D-glucose, pH 7.4) until all cardiac 
cells were isolated. The resulting cell suspension was centrifuged at 200 g for 8 min, 
and the cells were resuspended in complete Dulbecco’s modified Eagle’s medium 
(DMEM; Sigma), containing 2mM L-glutamine, 100U/ml penicillin, 100µg/ml 
streptomycin, 1000u/ml and 0,1 mM non-essential amino acids and supplemented with 
10% FBS (vol/vol). To exclude non-muscle cells, the isolated cells were first plated in 
tissue culture dishes at 37°C for 2 h under a water-saturated atmosphere of 5% CO2. 
The suspended cells were then collected and plated at a density of 1.0 x 105 cells/cm2 in 
10% FBS-complete DMEM. More than 90% of cells were cardiomyocytes as detected 
by immunostaining with antibody to mAchR M2 (Aoki et al., 2004). Cells were 
cultured for 24 h and then the culture medium was changed to 10% FBS-complete 
DMEM containing different stimuli: IL-4 (20 ng/ml), IFNγ+LPS (25U/ml and 1µg/ml, 
respectively) and 5:1 (parasite: cell ratio) trypomastigotes. Recombinant mouse IL-4 
and IFNγ were purchased from BioSource, International. LPS (Escherichia coli 
serotype O26:B6) was purchased from Sigma-Aldrich. Cells where then incubated for 
48h at 37ºC in 7% CO2 atmosphere. 
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IX. PBMCs, spleen and lymph node cell suspension 
 
Spleen and inguinal lymph nodes were aseptically removed from BALB/c mice 
and disaggregated in 40µm nylon cell strainers (Falcon). Blood was obtained by cardiac 
punction and treated with heparin. Single suspension cells were depleted of erythrocytes 
by hypotonic lysis, washed with cold PBS and processed for SDS-PAGE as described 
above. 
 
 
X. Peritoneal cells culture and infection 
 
Peritoneal cavity from BALB/c mice was washed with 7 ml of a solution of 
sucrose (116g/l) in PBS. Cells were then plated in complete RPMI (containing 2mM L-
glutamine, 100U/ml penicillin, 100µg/ml streptomycin, 1000u/ml and 0,1 mM non-
essential amino acids) with 5% FBS at 37ºC with 7% CO2. After 4h, non-adherent cells 
were removed by washing three times with warm PBS, and fresh complete RPMI was 
restored. Thus, trypomastigotes purified from supernatant of a Vero cell co-culture were 
added at the ratio of 5 parasites per adherent (mostly macrophages) cell. After 16h non-
internalized parasites were removed and macrophages were cultured in complete RPMI 
medium at 37ºC with 7% CO2 for 24 or 48h. For immunoblotting cells were washed 
twice with warm PBS and then detached from the plates using a cell scrapper (Falcon). 
Cells were processed for SDS-PAGE as previously described.  
 
XI. Isolation of CD11b+ cells from heart 
 
 10 to 12 BALB/c mice were infected i.p. with 2000 trypomastigotes Y strain. At 
21 days post infection, mice were euthanized in a CO2 chamber and hearts were 
aseptically removed, perfused with 10 ml PBS-heparin solution, and kept in cold HBSS. 
Then, hearts were pooled in a cell culture dish, washed thoroughly with HBSS and 
minced into small pieces with a sterile surgery blade. Heart pieces were then digested 
with an enzyme mixture as follows: 1x Trypsin (Gibco), 0,025 mg/ml collagenase type 
I, 0,2 u/ml DNAse I, 200 u/ml collagenase type IV in HBSS free (both collagenase and 
DNAse were purchased from Sigma). Digestion was repeated 5 consecutive times, 
during 15 minutes at 37oC. Cells released from digestions were added to an equal 
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volume of cold HBSS with Ca2+ and Mg2+ plus 10% fetal bovine serum (FBS) (in g/l: 
HBSS plus 0.14 CaCl2, 0.047 MgCl2, 0.049 MgSO4, 0.35 NaHCO3, and 1.0 D-glucose, 
pH 7.4) and the resulting cell suspension was centrifuged at 200 g for 8 min. 
Supernatant was discarded and cell pellet was resuspended in complete DMEM 
supplemented with 10% FBS (vol/vol).  
CD11b+ cells were selected by magnetic cell sorting using CD11b Microbeads, 
MACS LS columns and MACS Separators (Miltenyi Biotec GmbH) following 
manufacturer instructions. Cell purity of CD11b+ sorted population was analysed by 
FACS and results showed 95-99% of cell purity. 
For Ly6G+ cell sorting, anti Ly-6G MicroBead kit (Milteny Biotec GMbH) was used 
with the above mentioned separating system. Ly6G- fraction of the cell suspension was 
afterwards processed for CD11b+ cell sorting. 
 
XII. Proliferative assays 
 
CD11b+ cells were obtained as mentioned above, counted, resuspended in 
complete RPMI and 100.000 cells per well were plated in flat 96 well plates. Spleen cell 
suspension was obtained as mentioned above and T cells were purified using Pan T cell 
kit (Milteny Biotec GMbH) and MACS LS columns and separators (Mylteny Biotec 
GmbH) following manufacturer instructions. Sorted T cells were counted and 100.000 
cells per well were plated with or without CD11b+ purified cells isolated from heart 
from infected mice, blood from infected mice, and blood from non-infected mice. Cells 
were stimulated with 10µg/ml purified anti-CD3 (clone 145-2C11, BD Pharmingen) and 
2 µg/ml purified anti-CD28 (clone 37.51, BD Pharmingen) or with 5µg/ml concanavalin 
A and, where indicated, 24 µM Nω-Hydroxy-nor-L-arginine (nor-NOHA; Calbiochem), 
and/or 2mM NG-monomethyl-L-arginine (L-NMMA; Calbiochem) were added. After 
incubation at 37°C and 5% CO2 for 24 h, 1µCi [3H] thymidine (Amersham, Little 
Chalfont, UK) was added to each well. The cultures were harvested 18 h later and then 
processed for measurement of incorporated radioactivity in a liquid scintillation counter. 
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XIII. Flow cytometry 
 
Surface cell staining was performed in 96 well plates. Single cell suspensions 
were fixated with paraformaldehyde 1% in PBS for 1h at 4oC. Cells were washed with 
cold PBS throughout the whole staining procedure. Fc receptors on cells were blocked 
by incubating with purified anti-CD16/CD32 (Mouse BD Fc Block) (clone 2.4G2, BD 
Pharmingen) for 15 min. 4ºC. Cells were then stained with the following antibodies: 
Alexa 647-conjugated anti-CD11b (clone M1/70, BD Pharmingen), FITC-conjugated 
anti-F4/80 (clone BM8, e-Bioscience), Phycoerithrin (PE)-conjugated anti-CD11c 
(clone HL3, BD Pharmingen), FITC-conjugated anti-CD19 (clone MB19-1, e-
Bioscience), PE-conjugated anti-MHC class II (I-A/I-E) (clone M5/114.15.2, e-
Bioscience), FITC-conjugated anti-Ly-6C (clone AL-21, BD Pharmingen), PE-
conjugated anti-Gr-1 (clone RB6-8C5, e-Bioscience). The antibodies Rat IgM (clone 
R4-22, BD Pharmingen), Rat IgG2a (clone R35-95, BD Pharmingen), Rat IgG2b (clone 
A95-1, BD Pharmingen) were used as isotype controls. 
Cells were acquired on a FACSCalibur Cytometer (Becton Dickinson). Data were 
analysed with the FlowJo software. 
 
XIV. Statistical analysis 
 
For in vivo experiments, data are shown as means ± s.e. or s.d. from triplicate 
determination of a representative experiment out of the 3 to 5 performed. Results shown 
from in vitro experiments are representative of at least two experiments performed by 
duplicate. Significance was evaluated by Student’s t-test with Origin-Pro software; all 
differences mentioned were significant compared to controls (p < 0,05 or p < 0,01). 
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RESULTS 
 
I. Arginase I induction in hearts of mice infected with T.cruzi. 
  
 It is still unknown whether T.cruzi infection results in a different degree of 
pathology, but it is becoming accepted that it is likely to be related to host genetics. 
Infection of different strains of mice having distinct susceptibility or resistance to the 
parasite, in relation with their different genetic background, has been established as an 
experimental model for Chagas disease. Thus, we used BALB/c and C57BL/6 mice as 
susceptible and resistant experimental model of Chagas disease, respectively. Previous 
studies have already addressed the differences in parasitemia that exist between 
BALB/c and C57BL/6 mice, but to date no studies have reported parasite load in the 
heart, the most affected organ in Chagas disease. In order to investigate this, we infected 
BALB/c and C57BL/6 mice intraperitoneally with the Y strain of T. cruzi and parasites 
in heart were quantified at different d.p.i. by quantitative real time PCR. Figure 1 shows 
that maximum parasite load was detected in C57BL/6 heart at 14 d.p.i. and decreased 
thereafter. In contrast, maximal parasite burden in heart of BALB/c mice was somewhat 
delayed between 14-21 d.p.i. and remained elevated up to 42 d.p.i. Interestingly, burden 
was significantly higher in susceptible BALB/c than in resistant C57BL/6 mice from 14 
to 42 d.p.i., and more than 3 orders of magnitude higher in BALB/c than C57BL/6 mice 
at 21 d.p.i. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. T. cruzi DNA quantification in 
heart tissue of BALB/c and C57BL/6 
infected mice. DNA from heart tissue was 
isolated at indicated d.p.i. and qPCR was 
performed as previously described. T. 
cruzi DNA is expressed as pg of parasite 
DNA per mg of DNA from heart tissue 
sample. Results are represented as mean ± 
SD of triplicates of pooled DNA of 5 
different mice. All differences between 
BALB/c and C57BL/6 mice parasite load 
were statistically significant except at 7 
d.p.i. (p < 0.05). A representative 
experiment out of three performed is 
shown. 
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I.1 Expression of L-arginine metabolic enzymes and transporters in heart tissue of 
mice infected with T. cruzi. 
 
 Next, we addressed the levels of enzymes individual in L-arginine metabolism. 
Quantification of arginase I and arginase II mRNAs showed significantly higher 
expression in BALB/c than C57BL/6 mice at all d.p.i. analyzed (Fig 2a-b). In contrast, 
CAT-2 and iNOS mRNAs expression was higher in C57BL/6 than BALB/c mice at 14 
d.p.i (Fig. 2d-e). However, CAT-2 and iNOS mRNAs expression was much higher in 
BALB/c mice at 21 d.p.i. and in the case of iNOS expression higher levels remained at 
28 d.p.i. CAT-1 showed in BALB/c mice at 7 and 21 d.p.i, but no differences were 
observed at 14 and 28 d.p.i. (Fig. 2c). The induction of ODC mRNA expression was not 
significantly different from non-infected controls (Fig. 2f).  
Since arginase I mRNA showed major differences between C57BL/6 and 
BALB/c mice, further studies were performed to confirm that this was also occurring at 
the protein level. Arginase I protein induction in infected heart was much stronger in 
BALB/c than C57BL/6 mice and spanned from 14 to 42 d.p.i, in agreement with the 
mRNA data (Fig. 3a). Arginase I expression in C57BL/6 mice was observed only 
between 14 and 21 d.p.i. Moreover, arginase enzymatic activity nicely correlated with 
arginase I protein expression in heart extracts from both mice strains (Fig. 3b), being 
much higher again in BALB/c mice than in C57BL/6 mice peaking at 21 d.p.i. It is 
worth mentioning that, although arginase I protein was clearly detected by western blot 
technique in C57BL/6 mice, arginase activity levels, although higher than in non-
infected mice only showed significant differences at 14 d.p.i. in this strain of mice. 
iNOS protein expression was higher in infected BALB/c than infected C57BL/6 mice, 
and coincident with the peaks of arginase I expression in each strain. Although we did 
not observe significant changes in ODC mRNA expression, ODC protein levels were 
greater, in hearts from infected BALB/c (maximum expression at 21 d.p.i) and much 
lower in infected C57BL/6 mice (peaking at 14 d.p.i.) (Fig. 3a). This result indicates 
that ODC is regulated at the post-translational level in heart tissue of mice infected with 
T. cruzi. This is not surprising, since ODC is one of the most highly regulated enzymes 
in eukaryotic cells at posttranscriptional levels. 
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Figure 2. Quantification of  mRNA leves of enzymes and transporters involved in L-arginine metabolism in heart tissue 
during T. cruzi infection. RNA from heart tissue was isolated at different d.p.i. and qRT-PCR was performed. Results are 
expressed as the logarithm of RQ calculated from CT values as described in material and methods. mRNAs for: a) Arginase 
I; b) Arginase II; c) CAT-1; d) CAT-2; e) iNOS f) ODC. Empty bars indicate the values for BALB/c mice and filled bars the 
values for C57BL/6 mice. A representative experiment out of five is shown. Results are represented as mean ± SD of 3 
different mice. All differences observed in infected mice respect to non-infected mice were statistically significant except 
for: a) C57BL/6 at 7, 21, 28 and 48 d.p.i.; b) C57BL/6 at 7 and 48 d.p.i.; c) C57BL/6 at 7 d.p.i.; d) BALB/c at 7 and 42 d.p.i. 
and C57BL/6 at 7 d.p.i.; f) BALB/c and C57BL/6 at all d.p.i. Significant differences observed between BALB/c and 
C57BL/6 mice are indicated by an asterisk. (p < 0.05).  
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I.2 Arginase I expression in infected mice is restricted to heart tissue and 
 peritoneal cells. 
 
To determine whether arginase I induction upon T.cruzi infection was ubiquitous 
or restricted to heart tissue, we also studied the expression of arginase I and iNOS in 
peripheral blood mononuclear cells (PBMCs), spleen and lymph node from infected 
BALB/c mice at 21 d.p.i. In spleen and ganglia neither arginase I nor iNOS were 
induced. There was a slight induction of arginase I expression in PBMCs in comparison 
with the induction observed in heart tissue, but no iNOS was detected in PBMCs (Fig 
4a). 
 
Figure 3.  iNOS, ODC and arginase I 
protein expression and arginase activity 
in heart during T. cruzi infection. 
Protein extracts from heart tissue were 
isolated from 5 BALB/c and 5 C57BL/6 
mice at different d.p.i. and pooled for 
western blot analysis: a) Arginase I, 
iNOS, ODC expression and Ponceau 
staining of the same membrane; 
numbers indicate d.p.i. b) Arginase 
activity of the same tissue extracts, 
expressed as µg of urea produced per 
hour per mg of protein sample 
(µg/h/mg), was assessed by urea 
colorimetric determination. Empty bars 
indicate the values for BALB/c mice 
and filled bars the values for C57BL/6 
mice. All values for BALB/c mice were 
significantly higher compared to non-
infected mice except at 7 d.p.i. and in 
C57BL/6 were only significantly higher 
at 14 d.p.i. Asterisks indicate significant 
differences between BALB/c and 
C57BL/6 mice (p< 0.05). A 
representative experiment out of 5 is 
shown. 
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Arginase I and iNOS were also detected in peritoneal exudate cells (PECs) from 
infected mice. Arginase I protein in BALB/c increased as early as 7 d.p.i. showing the 
highest levels at 14-21 d.p.i. and decreasing thereafter. In C57BL/6 much lower levels 
were observed. Only a faint band in 14 d.p.i. lane was seen indicating that arginase I 
expression in PECs from infected BALB/c mice is much higher and longlasting than in 
PECs from infected C57BL/6 mice. iNOS protein showed similar expression levels in 
PECs from both strains of mice, but in PECs from BALB/c mice was detected only at 
14 and 21 d.p.i while in PECs from C57BL/6 mice iNOS expression was detected also 
at 28 d.p.i  (Fig. 4b). This expression pattern, although slightly different from the one 
found in heart tissue, nonetheless points out to a higher expression of arginase I in 
BALB/c infected mice compared with C57BL/6 mice in a time-dependent manner. In 
PECs, arginase I expression is already seen at 7 d.p.i. faster than in heart,  since mice 
are being infected intraperitoneally those are the first ones to encounter the parasite. 
Figure 4. iNOS and arginase I protein 
expression in different tissues. Protein 
extracts were isolated and analysed by 
western blot using anti-arginase I or anti-
iNOS antibodies and Ponceau staining. a) 
BALB/c heart tissue, peripheral blood 
mononuclear cells (PBMCs), spleen and 
lymph node were obtained from non-
infected (NI) and infected (I) mice at day 
21 post infection. Data are representative 
of at least two independent experiments. b) 
Peritoneal exudate cells  (PECs) from 5 
BALB/c or C57BL/6 mice of different 
d.p.i., as indicated, were collected and 
pooled as described in material and 
methods.  A representative experiment out 
of three is shown. 
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I.3. Arginase I modulation in hearts of iNOS deficient mice 
 
 In order to test the contribution of the iNOS enzyme to heart expression and 
modulation of arginase I, iNOS deficient mice (iNOS-/-) were infected with T. cruzi  and 
compared with the infected wild type strain C57BL/6.  
 
 
  
  
 Parasitemia in iNOS-/- mice did not significantly change respect to wild type 
mice (Fig. 5a); this fact agrees with some previous reports (Cummings and Tarleton, 
2004).  When parasite DNA was quantified in heart from infected iNOS deficient and 
C57BL/6 mice strains, parasite burden showed no significant differences between them 
(Fig. 5b). Despite the fact that neither parasite burden in blood or in heart tissue showed 
Figure 5. Parasite load in iNOS-/- 
infected mice. a) Parasitemia of 
infected wild type (C57BL/6) and 
iNOS-/- mice. Parasitemia was 
determined in blood from the tail 
as described in materials and 
methods. Results are presented as 
mean ± SE (n=6). A representative 
experiment out of three is shown. 
b) DNA from heart tissue was 
isolated at indicated d.p.i. and 
qPCR was performed as 
previously described. T. cruzi 
DNA is expressed as pg of 
parasite DNA per mg of DNA 
from heart tissue sample. Results 
are presented as mean ± SE (n=3).  
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any differences in iNOS deficient compared to wild type mice, heart arginase I 
expression (Fig. 6a) and arginase activity (Fig. 6b) were strongly increased in infected 
mice iNOS-/- compared to C57BL/6 mice. iNOS protein was induced heart homogenates 
from wild-type mice but, as expected, not in iNOS -/- mice (Fig. 6a). Thus, deletion of 
the iNOS gene triggered the increase in the induction of arginase I in heart tissue of 
mice infected with T. cruzi. 
 
 
 
 
 
II. Th2 cytokines induce arginase I in heart tissue of mice infected with T.cruzi. 
 
 Cytokines are known to play an important role in the induction and generation 
early phase and the setting of the immune response during T.cruzi infection, but in 
previous studies with resistant and susceptible mice, no clear Th1 or Th2 pattern was 
shown (Powell et al., 1998; Zhang and Tarleton, 1996a, 1996b). Moreover, arginase I 
can be induced by TGFβ, IL-10, PGE2, and Th2 cytokines (Boutard et al., 1995; 
Corraliza et al., 1995; Jost et al., 2003; Munder et al., 1998), while iNOS protein 
induction is mediated mostly by Th1 cytokines (MacMicking et al., 1997; Vila-del Sol 
et al., 2007). Thus, we next studied if Th1/Th2 cytokine levels in heart tissue were 
related with resistance and susceptibility to T.cruzi, and whether this related with 
arginase I expression. 
 
Figure 6. Arginase I and iNOS expression in heart tissue from iNOS-/- infected mice. a) Arginase I and iNOS expression in 
heart tissue extracts pooled from 3 wild-type and 3 iNOS -/- non-infected (NI) and infected (I) mice at 21 d.p.i. and Ponceau 
staining of the same membrane. b) Arginase activity of the same extracts expressed as µg of urea produced per hour per mg of 
protein sample. Results are presented as mean ± SE. Data are representative of at least two independent experiments. 
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II.1. Th1 and Th2 cytokines are induced in heart during T.cruzi infection. 
 
We evaluated the levels of several Th1 and Th2 cytokines in heart tissue from 
BALB/c and C57BL/6 mice infected with T. cruzi by quantitative mRNA RT-PCR. The 
results showed that IFNγ  and TNF presented maximum expression at 14 and 21 d.p.i. 
in C57BL/6 and BALB/c mice, respectively (Fig. 7a and b). These cytokines were 
significantly higher in C57BL/6 than BALB/c mice at 14 d.p.i. but this situation was 
switched between 21 d.p.i and later times, being higher in BALB/c than C57BL/6 mice. 
On the other hand, IL-4 and IL-13 showed maximum expression at 14 d.p.i. in both 
mouse strains, being higher in BALB/c than C57BL/6 mice through infection. 
Interestingly, IL-4 and, especially, IL-13 expression in BALB/c was maintained at 21 
d.p.i. (Fig. 7c and d). IL-10 expression in the heart was significantly increased by 
infection and followed kinetics similar to TNF (Fig. 7e). The induction of TGFβ  
mRNA expression observed was not statistically different from non-infected controls 
(Fig. 7f). Thus, no pure Th1 or Th2 patterns are linked to strain susceptibility or 
infection stage. However, the Th1/Th2 balance was higher for C57BL/6 (resistant) than 
for BALB/c mice (susceptible) and Th2 cytokines were higher in BALB/c than in 
C57BL/6 mice during infection. 
 
II.2. TNF and IFNγ  receptor deficient mice show a small increase of arginase I 
when infected with T.cruzi.  
 
 Despite the fact that Th2 cytokines have been reported to be responsible for 
arginase I induction in several in vivo and in vitro models, we also found high levels of 
Th1 cytokines in BALB/c mice expressing arginase I. In order to clarify the possible 
role of Th1 cytokines in arginase I induction, we infected mice deficient for TNF and 
mice deficient for the IFNγ receptor (IFNγR), two cytokines involved in Th1 response. 
It had previously been reported that mice deficient for TNF receptor (Castanos-Velez et 
al., 1998) and IFNγR-/- mice (Holscher et al., 1998) had increased susceptibility to 
T.cruzi infection and could not set up a proper immune response to eliminate the 
parasite and overcome the disease.  
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Figure 7. Expression of cytokines in heart tissue during T. cruzi infection. Total RNA from heart tissue was isolated at different 
d.p.i. from BALB/c and C57BL/6 mice and qRT-PCR was performed as described. Results are expressed as the logarithm of RQ 
calculated from CT values as described in materials and methods. mRNAs for: a) IFNγ; b) TNFα; c) IL-4; d) IL-13; e) IL-10 and f) 
TGFβ. Empty bars indicate the values for BALB/c mice and filled bars the values for C57BL/6 mice. A representative experiment 
out of three is shown. Results are represented as mean ± SD of 3 different mice. All differences observed in infected mice respect to 
non-infected mice were statistically significant except for: c) and d) C57BL/6 at 7 d.p.i.; f) BALB/c and C57BL/6 at all d.p.i.; 
Significant differences observed between BALB/c and C57BL/6 mice are indicated by an asterisk. (p < 0.05).  
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 TNF deficient mice infected with the Y strain of T.cruzi showed a significant 
increase in parasitemia compared to their wild-type littermates (B6129Sv) at 16 d.p.i. 
(Fig. 8a).  Longer times of infection could not be monitored since TNF deficient mice 
succumb to infection and most mice die at day 21 p.i. Arginase I expression in heart 
protein extracts from infected TNF deficient mice showed much reduced levels when 
compared with the infected wild-type mice at 18 d.p.i, the only time-point when this 
enzyme was detected (Fig. 8b). Surprisingly, no significant differences between these 
mice were observed when arginase activity was determined in the same protein lysates 
(Fig. 8c). iNOS protein was induced in wild-type mice at 18 d.p.i. but no protein was 
detected in TNF-/- mice (Fig. 8b),  probably due to the fact that TNF is needed for a 
proper  iNOS induction (Vila-del Sol et al., 2007).  
Figure 8. Parasitemia, arginase I and 
iNOS expression and arginase activity 
in heart tissue of TNF-/- mice during T. 
cruzi infection. a) Parasitemia was 
determined in blood from the tail as 
described in materials and methods. 
Results are presented as mean ± SE 
(n=4). Significant differences observed 
between TNF-/- and B6129Sv mice are 
indicated with an asterisk (p< 0.05). b) 
Arginase I and iNOS expression in 
heart tissue extracts pooled from 3 wild-
type and 3 TNF -/- mice at indicated d.p.i 
and Ponceau staining of the same 
membrane. c) Arginase activity of the 
same extracts expressed as µg of urea 
produced per hour per mg of protein 
sample; Results are presented as mean ± 
SE (n=3). A representative experiment 
out of two is shown.  
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 INFγR deficient mice also showed very high parasite numbers in blood when 
infected with a low inoculum of 500 parasites of the T.cruzi Y strain.  Parasites in blood 
13 d.p.i. were significantly much higher in IFNγR-/- mice when compared with their 
wild-type mice (129Sv) as seen in Fig. 9a. As in TNF deficient mice infection cannot be 
monitored longer than 16 d.p.i as mice die of infection. 
  
  When arginase I expression levels were determined in heart lysates from 
infected mice, arginase I was detectable in IFNγR-/- mice already at 14 d.p.i and 
remained high at 16 d.p.i.; while the wild-type mice showed very small arginase 
expression at 14 d.p.i and only at 16 d.p.i it reached comparable expression level to 
those of mice (Fig. 9b). 
Figure 9. Parasitemia, arginase I 
and iNOS expression, and 
arginase activity in heart tissue of 
IFNγR-/- mice during T. cruzi 
infection. a) Parasitemia was 
determined in blood from the tail 
as described in materials and 
methods. Results are presented as 
mean ± SE (n=3). Significant 
differences observed between 
INFγR-/- and 129Sv mice are 
indicated with an asterisk (p< 
0.05). b) Arginase I and iNOS 
expression in heart tissue extracts 
pooled from 3 wild-type and 3 
INFγR-/- mice at the indicated 
d.p.i, and Ponceau staining of the 
same membrane. c) Arginase 
activity of the same extracts 
expressed as µg of urea produced 
per hour per mg of protein sample; 
Results are presented as mean ± 
SE (n=3). A representative 
experiment out of two is shown.  
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 Despite protein expression, analysis of the arginase activity of these heart lysates did 
not reveal any significant difference when comparing IFNγR deficient mice and the 
wild-type at any time-point analyzed and very low levels were detected (Fig. 9c). Again, 
iNOS expression was detected in the wild-type mice while no band corresponding to 
iNOS protein was seen in the IFNγR -/- mice, probably because IFNγ also is (as TNF) a 
very important factor for iNOS induction (Munoz-Fernandez et al., 1992). 
 
II.3. IL-10 deficient mice show a high susceptibility to T.cruzi infection and  no 
arginase I or iNOS induction. 
 
 Although IL-10 is not considered a typical Th2 cytokine, it has been reported to 
be capable of inducing arginase in several biological models. This issue and the fact that 
mRNA IL-10 levels detected in hearts of infected BALB/c mice compared with 
C57BL/6 were remarkable, prompted us to study whether IL-10 had any role in arginase 
I induction in heart of mice when infected with T.cruzi. For this purpose, we infected 
IL-10 deficient mice and their wild-type strain (129Sv). When infected with Y strain 
trypomastigotes, IL-10 deficient mice showed extreme susceptibility to the infection, 
with most mice dying after 10 d.p.i.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. b. 
Figure 10.  Parasite load in IL-10-/- infected mice. a) Parasitemia of infected wild type 129Sv and IL-10-/- mice. a) Parasitemia 
was determined in blood from the tail as described in materials and methods. Results are presented as mean ± SE of values from 
two independent experiments (n=6). b) DNA from heart tissue was isolated at indicated d.p.i. and qPCR was performed as 
previously described. T. cruzi DNA is expressed as pg of parasite DNA per mg of DNA from heart tissue sample. Results are 
shown in a scatter dot graph where values represented are from two independent experiments and the line indicates the mean of 
these values. Significant differences observed between IL-10-/- and 129Sv mice are indicated with an asterisk (p< 0.05). 
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However, in these mice both parasite number in blood at 10 d.p.i., and parasite burden 
in heart tissue, were significantly lower than the infected wild-type mice (Fig. 10). 
mRNA levels of arginase I, arginase II  and iNOS in heart showed a small but 
significant increase in infected mice when compared to non infected. However, mRNA 
levels for Arginase I and II were significantly lower in infected IL-10-/- when compared 
to the wild-type (Fig. 11a and b). mRNA levels for iNOS in heart from infected IL-10 
deficient mice at 11 d.p.i. did not show significant differences when compared to the 
wild-type (Fig 11c). Arginase I and iNOS protein expression were not detected in heart 
lysates of these infected mice, neither in IL-10 deficient or wild-type (Data not shown). 
In agreement with this, arginase activity in the same heart lysates showed no significant 
increase of arginase activity after T.cruzi infection and also no significant differences 
between IL-10 deficient and wild-type mice (Fig. 11d).  
 
 
 
Figure 11. Arginase I, arginase II and iNOS expression in heart tissue of IL-10-/- during T. cruzi infection. Total RNA from heart 
tissue was isolated and qRT-PCR was performed as described for the following: a) Arginase I; b) Arginase II; c) iNOS. No 
arginase I or iNOS expression was detected in heart tissue extracts pooled from 3 wild-type and 3 IL-10-/- non-infected and 
infected mice at 11 d.p.i. d) Arginase activity of the same extracts expressed as µg of urea produced per hour per mg of protein 
sample (µg/h/mg). Results are presented as mean ± SE of values from two independent experiments (n=6). 
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 Thus, no conclusion can be drawn from these experiments, probably due to the 
early mortality of IL-10-/- mice upon infection, which does not allow the ongoing of the 
immune response to trigger neither arginase I or iNOS protein expression. However, 
mRNA levels for arginase I and II were lower in hearts of IL-10-/- mice indicating that, 
in the development of a proper immune response, IL-10 might be contributing to 
arginase induction in hearts of infected mice.  
 
II.4. IL-13, alone or in cooperation with IL-4, triggers arginase I induction during 
T.cruzi infection. 
 
 IL-4 and IL-13 were the only cytokines whose mRNA levels were significantly 
higher in BALB/c mice than in C57BL/6 at all time points analyzed upon infection. 
This, together with the fact that Th2 cytokines, and specially IL-4, have been reported to 
induce arginase in several in vitro and in vivo biological models made them the best 
candidates for arginase I induction in heart tissue during T.cruzi infection. To test this 
hypothesis, we infected IL-4 and IL-4R deficient mice.  
  
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
Figure 12. Parasite load in IL-4R-/- infected mice. a) Parasitemia of infected wild type BALB/c and IL-4R-/- mice. Parasitemia 
was determined in blood from the tail as described in materials and methods. Results are presented as mean ± SE (n=6). A 
representative experiment out of two is shown. b) DNA from heart tissue was isolated at indicated d.p.i. and qPCR was 
performed as previously described. T. cruzi DNA is expressed as pg of parasite DNA per mg of DNA from heart tissue sample. 
Results are presented as mean ± SE (n=3). Significant differences (p< 0.05) found between IL-4R-/- and BALB/c mice are 
indicated with an asterisk. 
 
 
a. b
. 
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 IL-4R deficient mice, which lack the common α chain of IL-4 and IL-13 
receptors, have impaired signalling for both of these cytokines. When infected with Y 
strain of T.cruzi, no significant differences comparing with the wild-type mice 
(BALB/c) were observed in the parasitemia through the infection (Fig. 12a). However, 
when parasite burden was quantified in heart tissue, wild-type mice showed 
significantly higher around (100 fold) parasite burden than IL-4R deficient mice at 14 
and 21 d.p.i. (Fig. 12b). As shown in figure 13a., arginase I expression in heart lysates  
was much higher in wild-type infected mice spanning from 7 to 28 d.p.i., than in IL-4R 
deficient, where a nice induction could only be detected at 14 and 21 d.p.i,, when it 
reached the highest level. Those arginase I expression levels correlated with arginase 
activity from the same heart homogenates (Fig. 13b). Arginase activity in hearts from 
IL-4R deficient mice showed significantly diminished activity at 14, 21 and 28 d.p.i 
when compared to the wild-type.  
 
 
 iNOS expression in heart homogenates from infected wild-type mice was higher 
compared to IL-4R deficient mice. However, expression of iNOS was restricted to 21 
d.p.i in wild-type mice while its induction lasted longer in IL-4R deficient mice (from 
14 to 21 d.p.i). 
    
Figure 13. iNOS, and arginase I protein expression 
and arginase activity during T. cruzi infection in 
heart tissue from IL-4R-/-  mice. Protein extracts from 
heart tissue were isolated from 3 IL-4R-/- and 3 
BALB/c mice at different d.p.i. and pooled for 
western blot analysis. a) Arginase I, iNOS expression, 
and Ponceau staining of the same membrane; b) 
Arginase activity of the same tissue extracts, 
expressed as µg of urea produced per hour per mg of 
protein sample. Results are represented as mean ± SE 
(n=3). Asterisks indicate significant differences 
between BALB/c and IL-4R-/- mice (p< 0.05). 
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In IL-4 deficient mice T.cruzi infection, no significant differences were observed in 
parasitemia compared to the wild-type (Fig. 14a). Arginase I expression was induced in 
the heart of IL-4-/- infected mice but its expression did not differ from the one observed 
in hearts of infected wild-type mice (Fig. 14b). However, arginase activity in the same 
heart homogenates from infected mice was significantly higher in IL-4 deficient when 
compared to the wild-type mice (Fig. 14c). iNOS protein in heart lysates from infected 
IL-4 deficient were higher than in 129Sv mice (Fig. 14b). 
  
 
 
 
Figure 14. Parasitemia, arginase I and 
iNOS expression, and arginase activity 
in heart tissue during T. cruzi infection 
of IL-4-/- mice. a) Parasitemia was 
determined in blood from the tail as 
described in materials and methods. 
Results are presented as mean ± SE 
(n=3). b) Arginase I and iNOS 
expression in heart tissue extracts 
pooled from 3 wild-type (129Sv)  and 3 
IL-4-/- non-infected (NI) and infected (I) 
mice at 21 d.p.i. Ponceau staining of the 
membrane is shown. c) Arginase 
activity of the same extracts expressed 
as µg of urea produced per hour per mg 
of protein sample; Results are presented 
as mean ± SE (n=3). Significant 
differences observed between IL-4-/- and 
129Sv mice are indicated with an 
asterisk (p< 0.05). A representative 
experiment out of two is shown.  
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 Those results of T. cruzi infection of IL-4 and IL-4R deficient mice indicate that 
IL-4 itself is not responsible for arginase I induction in hearts from T.cruzi infected 
mice, although we can not exclude that it can cooperate with IL-13 in this purpose. 
 
II.5. Microsomal Prostaglandin E2 synthase-1 (mPGES-1) is significantly 
induced in hearts of mice infected with T. cruzi. 
 
 The prostaglandin E2 (PGE2) has been shown to induce arginase I in bone 
marrow derived macrophages (BMM). Also, it has been reported that the uptake of 
apoptotic cells during T. cruzi infection causes release of PGE2 (Freire-de-Lima et al., 
2000). These facts lead us to analyze mRNA levels for the most common inducible 
isoform of prostaglandin I synthase: m-PGES-1 during T.cruzi infection in hearts of 
infected mice. Fig. 15 shows that mPGES-1 mRNA was significantly increased in heart 
of both BALB/c and C57BL/6 mice upon infection being significantly higher in 
BALB/c than C57BL/6 mice at 21 d.p.i. Thus, PGE2 might be contributing to arginase I 
induction in heart tissue during T.cruzi infection. However, in C57BL/6 mice in PGES-
1 levels remained elevated for longer periods after infections. 
 
  
 
 
 
 
 
Figure 15. mRNA quantification of microsomal prostaglandin E2 synthase- 1 (mPGES-1) in heart tissue during T. cruzi 
infection. RNA from heart tissue was isolated at different d.p.i. and qRT-PCR was performed. Results are expressed as the 
logarithm of RQ calculated from CT values as described in material and methods. Empty bars indicate the values for 
BALB/c mice and filled bars the values for C57BL/6 mice. Results are represented as mean ± SD of 3 different mice. All 
differences observed in infected mice respect to non-infected mice were statistically significant except for 7 d.p.i. 
Significant differences observed between BALB/c and C57BL/6 mice are indicated by an asterisk. (p< 0.05). A 
representative experiment out of three is shown. 
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III. Cardiomyocytes express arginase II and iNOS while arginase I is expressed by 
CD68+ cells infiltrating heart tissue of T. cruzi -infected mice. 
 
III.1. Arginase II and iNOS enzymes are expressed in cardiomyocytes in hearts of 
infected mice 
 
To determine the cellular source of arginase and iNOS protein detected in the 
hearts of infected mice, we performed immunohistochemical staining. Fig 16 shows 
staining of a high percentage of cardiac fibres for both arginase II and iNOS in BALB/c 
infected mice (Fig. 16c and 16d) compared to non-infected mice (Fig. 16a and 16b). 
Non-specific staining was detected when slides from hearts of infected mice were 
incubated with the isotypic antibody (Fig. 16 e).  
 
 
 
 
 
 
 
III.2. Arginase I does not colocalize with F4/80 or CD11c markers. 
 
When processed and analyzed by confocal microscopy, hearts from infected 
BALB/c mice at 21 d.p.i. showed an infiltrate composed by arginase I positive cells 
(Fig. 17f); no staining for this enzyme was observed in cardiomyocytes or endothelial 
Figure 16. Arginase II and iNOS expressing cells in heart tissue of BALB/C mice during acute T. cruzi infection. Hearts from non 
infected mice and infected mice at 14 d.p.i. were analyzed by immunohistochemistry as described. a) Non-infected tissue stained 
with anti arginase II antibody, and b) with anti iNOS antibody. c) Infected tissue stained with anti arginase II antibody, and d) 
with anti iNOS antibody. e) Isotypic antibody control staining. Data are representative of several sections analyzed in at least 3 
different mice. Magnification x1000. 
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cells. Arginase I-positive infiltrating cells showed a macrophage-like morphology (Fig 
17b, 18b and 19f). F4/80 and CD11c markers, as markers of macrophages and dendritic 
cells respectively, were tested in order to find out the arginase-1 expressing cell type; 
however, none of the antibodies stained tissue sections of hearts from T.cruzi infected 
mice (Fig 17a and 18a). As a control of the immunoreactivity of those antibodies, 
spleen sections from non-infected BALB/c mice were stained for these cell-markers 
(Fig 17e and 18e). 
  
  
 
 
 
 
 
III.3. CD68+ infiltrating cells are responsible for arginase I expression. 
 
 Despite the negative result with macrophage markers above, we found that 
CD68, a tissue-macrophage marker with a predominantly intracellular expression, co-
localized with arginase I (Fig. 19e to 19h) in tissue sections of hearts from T. cruzi 
infected mice. Heart tissue from non-infected mice showed a weak staining with anti-
CD68 and anti-arginase I antibodies of some infiltrated resident cells (Fig. 19a to 19d). 
No specific staining was observed in sections stained with isotypic antibodies (Fig. 19e 
and 19f).  
Figure 17. Arginase I and F4/80 expressing cells in BALB/c mice heart tissue during acute T. cruzi infection. Tissue 
sections obtained from hearts of BALB/c mice 21 d.p.i. and from spleen from non-infected mice were analysed by 
immunofluorescence confocal microscopy as described. Heart infected tissue stained with a) anti F4/80 antibody; b) with 
anti arginase I antibody; c) phase contrast; d) merge of a, b, and c. Spleen section stained with e) anti F4/80 antibody; f) 
anti-arginase I antibody; g) phase contrast; h) merge of e, f, and g. Magnification is x400. Data are representative of several 
sections analyzed in at least 3 different mice. 
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In order to clarify whether the higher arginase I expression seen in BALB/c mice 
compared to C57BL/6 mice was due to differences in the amount of macrophages 
infiltrating heart tissue, we evaluated the extension of CD68+ cell infiltration in BALB/c 
and C57BL/6 mice by quantification of CD68 mRNA. CD68+ cell infiltration was 
induced upon infection, being maximal at 14 d.p.i. in both mouse strains and 
interestingly, no statistically significant differences were observed between them (Fig. 
19k). This similarity in cell infiltration contrasted with the observed differences in 
arginase expression, suggesting that arginase I expression was higher in CD68+ cells 
from infected BALB/c than C57BL/6 mice. 
 
 
 
 
 
Figure 18. Arginase I and CD11c expressing cells in BALB/c mice heart tissue during acute T. cruzi infection. Tissue sections 
obtained from hearts of BALB/c mice 21 d.p.i. and from spleen from non-infected mice were analysed by immunofluorescence 
confocal microscopy as described. Heart infected tissue stained with a) anti CD11c antibody; b) with anti arginase I antibody; 
c) phase contrast; d) merge of a, b, and c. Spleen section stained with e) anti CD11c antibody; f) anti-arginase I antibody; g) 
phase contrast; h) merge of e, f, and g. Magnification is x400. Data are representative of several sections analyzed in at least 3 
different mice. 
 
                                                                         59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
III.4. Arginase I expression in primary cultures of cardiomyocytes and 
macrophages  
 
iNOS and arginase II induction, but no arginase I, had been reported during T. 
cruzi-infection of cardiomyocytes in vitro (Aoki et al., 2004; Machado et al., 2000). 
Thus, we infected cardiomyocytes in vitro and analyzed arginase I and iNOS 
expression. iNOS but no arginase I protein was induced by infection in cardiomyocytes 
Figure 19. Arginase I and CD68 expressing cells in BALB/c mice heart tissue during acute T. cruzi infection. Tissue 
sections obtained from hearts of BALB/c mice at 21 d.p.i. were analysed by immunofluorescence confocal microscopy as 
described. Non-infected tissue stained with a) anti CD68 antibody; b) with anti arginase I antibody; c) phase contrast; d) 
merge of a and b. Infected tissue section stained with e) anti CD68 antibody; f) anti-arginase I antibody; g) phase contrast; 
h) merge of e and f. Boxed regions are shown at two-fold magnification of original (x400) in insets. The scale bar is 20µm. 
Data are representative of several sections analyzed in at least 3 different mice. k) Total RNA from heart tissue was isolated 
at 21 d.p.i. and CD68 quantitative RT-PCR was performed as described. Empty bars indicate the values for BALB/c mice 
and filled bars the values for C57BL/6 mice. Results are represented as mean ± SD of 3 different mice. All values for 
BALB/c and C57BL/6 mice were significantly higher compared to non infected mice. A representative experiment out of 
three is shown. 
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(Fig. 20a). IL-4 triggered a strong arginase I induction in uninfected cardiomyocytes. 
This IL-4-dependent arginase I induction in non-infected cardiomyocytes was partially 
inhibited by T. cruzi infection. In contrast, the IFN-γ+LPS-dependent iNOS induction 
observed in non-infected cardiomyocytes was strongly potentiated by T. cruzi infection 
of those cells. Therefore, iNOS expression in cardiac cells can be directly triggered by 
the parasite and is probably responsible for the inhibition of IL-4- dependent arginase I 
expression in these cells (Fig 20a). 
 
 
 
T. cruzi infection triggers NO production in IFN-γ activated macrophages but the 
parasite itself does not induce production of NO in this cell type (Bergeron and Olivier, 
2006); we corroborated those results. Moreover, we found that in vitro infection of 
BALB/c mice resident peritoneal macrophages did not increase arginase I expression, 
in fact a decrease was observed over the basal levels (Fig. 20b).  By extrapolating, those 
in vitro results to “in vivo” ones, we can suggest that arginase I induction seen in CD68+ 
heart infiltrating cells is not likely to be triggered by the parasite but rather by the 
inflammatory environment in the heart set off during the immunological response 
against the parasite. 
 
 
Figure 20. Expression of arginase I and 
iNOS in BALB/c cardiomyocytes and 
peritoneal macrophages infected with 
T.cruzi in vitro. a) Western blot of 
neonatal cardiomyocyte cultures non-
infected (NI) and infected (I) in vitro with 
T. cruzi trypomastigotes cultured with 
medium alone (C), IL-4, LPS+ IFN-γ as 
indicated. Arginase I, iNOS and actin 
expression is shown. b) Arginase I, iNOS 
and actin expression in non-infected (NI) 
and infected (I) macrophage cultures; 
iNOS expression was not detected (N.D.). 
Results shown are representative of at least 
3 experiments. 
                                                                         61 
IV. CD11b+ cells purified from hearts of infected mice do not show a clear M1 or 
M2 pattern but exert NO mediated T cell suppression. 
 
IV.1. Purified CD11b+ cells from hearts of infected mice do not show a polarized 
M1 or M2 signature. 
 
 In order to determine whether heart tissue infiltrating CD11b+ cells belonged to 
the M2 type macrophages, we purified CD11b+ cells from hearts of infected mice by 
magnetic sorting and performed qPCR for different genes already described to be 
transcriptionally induced in M2 macrophages in vivo by different stimuli or parasites 
(Ghassabeh et al., 2006). Results in Table 1 show that only 5 out of 10 genes of the 
described gene signature: Prosaposin, Triggering receptor expressed on myeloid cells 2 
(Trem2), Chitinase 3-like 3 (Ym), Cadherin-1 and Folate Receptor-2 (Folr2) but not 
Resistin like alpha (Fizz1) Platelet-activating factor acetylhydrolase (Pafah), 
Selenoprotein P (Sep), Macrophage galactose N-acetyl-galactosamine specific lectin 2 
(Mgl2), and Macrophage mannose receptor (Mmr), were transcribed in our cells 
purified from infected hearts indicating that these CD11b+ cells had no clear M1 or M2 
polarization. 
 
IV.2. Phenotypic characterisation of CD11b+ purified cells: Myeloid suppressor 
cells. 
 
 Next, we approached characterization of our population of purified CD11b+ cells 
from hearts from infected mice using flow cytometer analysis. For this, most common 
markers for CD11b+ populations were used. These cells showed no staining for F4/80 or 
Table 1. mRNA quantification of genes related to M2 
activation in CD11b+ heart infiltrating cells . RNA 
was isolated from CD11b+ population purified from 
hearts of BALB/c mice 21 d.p.i. and qRT-PCR was 
performed. Values are relative to those obtained from 
CD11b+ population purified from peritoneal exudates 
from non-infected BALB/c mice. Results are 
expressed as RQ, calculated as described and 
normalized by S12 gene expression. Asterisks 
indicate that at least five-fold induction was detected 
in at least two of the three experiments performed. 
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CD11c, markers for some subset of tissue macrophages and dendritic cells respectively 
corroborating immunohistochemical analysis (Fig. 21a and 21c); also, CD 19 marker, 
present in B cells was not present in our isolated population (Fig. 21b).  Purified cells 
did express MHC class II, which indicates that they represent mature cells capable of 
presenting antigen to T cells (Fig. 22c). 
  
 
 
 
 
 
 
 
  
  
 
 
 
   
 Gr-1 marker is highly expressed on granulocytes, but has been also shown to be 
expressed in a subset of myelomonocytic cells named myeloid suppressor cells. Fig 22a 
shows that there are two different populations according to Gr-1 expression, CD11b+ 
Gr1high cells and CD11b+ Gr-1int cells. These two populations also vary on their 
expression of Ly-6C (Fig. 22e), mainly a monocytic cell marker, but also some 
expression is detected in neutrophils and dendritic cells. Fig 22 d shows that infiltrating 
cells are composed of two main populations: CD11b+ Gr-1high Ly6Cint, which have been 
related to granulocyte CD11b+ cells and CD11b+ Gr-1int Ly6Chigh, related to MSCs.  
 
IV.3. Monocytes (CD11b+ Gr-1int Ly6Chigh) but not granulocytes (CD11b+ Gr-
1highLy6Cint) are responsible for arginase I and iNOS expression. 
 
  Arginase I and iNOS expression were analysed in purified CD11b+ population 
from hearts from T.cruzi infected mice. At 21 d.p.i. CD11b+ cells were purified also 
from blood of the same infected mice or from non-infected mice. CD11b+ cannot be 
Figure 21. Phenotypic characterization of CD11b+ population purified from hearts of infected mice. CD11b+ population was 
purified from hearts of BALB/c infected mice as described in methods and materials. Cells were then stained for CD11b and 
for: a) CD11c, b) CD19 and c) F4/80. Numbers indicate inside panel % of positive cells of the gated populations. Data are 
representative of at least 3 experiments performed.  
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isolated from the hearts of uninfected mice since they do not infiltrate the heart. Fig 23 
shows that CD11b+ cells purified from heart of infected mice were the only population 
expressing both iNOS and arginase I enzymes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to determine whether this arginase I and iNOS expression was 
expressed in CD11b+ Gr-1int Ly-6Chigh or in the CD11b+ Gr-1high Ly-6Cint subset 
infiltrating the heart, we depleted Ly-6G+ cells from the total heart and blood isolated 
population by positive selection eluting then heart and blood populations expressing low 
or no levels of Ly-6G on membrane. Eluted heart and blood Ly-6G- populations were 
then subject to CD11b+ selection. Fig 24 shows how remaining CD11b+ cells were the 
cell subset responsible for arginase I and iNOS expression in heart tissue and for the 
low arginase I expression found in PBMCs. 
 
Figure 22. Expression of Gr-1, Ly-6C and MHC class II in the CD11b+ population purified from hearts of infected mice. 
CD11b+ population was purified from hearts of BALB/c infected mice as described in methods and materials, cells were then 
stained for CD11b and for: a) Gr-1, c) MHC class II, e) Ly-6C. Or for: b) Gr-1 and Ly-6C. d) Overlay in e from CD11b+ Gr-1+ 
populations in a. Numbers inside panels indicate % of positive cells of gated populations. Data are representative of at least 3 
experiments performed.  
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Because anti Gr-1 antibodies recognize both Ly-6C and Ly-6G molecules, in 
this case, depleting high Ly-6G+ expressing cells helped us distinguish between Gr-1high 
and Gr-1int populations; Gr-1high Ly-6Cint expressing cells were depleted by Ly-6G 
positive depletion while Gr-1int Ly-6Chigh were present in the eluted population which 
was afterwards selected for CD11b. Altogether, this data indicate that CD11b+ Gr-1int 
Ly-6Chigh cells corresponding to a MSC phenotype are the population subset responsible 
for arginase I and iNOS expression 
 
 
  
 
 
 
Figure 23. Expression of arginase I, iNOS and actin in sorted CD11b populations from heart and blood of infected and non-
infected mice. CD11b+ population was purified from hearts or blood of infected (21 d.p.i) or non-infected BALB/c mice as 
described in methods and materials; positive and negative fractions of sorted cells were then processed for western blot 
analysis using anti-arginase I, anti-iNOS, and anti-actin antibodies. + or – signs indicate positive or negative fraction of CD11b 
sorted population. Results shown are representative of at least three experiments performed. 
 
Figure 24. Expression of arginase I, iNOS and actin in sorted Ly-6G and CD11b populations from heart and blood of infected 
mice. Ly-6G+ population and afterwards CD11b+ population were purified from hearts or blood of infected BALB/c mice at 21 
d.p.i as described; positive and negative fractions of sorted cells were then processed for western blot analysis using anti-arginase 
I, anti-iNOS, and anti-actin antibodies. + or – signs indicate positive or negative fraction of Ly6G and/or CD11b sorted 
population. Results shown are representative of at least three experiments performed. 
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IV.4. Arginase modulates T cell suppression derived from iNOS activity. 
 
 In order to establish the capability of the CD11b+ Ly-6Chigh Gr-1int subset of the 
cell population purified from hearts of infected mice to suppress T cell response, and act 
as MSCs, we performed proliferation assays. T cells purified from spleen from non-
infected syngeneic mice were activated with concanavalin A and co-incubated with 
purified CD11b+ cells from heart of infected mice or with CD11b+ cells from blood of 
non-infected mice. iNOS and arginase inhibitors were added to assess the differential 
role of the putative inhibition of these enzymes. 
 
  
 
  
 
 
  
 
 Fig 25 shows proliferation expressed as a ratio of counts per minute (c.p.m.) of T 
cells incubated with CD11b+ cells purified from hearts of infected mice divided by 
c.p.m. from T cells incubated with CD11b+ cells purified from blood of non-infected 
mice. Impaired proliferation of T cells can be observed when incubated with CD11b+ 
cells purified from hearts of infected mice in comparison with CD11b+ cells from blood 
of non-infected mice. When arginase specific inhibitor nor-NOHA was added to the 
cell culture no prevention of the inhibition of cell proliferation was observed compared 
Figure 25. T-cell suppressive activity of purified CD11b+cells from hearts of infected mice. CD11b+ population was purified 
from hearts of infected BALB/c mice at 21 d.p.i and from blood of non-infected BALB/c mice as previously described. 
CD11b+ cells were incubated with T cells isolated from spleen from a non-infected mouse with and, where indicated, with or 
without the following inhibitors: nor-NOHA 24µM and L-NMMA 2mM. Data are given as proliferation ratio: counts per 
minute (c.p.m.) of T cells incubated with CD11b+ cells isolated from hearts of mice 21 d.p.i. / c.p.m. of T cells incubated with 
CD11b+ cells isolated from non-infected blood. One representative experiment out of four is shown. Results are represented as 
mean ± SE of triplicates. Asterisks indicate significant differences (p< 0.05) when compared with the control condition except 
when a line indicates the two conditions being compared. 
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to control non-treated cells, in fact, a further small decrease in proliferation was 
detected. However, when iNOS inhibitor L-NMMA was added, proliferation was 
significantly restored. Moreover, when both arginase and iNOS inhibitors were added to 
the culture, reestablishment of cell proliferation was even greater than with only L-
NMMA treatment. These results indicate that NO released by iNOS or H2O2 released as 
a consequence of both iNOS and arginase activity are exerting a potent 
immunosuppressant activity and arginase is modulating this immunosuppresion. 
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DISCUSSION 
 
Heart leukocyte infiltration is thought to play an important role in the 
myocarditis associated to T. cruzi infection both in the acute and the chronic phase. Up 
to date, most of the research in the field has focused in the characterization of T cells 
present in heart inflammatory infiltrate, while very few reports have addressed the role 
of monocytes/macrophages in the myocarditis of the chronic or acute phase. 
Furthermore, macrophages may become activated by different pathways, that play 
different and somehow opposite roles (Mantovani et al., 2004; Mills et al., 2000). This, 
prompted us to analyze the role of macrophages and its activation state in acute 
myocarditis associated to T. cruzi infection. 
 
I. Enzymes involved in L-arginine metabolism in the heart of mice infected with T. 
cruzi. 
 
Our results show for the first time that arginase expression is strongly induced in 
heart tissue during acute T. cruzi infection in mice. However, this takes place together 
with an increased expression of iNOS. Besides, mRNA levels for CAT-1 and CAT-2 
were induced in a time-dependent manner associated to iNOS and arginase I protein 
induction. The peak of parasite load correlated with peaks of arginase I and iNOS 
expression in heart tissue. This was observed in both susceptible BALB/c and resistant 
C57BL/6 mice, so no obvious relationship with susceptibility can be drawn. However, 
arginase I expression in susceptible BALB/c mice was higher and persisted for a longer 
period of time than in C57BL/6 mice, which controlled more efficiently the infection. 
Besides, ODC protein expression was also induced during the acute phase, likely 
resulting in an increment in polyamines synthesis needed for parasite replication.  
Arginase I and iNOS expression were not equally induced in the different tissues 
or cells tested. Thus, these proteins were detected specifically in heart and in PECs, and, 
in the case of arginase, to a lesser extent in PBMCs. PECs showed an expression 
pattern, that although slightly different from the one found in heart tissue also points out 
to a time-dependent higher expression of arginase I in BALB/c infected mice compared 
with C57BL/6 mice. In PECs, arginase I expression is detected earlier in the infection 
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than in heart likely reflecting the fact that mice are being infected intraperitoneally and 
those cells are the first ones to encounter the parasite. 
Although many reports describe an important role for iNOS mediated NO 
production to control T. cruzi infection in vitro (Gazzinelli et al., 1992; Metz et al., 
1993; Munoz-Fernandez et al., 1992; Pakianathan and Kuhn, 1994; Plasman et al., 
1994), infected iNOS deficient mice did not show any differences in parasite burden 
present in blood or in heart in comparison to wild-type infected mice. This suggests that 
in vivo, the toxic effect of iNOS derived products is not essential for parasite control or 
that it might be compensated by other NO synthases. Alternatively, NO may have 
opposite dual effect in vivo. Besides being cytotoxic for the parasite, iNOS derived NO 
may also contribute to parasite replication by inducing immunosuppresion of T. cruzi 
specific immune responses (Goni et al., 2002). Thus, it is possible that mice lacking 
iNOS, have less immunosuppresion in vivo leading to a better control of parasite 
replication despite having lower amount of the cytotoxic NO. Both mechanisms may be 
compensating each other, being the result the apparent lack of effect in replication. 
Interestingly, Arginase I and iNOS are crossregulated by their products. In this 
regard iNOS deficient mice infected with T. cruzi showed very high arginase I 
expression and arginase activity in heart compared to wild-type mice. Despite this 
arginase activity increase, no significant differences were detected in parasite burden in 
the heart, prompting us to conclude that arginase induction during infection is not 
exclusively related to parasite proliferation, probably due to the fact that ODC, as the 
limiting enzyme of the polyamine synthesis pathway, is known to be strictly regulated. 
Thus, an increase in arginase is not directly translated into an increase in polyamines. In 
this regard, it is important to mention that other authors (Holscher et al., 1998) have 
reported extreme susceptibility to T. cruzi infection with a very high parasitemia in a 
different iNOS deficient mouse strain. Further studies that address the reasons of this 
different response, such as genetic backgrounds, or different T. cruzi strains are needed 
in order to assign a clear and reliable role for this enzyme in T. cruzi infection.  
 
II. Th1 and Th2 cytokines are expressed in heart during T. cruzi infection. 
 
Arginase I and iNOS expression have been described to be regulated 
respectively by Th2 and Th1 cytokines. However, our analysis showed that both Th1 
and Th2 cytokines were induced upon infection in both BALB/c and C57BL/6 hearts. It 
                                                                         70 
is generally accepted that in many parasitic diseases, BALB/c susceptible mice mainly 
produce Th2 cytokines whereas C57BL/6 resistant mice Th1 cytokines (Fresno et al., 
1997). However, we found that this Th1/Th2 dichotomy is not so strict in T. cruzi 
infection at least in the heart. Nonetheless, heart Th1/Th2 balance is higher in C57BL/6 
than BALB/c mice, and the levels of Th2 cytokine expression were always higher and 
persisted longer in susceptible mice compared with resistant mice.  
Very few studies have addressed the profile of Th1/Th2 cytokines in the heart 
and resistance/susceptibility to T. cruzi infection. In a previous report (Talvani et al., 
2000), have also found that hearts of C57BL/6 mice have mRNA for both Th2 (IL-4, 
IL-10) and Th1 (IFNγ) cytokines. Other authors (Zhang and Tarleton, 1996a) were 
unable to detect Th2 cytokines in infected hearts of C57BL/6 mice by 
immunohistochemistry and showed very low levels of IFNγ producing cells. The reason 
of this apparent discrepancy may rely in the lower sensitivity of immunohistochemistry 
compared to our quantitative PCR. 
Different mice lacking Th1 or Th2 cytokines were infected in order to establish a 
role for this cytokines in arginase I regulation and induction. IFNγR-/- and TNF-/- mice 
as representatives of proinflammatory/Th1 cytokines, had, as previously described, an 
increased susceptibility to T. cruzi infection presenting very high parasitemias and 
dying before 21 d.p.i. Both TNF and IFNγ are needed for iNOS induction (Munoz-
Fernandez et al., 1992; Vila-del Sol et al., 2007), and our data corroborate this fact, 
since no iNOS was detected in hearts of neither TNF nor IFNγ deficient infected mice. 
This iNOS absence however, did not result in a high arginase I induction; this apparent 
contrast with data from iNOS-/- mice in which arginase I induction was increased. The 
differences between these models are not easy to explain but may reflect that genetic 
deletion completely eliminates iNOS function whereas in cytokine-deleted mice some 
background NOS may exist. Alternatively iNOS deficiency may require TNF or IFNγR 
signalling to induce arginase I. 
 IFNγR-/- mice infected with T. cruzi had similar levels of arginase I enzyme and 
showed a significant increase in arginase activity that did not differ statistically when 
compared to the wild-type. When infected with T. cruzi, TNF-/- mice showed lower 
levels of arginase I expressed in heart in comparison to the wild-type. However, when 
arginase activity from the same heart lysates was determined at 18 d.p.i., it was 
significantly increased in both TNF-/- and wild-type mice and statistical analysis did not 
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reveal significant differences between them, which might account for a compensating 
arginase II induction in this mice. The fact that in hearts of these mice arginase I was 
not highly induced with T. cruzi infection despite the absence of iNOS protein pointed 
to a regulating mechanism for arginase I other than the crossregulation with iNOS 
products. 
 In the onset of an immune response against T. cruzi, IL-10, TGFβ and Th2 
cytokines as IL-4 and IL-13 counteract the excess of initially triggered pro-
inflammatory response that, when excessive, can result in host damage. The lack of an 
appropriate Th1 mediated response in IFNγ and TNF deficient infected mice might not 
trigger a suitable compensating IL-10, TGFβ and Th2 cytokine mediated reaction that 
accounts for arginase I induction in heart. In this regard, IL-10 deficient mice infected 
with T. cruzi showed severe pathology and died in the early acute phase due to TNF 
mediated septic shock. However, IL-10 deficient mice presented lower parasitemia than 
wild-type mice in agreement with previous results (Holscher et al., 2000). Moreover, we 
found that the difference was seen also in parasite load in heart tissue. Arginase I and 
iNOS protein were not detected in heart tissue of these infected mice and arginase 
activity showed no significant increase in infected mice compared to the non-infected. 
However, when mRNA levels for arginase I, arginase II and iNOS were studied in 
hearts of infected IL-10-/- and wild-type mice, a small but significant induction was 
detected for these three genes. Moreover both arginases showed statistically lower 
levels in IL-10 deficient, when compared to the wild-type mice while no significant 
differences were seen in the same comparison for the iNOS gene.  
When infected with T. cruzi, IL-10-/- mice die very early in the course of the 
infection and none of the enzymes subject of study were yet detected, although the data 
from mRNA suggest a possible role of IL-10 in arginase induction.  
Analysis of mRNA levels in hearts from BALB/c and C57BL/6 mice infected 
with T. cruzi showed that IL-4 and IL-13 levels were had statistically higher in BALB/c 
mice than in C57BL/6 mice at all d.p.i. analyzed. IL-4R-/- mice, which have impaired 
signalling for both IL-4 and IL-13, showed no differences in parasitemia in comparison 
to the wild-type mice when infected with T. cruzi.  However, parasite burden in heart 
tissue was significantly decreased in infected IL-4R deficient mice when compared to 
infected wild-type mice at 14 and 21 d.p.i. Moreover, arginase I expression in these 
hearts was higher in wild-type than in IL-4R deficient mice and also, arginase activity 
from the same lysates was much lower in IL-4R-/- when compared to the wild-type. 
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Thus, arginase I expression and arginase activity in hearts of mice infected with T. cruzi 
depends to a certain level on IL-13 and/or IL-4 signalling. iNOS expression is also 
slightly reduced in IL-4R deficient mice. In contrast, when IL-4 deficient mice were 
infected with T. cruzi, arginase I induction in heart tissue compared to the wild-type was 
not diminished but rather presented higher levels. Arginase activity was also 
significantly higher in hearts from IL-4 deficient mice when compared with wild-type. 
These results indicate that IL-4 is not implicated in arginase I induction in hearts of 
mice infected with T. cruzi. Since IL-4R seems to be involved, this suggests that this 
responsibility relies mainly in IL-13 or alternatively a cooperation of both IL-4 and IL-
13 cytokines is needed.   
However, other agents and inflammatory mediators have been described to be 
able to induce arginase I which might also be involved in its regulation. The work of 
(Freire-de-Lima et al., 2000) shows that the induction of ODC expression could be due 
to the uptake of apoptotic cells during T. cruzi infection, which causes release of PGE2 
and induction of TGF-β. Since the ODC substrate depends mainly on arginase, its 
induction could be mediated by TGF-β. However, a very weak induction of TGF-β 
mRNA was observed, as compared with other cytokines, suggesting that TGF-β is not 
responsible for the arginase I induction in our model. This is sharp contrast with original 
studies from (Zhang and Tarleton, 1996b) in which TGF-β expressing cells were highly 
abundant in the hearts of C57BL/6 by immunohistochemistry. Despite being much more 
sensitive the PCR technique to detect TGF-β mRNA, this cytokine was found in both 
strains of infected mice. The reason for the discrepancies are unknown, but may rely on 
the different strains of T. cruzi used to infect the mice or that unchecked cross-reaction 
of the TGF-β antibodies used in Zhang’s studies. On the other hand, m-PGES-1 
expression was significantly higher in BALB/c respect to C57BL/6 mice at 21 d.p.i., 
indicating that PGE2 could partially contribute to the increased arginase I expression 
observed in BALB/c mice compared to C57BL/6 mice.  
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III. Cell type expressing iNOS, Arginase II and Arginase I in heart tissue from T. 
cruzi infected mice. 
 
We also analyzed the expression of these enzymes at the cellular level in heart 
tissue sections. We found that iNOS and arginase II were expressed in cardiomyocytes 
of infected BALB/c mice in agreement with previous reports that attributed a role for 
arginase II in cardiomyocyte survival (Aoki et al., 2004) and contractility (Steppan et 
al., 2006). Interestingly, arginase I expression was detected for the first time only in 
CD68+ infiltrating macrophages, and according to protein expression, arginase I was 
very likely responsible of arginase enzymatic activity in heart tissue. Moreover, analysis 
of the number of infiltrating macrophages, by quantifying CD68 by qRT-PCR in heart 
tissue, showed that they were very similar in BALB/c and C57BL/6 mice. This indicates 
that the differences in cell number of infiltrating macrophages were not responsible for 
the increased arginase I expression and activity seen in BALB/c mice. Rather, heart 
infiltrating macrophages in infected BALB/c mice expressed more arginase I per cell 
than in C57BL/6. 
 We also found that T. cruzi infection triggered iNOS expression in 
cardiomyocytes, in agreement with previous observations (Machado et al., 2000). 
However, the parasite was unable to induce the expression of arginase I in 
cardiomyocytes and neither arginase I and iNOS in resident peritoneal macrophages. 
 Together, the in vitro and in vivo infection data suggest that induction of iNOS 
expression in cardiomyocytes could be triggered by the parasite, while arginase I 
expression in macrophages depends on Th2 cytokines, mainly IL-13. And additional 
contribution of IL-4, IL-10 and PGE2 cannot be excluded. Interestingly, we found that 
cardiomyocytes expressed arginase I upon IL-4 stimulation in vitro, while the parasite 
alone was unable to induce its expression. However, arginase I was not observed in 
cardiac cells of infected BALB/c mice even though IL-4 was detected in cardiac tissue. 
Since infection partially inhibited IL-4-induced arginase I in vitro, it is likely that a 
similar mechanism is operating in vivo. 
It is important to note that iNOS protein was not detected in circulating PBMCs 
in agreement with previous reports (Fabrino et al., 2004) rather in heart tissue, 
suggesting a specific important role of iNOS in this organ. A discrete induction of 
arginase I compared to the one detected in heart tissue was observed in circulating 
PBMCs but not in other lymphatic organs from acutely infected mice. This indicates 
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that arginase I is preferentially induced in macrophages infiltrating the heart and that its 
induction is mediated by the above-mentioned cytokines and also PGE2 in an organ 
specific manner and not systemically.  
 
 
IV. Myeloid suppressor cells infiltrating hearts of mice infected with T. cruzi. 
 
Isolation of CD11b+ cells from heart inflammatory infiltrate of infected mice 
allowed us to study and functionally characterize these arginase I and iNOS expressing 
cells. In this regard, the population of infiltrating CD11b+ cells did not show a clearly 
polarized M2 or M1 pattern when several genes, already described to be induced in 
several models of M2 populations (Ghassabeh et al., 2006), were analyzed. According 
to the surface markers expressed in sorted CD11b+ population from hearts of mice 
infected with T. cruzi, these cells did not show staining for CD11c or F4/80 markers, 
which agrees with results encountered in the immunofluorescence staining of heart 
tissue sections, and neither for CD19 marker indicating that the numerous CD11b+ 
population isolated from inflammatory infiltrate is not corresponding to dendritic cells, 
or B cells. Despite the fact that F4/80 marker of mature tissue macrophages was not 
detected, immunofluorescence of heart sections showed a CD68+ population indicating 
that a high percentage of infiltrating cells are macrophages.  Also, those CD11b+ cells 
showed MHC class II expression suggesting a mature population capable of presenting 
antigen to T cells. Maybe the most important phenotypic characteristic of this CD11b+ 
population was the expression of the Gr-1 molecule. Gr-1, also known as Ly6-G, is 
highly expressed in granulocytes, and to a lesser extent, in a subset of monocytes, which 
have been reported to have the ability of suppressing distinct T cell responses and are 
commonly grouped under the name: myeloid suppressor cells (MSCs) (Bronte et al., 
2000; Bronte and Zanovello, 2005). The anti-Gr-1 antibody RB6-8C5 used in our 
analysis recognizes not only Ly6-G but also Ly6-C molecule, which is expressed in 
monocytes and in certain populations of neutrophils, dendritic cells and lymphocytes. 
According to the expression of Gr-1 and Ly6-C, CD11b+ cells isolated from hearts of 
infected mice showed two distinct populations: CD11b+ Gr-1int Ly6-Chigh, corresponding 
with MSCs phenotype, and CD11b+ Gr-1high Ly6-Cint which corresponds with 
granulocyte phenotype population.  
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Arginase I and iNOS expression was found in infiltrating CD11b+ cells from 
hearts from infected mice, and in much lower levels arginase was seen in CD11b+ from 
blood from infected mice but none of the enzymes was detected in CD11b+ from blood 
from non-infected mice. Depletion of Ly6-G+ cells with magnetic beads using 1A8 
clone specific for granulocyte cells (Daley et al., 2008) prompt us to the conclusion that 
CD11b+ Gr-1int Ly-6Chigh CD68+ F4/80- cells present in the heart inflammatory infiltrate 
of mice infected with T. cruzi, were responsible for arginase I expression observed in 
this organ and moreover, these cells also presented iNOS protein expression. No single 
report has analyzed the myeloid infiltrating cells in the hearts on T. cruzi infected mice. 
Nonetheless, in Trypanosoma congolense, infected BALB/c mice macrophages 
expressing both iNOS and arginase I were detected being this expression associated 
with pathology (Noel et al., 2002). 
Besides, in acute T. cruzi strong suppression of T lymphocyte responses 
mediated by myeloid cells expressing NO has been described (Goni et al., 2002). 
Similarly, CD11b+ cells from hearts of infected mice also showed a strong suppression 
of T cell proliferation when co-cultured with T cells isolated from spleen of non-
infected mice. This impaired proliferation was even more pronounced in the presence of 
arginase inhibitor. However, only when iNOS enzyme was inhibited T cell proliferation 
was mostly restored, and an even greater recover of T cell proliferation was observed 
when both arginase and iNOS inhibitors were added simultaneously to the cell culture. 
Different mechanisms have been described to mediate T cell suppression for arginase, 
and/or iNOS enzymes. When both enzymes are being induced, competition for the 
common substrate L-arginine leads to the depletion of this amino acid from the 
extracelular milieu; with very low L-arginine concentrations, iNOS enzyme decreases 
NO formation in order to produce superoxide, which, due to its unstable nature, is 
converted to H2O2 responsible for toxicity and impaired T cell proliferation 
(Kusmartsev et al., 2004). If depletion of L-arginine occurs, arginase inhibition by nor-
NOHA would result in higher availability of L-Arginine substrate for iNOS enzyme and 
production of NO and peroxinitrites that would aggravate even more the inhibition of 
the T cell response. But then, why both arginase and iNOS inhibitors reestablish on a 
greater way T cell proliferation than when iNOS inhibitor alone is present? This might 
be due to arginase-mediated depletion of L-arginine that might cause inhibition of T cell 
activation by decreasing CD3ζ expression (Rodriguez et al., 2003). Thus, arginase I has 
a complex way of modulating iNOS mediated impairment of T cell proliferation.   
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On one hand, few studies have addressed the role of arginase I in heart related to 
pathology. On the contrary, the role of NO in cardiac physiology has been widely 
studied (Shah and MacCarthy, 2000). For example, excessive NO production by iNOS 
may lead to myocarditis in many models including infectious models as Coxsackie virus 
induced myocarditis, which had some features similar to T. cruzi induced myocarditis 
(Girones and Fresno, 2003). Thus, arginase I induction in the heart, besides 
immunosupression, may be also a modulator of myocardial function (Post and Pieske, 
2006) and attenuate an excessive NO signaling, thus protecting heart from NO mediated 
damage. In this regard, iNOS-derived NO plays an important role in ventricular dilation 
in acute murine chagasic myocarditis (Chandra et al., 2002) 
In summary, we have analyzed the arginine metabolism enzymes in heart and 
showed for the first time that arginase I is expressed by infiltrated MSCs during acute 
experimental T. cruzi infection. Moreover, arginase I is induced by IL-13 probably in 
cooperation with IL-4, IL-10 and PGE2 and has a complex dual role during T. cruzi 
infection by, on one side providing abundant substrate for ODC enzyme and the 
polyamine pathway, which might result in higher parasite proliferation, and on the other 
side by modulating iNOS mediated T cell suppression.  
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CONCLUSIONS 
 
 
 
Results obtained in this thesis yielded the following conclusions: 
 
 
1. Arginase I is induced in heart of mice infected with T. cruzi correlating with the 
parasite load in this organ. 
 
2. Arginase I induction during T. cruzi infection is restricted to heart and PECs. 
 
3. Arginase I induction in heart of mice infected with T. cruzi requires IL-4R signaling 
likely mediated by IL-13 with a possible cooperation with IL-4, IL-10 and PGE2. 
 
4. iNOS is expressed in cardiomyocytes and CD11b+ Gr-1int Ly-6Chigh infiltrating cells 
in heart tissue from infected mice, while arginase I expression is restricted to CD68+ 
CD11b+ Gr-1int Ly-6Chigh infiltrating population. 
 
5. CD11b+ cells present in heart inflammatory infiltrate of mice infected with T. cruzi 
do not have a clear polarized M1 or M2 pattern of gene expression 
 
6. CD11b+ cells present in heart inflammatory infiltrate of mice infected with T. cruzi 
expressing iNOS and arginase I show a myeloid suppressor cell phenotype and 
modulate T cell proliferation in vitro. 
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RESUMEN  
 
  
 
 En la enfermedad de Chagas, causada por Trypanosoma cruzi, los macrófagos y 
los cardiomiocitos son las dianas principales de la infección. Por otro lado, los 
macrófagos de pueden activar en diferentes vías por citoquinas Th1 o Th2 dando lugar a 
activación clásica o alternativa, lo que resulta en una respuesta distinta. Estas vías 
diferentes se distinguen a menudo por la expresión de varias enzimas implicadas en el 
metabolismo de la L-arginina en tejido cardiaco durante la infección in vivo de ratones 
BALB/c y C57BL/6. Encontramos que la expresión de la óxido nítrico sintasa inducible 
(iNOS), arginasa I y arginasa II, así como la ornitina decarboxilasa, eran mucho 
mayores en ratones BALB/c comparada con C57BL/6 y relacionada con la carga 
parasitaria en tejido cardiaco. Citoquinas de tipo Th1 y Th2 se expresan en tejido 
cardiaco de las dos cepas infectadas, pero el balance Th1/Th2 era predominantemente 
Th1 en ratones C57BL/6 y Th2 en ratones BALB/c en el pico de carga parasitaria 
durante la infección. Usando ratones genéticamente deficientes en varias citoquinas o en 
sus receptores, encontramos que la IL-13, probablemente cooperando con IL-4, IL-10 y 
prostaglandina E2 están induciendo la expresión de arginasa I. iNOS y arginasa II se 
expresan en cardiomiocitos. Interesantemente, macrófagos CD68+ infiltrados en corazón 
fueron el principal tipo celular expresando arginasa I. Cuando fueron purificadas, las 
células CD11b+ infiltradas en corazón que expresan ambas arginasa I e iNOS no 
presentaron un patrón definido de activación M1/M2, pero sí mostraron un fenotipo 
característico de células mieloides supresoras. Además, estas células CD11b+ 
modularon la proliferación de células T in vitro. Por tanto, la arginasa I puede 
influenciar la superviviencia del parásito, y podría estar también regulando la respuesta 
inflamatoria de las células T durante la infección. 
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INTRODUCCIÓN 
 
I. Enfermedad de Chagas 
 
I.1. Aspectos generales y ciclo de vida. 
 
 La tripanosomiasis americana, o enfermedad de Chagas, es un desorden 
multisistémico que, de acuerdo con el último informe de la OMS, afecta 
aproximadamente a 18 millones de personas con 120 millones en riesgo. Se trata de una 
enfermedad endémica en América Latina donde se distribuye a través de 18 países 
desde el cono sur del continente (Fig. 1), hasta Méjico (WHO, 2002) 
 La transmisión de esta enfermedad a los humanos ocurre fundamentalmente de 
tres maneras distintas: Vía insecto vector, transfusión de sangre infectada, y transmisión 
vertical. 
 Trypanosoma cruzi, un protozoo flagelado de la familia Kinetoplastidae, fue 
identificado por primera vez por por Carlos Chagas en 1909 como agente causal de la 
enfermedad que se llamó así en su honor. Este parásito presenta un ciclo de vida 
complejo que implica varias etapas tanto en vertebrados como en el insecto vector. T. 
cruzi  tiene tres morfologías distintas: epimastigote, que se replica en el insecto vector 
triatomino, tripomastigote, que infecta las células del hospedador vertebrado, y 
amastigote, que se replica intracelularmente dentro de las células del hospedador 
(Burleigh and Andrews, 1998; Tanowitz et al., 1992). 
 La trasmisión de T.cruzi a humanos ocurre cuando las heces liberadas, mientras 
succiona sangre del hospedador vertebrado, por el insecto triatomino que contienen 
tripomastigotes metacíclicos infectivos, penetran a través de la piel en el torrente 
sanguíneo. Es allí donde las formas flageladas del parásito infectan una amplia variedad 
de células del hospedador (fundamentalmente macrófagos y cardiomiocitos). Una vez 
en el interior de las células, las formas tripomastigote se transforman a amastigote, los 
cuales de multiplican intracelularmente. Después de ésto, los amastigotes salen de la 
célula y dan lugar a trypomastigotes, que son liberados al torrente sanguíneo donde se 
diseminan e infectan nuevas células otra vez. Es en esta etapa cuando los parásitos 
pueden ser succionados del torrente sanguíneo por la chinche triatomina mientras se 
alimenta de sangre. Una vez alcanzan la tripa del insecto, los tripomastigotes se 
                                                                         96 
trasforman en epimastigotes, y se multiplican a través del tracto digestivo hasta que 
alcanzan los intestinos donde se transforman en tripomastigotes metacíclicos y son 
liberados junto con las heces cuando el insecto se alimenta de sangre del hospedador 
vertebrado. 
 Los individuos que residen en las áreas rurales de América Latina son los que se 
encuentran en un mayor riesgo de infección, porque los insectos viven en las cabañas y 
se alimentan constantemente picando a sus habitantes durante la noche. La OMS ha 
dirigido varios programas para la eliminación del insecto vector, y para la educación en 
la comprensión de la salud con un fuerte éxito en el cono sur donde la incidencia ha 
bajado del orden de un 70% desde 1985. También se necesita realizar un examen de la 
sangre para prevenir la transmisión a través de transfusión sanguínea para poder 
prevenir y controlar la enfermedad. Dos fármacos (benznidazol y nifurtimox) están 
disponibles para el tratamiento de la fase aguda de esta enfermedad pero, además de 
tener un porcentaje muy alto de efectos secundarios, no son útiles para la fase crónica de 
la enfermedad. Además, hasta la fecha, sigue faltando una inmunoterapia efectiva o una 
vacuna. 
 
I.2. Clínica de la enfermedad.  
 
 Se pueden distinguir dos fases, aguda y crónica, en la enfermedad de Chagas 
(Kirchhoff, 1993; Prata, 2001; Tanowitz et al., 1992). En la fase aguda, pocos días 
después de la infección, aparece una lesión inflamatoria local en el sitio de infección 
donde los tripomastigotes metacíclicos infectan y experimentan las primeras rondas de 
multiplicación. Entonces, ocurre la diseminación del parásito por el cuerpo y los 
tripomastigotes sanguíneos se pueden observar fácilmente (parasitemia); un pequeño 
número de pacientes desarrollan síntomas de afección cardiaca que refleja una 
miocarditis severa subyacente. Esto puede conducir a un fallo cardiaco, responsable de 
las pocas muertes que ocurren en la fase aguda de la enfermedad de Chagas. También 
puede presentarse meningoencefalitis, especialmente en algunos pacientes 
inmunosuprimidos (Hoff et al., 1978). No obstante, la fase aguda de la enfermedad 
permanece fundamentalmente no diagnosticada sin síntomas graves. En cambio, las 
manifestaciones más comunes y la patología más severa de la enfermedad aparece 
muchos años (de 10 a 30) después de la infección por T. cruzi en aproximadamente 30% 
de las personas infectadas, en lo que se conoce como la fase crónica de la enfermedad. 
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Durante esta fase, los parásitos circulantes no se pueden detectar en sangre, pero se 
produce daño progresivo que implica al esófago, colon y corazón. En la fase crónica, el 
corazón es es el órgano más afectado; frecuentemente se desarrolla cardiomiopatía 
siendo el fallo congestivo de corazón la causa más común de muerte de éstos pacientes. 
 
I.3. Modelo experimental para la enfermedad de Chagas: el ratón. 
 
 El ratón, por su tamaño pequeño y su fácil mantenimiento, ha sido el animal 
preferido para un gran número de experimentos. Los ratones son susceptibles a la 
infección por T cruzi y desarrollan fase aguda y crónica en cierto modo similar a la 
patología descrita en humanos. 
 Sin embargo, tanto las cepas de ratón como de parásito, al igual que el 
procedimiento de inoculación, determinan la susceptibilidad y la patogénesis de la 
enfermedad de Chagas en el modelo de ratón, pero, a pesar de las diferencias, los 
ratones muestran una fase aguda donde la forma sanguínea del parásito puede ser 
detectada en sangre mediante técnicas microscópicas abarcando desde los 7 a los 30 
días. Después de este periodo, la fase crónica comienza a desarrollarse; no se pueden 
detectar parásitos en sangre, y se puede observar cardiomiopatía chagásica en estudios 
histopatológicos de ratones infectados.  
 
II. Respuesta inmune en la enfermedad de Chagas. 
 
 La infección por T. cruzi desencadena una respuesta inmune compleja. Como 
patógeno intracelular, implica un intricado, y todavía no bien entendido mecanismo de 
interacción de muchos mecanismos humorales y celulares de la inmunidad innata y 
adaptativa. 
 
II.1. Inmunidad innata 
 
 Como parte de la primera barrera que el parásito encuentra después de entrar en 
el hospedador, moléculas y células efectoras de la inmunidad innata juegan un papel 
muy importante en la respuesta inmunológica contra T. cruzi. 
 Después de romper la barrera de la piel, el parásito entra en la sangre y tejidos, y 
desata la respuesta temprana del complemento y las proteínas de fase aguda (Proteína C 
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reactiva, componente amiloide P del suero, α2Macroglobulina). Estas moléculas se unen 
a T. cruzi y media su endocitosis mediada por receptor. También, macrófagos y 
células dendríticas expresan en su superficie el receptor de manosa, que reconoce 
carbohidratos con patrones moleculares que no se encuentran en las células del 
hospedador. 
 T. cruzi también es capaz de entrar activamente en una gran variedad de tipos 
celulares, especialmente macrófagos, desencadenando una diversidad de interacciones 
moleculares que movilizan la respuesta de la inmunidad innata del hospedador. Los 
macrófagos secretan IL-12 que activa a las células NK para producir IFNγ  (Aliberti et 
al., 1996), esta citoquina actúa recíprocamente en macrófagos los cuales liberan TNF 
para actuar sinérgicamente junto con la IL-12 e IFNγ e inducir la producción de NO es 
estas células (Abrahamsohn and Coffman, 1996; Munoz-Fernandez et al., 1992). Sin 
embargo, hay varias evidencias que apoyan el hecho de que la respuesta inflamatoria 
está autorregulada y que la activación del macrófago y la producción de NO está 
reducida por las llamadas citoquinas anti-inflamatorias. Se ha encontrado que la IL-10 
se requiere para prevenir una respuesta excesiva pro-inflamatoria durante la infección 
por T. cruzi (Gazzinelli et al., 1992; Hunter et al., 1997; Reed et al., 1994), y algo 
similar ocurre con TGFβ (Silva et al., 1991) aunque esta citoquina puede tener otras 
funciones además de la regulación inmune (Hall and Pereira, 2000; Ming et al., 1995). 
Algunos autores reivindican que la IL-4 está también regulando a la baja el IFNγ y la 
inflamación cuando se encuentra cooperando con la IL-10 (Abrahamsohn et al., 2000), 
pero otros informes muestran que ésta citoquina tendría efectos parecidos a aquellos del 
IFNγ con actividad tripanocida (Golden and Tarleton, 1991; Wirth et al., 1989). Aunque 
el papel de la IL-13 no esta claro de momento, se ha descrito que esta citoquina pudiera 
estar implicada en la regulación de la liberación de IFNγ (Antunez and Cardoni, 2001). 
 Los macrófagos expuestos al IFNγ se vuelven muy efectivos como células 
presentadoras de antígenos (APCs) e interaccionan y presentan péptidos a los linfocitos 
T. Además, el TNF es capaz de inducir la maduración de células dendríticas y su 
migración desde la piel y mucosa a los órganos linfoides para empezar a activar la 
expasión de linfocitos específicos para antígenos microbianos (Fearon and Locksley, 
1996). Pero no sólo las APCs profesionales son capaces de presentar péptidos del 
parásito, la habilidad de T. cruzi para invadir un alto número de tipos celulares de 
mamíferos los implica en la respuesta inflamatoria e inmunológica. Se ha demostrado 
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que los cardiomiocitos responden a la infección liberando NO, citoquinas y 
quimioquinas (Fichera et al., 2004; Machado et al., 2000). 
 
II.2. Inmunidad adaptativa 
 
 La respuesta inmunológica frente a T. cruzi también implica activación de los 
componentes de la respuesta adaptativa humoral y celular. La infección aguda 
experimental por T. cruzi en el modelo murino desencadena una activación intensa y 
policlonal de linfocitos B, que implica una superproducción de inmunoglobulinas (Ig). 
La respuesta frente a los antígenos en esta fase representa sólo una pequeña fracción de 
la Ig total producida (Minoprio et al., 1989). Esta respuesta policlonal es ampliamente 
dependiente de las células CD4+ T cooperadoras (Minoprio et al., 1989). 
 La importancia de las dos subpoblaciones principales de linfocitos T, CD4+ y 
CD8+, a la hora de controlar la infección está ampliamente establecido. T. cruzi es capaz 
de infectar prácticamente cualquier tipo celular en los tejidos del hospedador (Lenzi et 
al., 1996); después de escapar de la vacuola parasitófora en el citoplasma (Nogueira and 
Cohn, 1976), los antígenos del parásito serán procesados y presentados en el contexto 
de la molécula de MHC de clase I, la cual será reconocida por las células T CD8+ 
efectoras. Por otro lado, los parásitos muertos, antígenos solubles del parásito, o 
parásitos que no pudieron escapar de la vacuola parasitófora (McCabe et al., 1984), 
serán presentados sólo por APCs profesionales a través de MHC de clase II a las células 
T CD4+, que cooperarán con las células B para inducir anticuerpos. Además, a pesar de 
que los ratones deficientes en células B sucumben a la infección (Kumar and Tarleton, 
1998), la respuesta inmunológica protectiva parece depender en su mayoría de las 
células CD8+ que producen IFNγ. Las células T CD8+ citotóxicas son capaces de 
controlar la infección a través de un mecanismo de perforina/granzyma de muerte para 
células infectadas y/o apoptosis mediada por FAS (Kumar and Tarleton, 1998). Sin 
embargo, hay trabajos indicando que las células T CD8+ no pueden controlar 
completamente la infección porque se vuelven carentes de respuesta (Martin and 
Tarleton, 2004). 
  Las citoquinas juegan un papel clave en la regulación tanto de la inducción, 
como del tipo de respuesta inmunológica, pero no se ha visto una polarización clara 
hacia Th1 versus Th2 estudiando ratones susceptibles o resistentes a la infección por T. 
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cruzi (Powell et al., 1998; Zhang and Tarleton, 1996a, 1996b). Por lo tanto, el papel de 
las citoquinas Th1/Th2 durante la infección no ha sido establecido por el momento. 
 Además, se han sugerido una variedad de quimioquinas que juegan un papel 
clave en el influjo de células inmunológicas a los tejidos diana durante la infección, 
revisado en (Silva et al., 1991; Teixeira et al., 2002). CCR5 y sus ligandos, juegan un 
papel central en la migración de células T al corazón (Machado et al., 2005) y en la 
proliferación del parásito (Hardison et al., 2006), CXCL9 y CXCL19, no afectan a la 
migración de los leucocitos, pero si se bloquean con anticuerpos neutralizantes, dan 
lugar a una reducción en la carga parasitaria en corazón (Hardison et al., 2006). 
Además, quimioquinas como CXCL12 y CCL4, han sido implicadas en la migración y 
el desarrollo de timocitos (Mendes-da-Cruz et al., 2006). En conjunto, hay una red 
compleja, en la que quimioquinas específicas juegan distintos papeles en la 
patofisiología de la enfermedad. 
 
II.3. Autoinmunidad e inmunomodulación. 
  
 Entre todos los posibles mecanismos responsables de la patogénesis de la 
enfermedad crónica de Chagas, la autoinmunidad es una de las que ha recibido más 
apoyo experimental pero también ha creado más controversia (Girones et al., 2005; 
Girones and Fresno, 2003; Kierszenbaum, 1986, 1999; Levin, 1996; Soares et al., 2001; 
Tarleton, 2001, 2003). Por otro lado, hay estudios que sugieren que la persistencia del 
parásito en los tejidos del hospedador es la clave de la patogenia de la forma crónica de 
la enfermedad puesto que el tratamiento disminuye la severidad de la enfermedad 
(Tarleton, 2001). 
 Varios mecanismos pueden explicar cómo un patógeno infeccioso puede romper 
la auto-tolerancia inmunológica. Entre ellos, mimetismo molecular, “bystander 
activation”, y activación policlonal de linfocitos son mecanismos que han sido 
ampliamente documentados en la enfermedad de Chagas (Girones et al., 2005; 
Kierszenbaum, 2003). Sin embargo, ninguno de estos tres mecanismos es exclusivo y, 
cualquier combinación de los mismos o los tres pueden estar teniendo lugar. 
 Un aspecto importante, y normalmente no considerado, es el papel de las células 
T reguladores (Tregs), de las cuales se ha descrito que suprimen respuestas 
autoinmunes. Además de las clásicas Tregs que salen del timo, hay otras, Tr1 y Th3, las 
cuales adquieren capacidad reguladora en la periferia (Battaglia et al., 2002). Por lo 
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tanto, una definición del papel de las Tregs durante las infección por T. cruzi, puede 
contribuir a iluminar los mecanismos que controlan la patogénesis observada en la 
enfermedad de Chagas crónica. 
 
III. Regulación de las respuestas inmunológicas por el metabolismo de la L-
arginina. 
  
 La L-arginina puede ser metabolizada dentro de las células por dos enzimas 
principales, la arginasa y la óxido nítrico sintasa inducible (iNOS) para dar lugar a urea 
y L-ornitina, y L-citrulina y óxido nítrico (NO) respectivamente.  
 La L-arginina también puede ser metabolizada a través de una vía menos 
conocida por la Arginina Decarboxilasa (ADC) que produce Agmatina, la cual puede 
regular tanto la producción de óxido nítrico como la síntesis de poliaminas (Satriano, 
2004). 
 Los transportadores de aminoácidos catiónicos CAT-1, CAT-2, y CAT-3 son 
una familia de proteínas transmembrana que transfieren L-arginina (entre otros 
aminoácidos catiónicos) desde el exterior al compartimento intracelular para compensar 
la degradación producida por la arginasa y la iNOS. La expresión de CAT-3 está 
restringida al cerebro (Verrey et al., 2004), pero CAT-1 y CAT-2 están presentes en 
macrófagos y en algunos casos, se ha descrito que juegan un papel regulando la 
activación del macrófago en respuesta a parásitos (Wanasen et al., 2007; Yeramian et 
al., 2006). 
 
III.1. Arginasa  
 
 Hasta la fecha, se han descrito en mamíferos dos isoformas de arginasa. Estas 
isoformas está codificadas por dos genes distintos y tienen distinta localización 
subcelular (Jenkinson et al., 1996). 
 La Arginasa I, también conocida como arginasa hepática, está localizada en el 
citoplasma, y se expresa altamente en el hígado, pero también, de manera más 
restringida en otros tipos celulares, como los macrófagos. Esta isoforma se induce 
principalmente por citoquinas de tipo Th2 (IL-4, IL-13) (Corraliza et al., 1995; Munder 
et al., 1998), y también IL-10, TGFβ, factor estimulador de colonias de monocitos y 
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granulocitos (GM-CSF) y prostaglandina E2 (PGE2) (Boutard et al., 1995; Corraliza et 
al., 1995; Jost et al., 2003). 
 La arginasa II, está localizada en la mitocondria; se expresa en una amplia 
variedad de tejidos y de tipos celulares, fundamentalmente en el riñón (Levillain et al., 
2005), pero también en próstata, intestino delgado (Gotoh et al., 1997), y cardiomiocitos 
(Aoki et al., 2004). Esta isozima está inducida fundamentalmente por LPS y dibutiril 
AMPcíclico (Gotoh et al., 1996). 
 Las dos isoformas de la arginasa catalizan la misma reacción y no se ha descrito 
todavía una clara distinción en funciones para cada una de ellas, se trata de un aspecto 
actualmente en debate (Cederbaum et al., 2004). 
 La arginasa está implicada en el ciclo de la urea catalizando la conversión de L-
arginina a L-ornitina y urea. Después, la L-ornitina puede ser metabolizada por la 
Ornitina Aminotrasferasa para aumentar la L-prolina, la cual es responsable de la 
síntesis de colágeno. Por otro lado, la Ornitina Decarboxilasa (ODC), es la enzima clave 
de la ruta de las poliaminas; aumenta la producción de poliaminas que son necesarias 
para la proliferación de todas las células eucariotas. ODC es una enzima de eucariotas 
altamente regulada con una de las vidas medias más cortas descrita en mamíferos, 
fundamentalmente por la unión de la antizima (AZ) que dirige la degradación de la 
ODC por el proteasoma 26 S (Pegg, 2006). 
 
III.2 iNOS 
 
 Junto con otras isoformas de la NOS (nNOS en tejido neuronal, y eNOS en 
células endoteliales), iNOS cataliza la oxidación de L-arginina a L-citrulina y NO, con 
la formación del intermediario Nω-hydroxy-L-Arginine (NOHA). 
 La isoforma iNOS se encuentra en una gran diversidad de tipos celulares en el 
sistema inmune (Wu and Morris, 1998) y también en cardiomiocitos (Tsujino et al., 
1994). El inductor más común de la iNOS es IFNγ combinado con LPS, pero también 
otras citoquinas como la IL-12, IL-1, y TNF. 
 La iNOS genera tanto NO como ión superóxido (O2-) que conduce a la 
formación de peroxinitritos (ONOO-) (Xia and Zweier, 1997). Sin embargo, 
concentraciones muy bajas de L-arginina pueden dar lugar a baja formación de NO y 
alta generación de superóxido, que es muy inestable y es convertido a peróxido de 
hidrógeno (H2O2) y oxígeno (Kusmartsev et al., 2004). 
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 NO, especies reactivas del nitrógeno (RNOS) como ONOO-, y especies 
reactivas del oxígenos (ROS) como el O2- y H2O2, producidas por la iNOS, se sabe que 
son mecanismos muy eficientes a la hora de luchar contra patógenos, pero también 
tienen una alta autotoxicidad y, cuando se encuentran en cantidades excesivas, pueden 
causar patología.  
 
III.3. Balance de arginasa e iNOS. 
 
 Hay una regulación cruzada muy importante entre los productos de las 
reacciones de la iNOS y de la arginasa. Se ha descrito que Nω-hidroxi-L-arginina 
(NOHA), una forma intermedia en la síntesis de NO, inhibe arginasa (Daghigh et al., 
1994) y se ha mostrado que las poliaminas pueden estar afectando a la expresión de 
iNOS (Mossner et al., 2001; Sonoki et al., 1997); además, la arginasa se ha implicado 
en la regulación a la baja de la iNOS vía depleción de L-arginina, puesto que el 
descenso en la disponibilidad de este aminoácido bloquea la síntesis de la iNOS y su 
estabilidad (El-Gayar et al., 2003; Lee et al., 2003). Es importante destacar que arginasa 
e iNOS comparten L-arginina como sustrato y que, a pesar de que la constante de 
afinidad de la iNOS para la L-arginina sea 1000 veces mayor que la de la arginasa, la 
Vmax de ésta es mas de mil veces más rápida que la de la iNOS, lo que resulta en una 
utilización similar del sustrato por parte de estas dos enzimas (Wu and Morris, 1998). 
 Debido a el hecho de que comparten sustrato, estas enzimas se han implicado en 
la regulación del balance Th1/Th2 durante los procesos inmunológicos, y han sido 
usadas como marcadores de activación M1/M2 (Mills et al., 2000). 
 
III.4. Metabolismo de la L-arginina en enfermedades parasitarias. 
 
 Varias infecciones por bacterias intracelulares pueden presentar una evolución 
modificada por las rutas arriba mencionadas; éste es el caso, por ejemplo, de 
Helicobacter pylori (Gobert et al., 2002; Gobert et al., 2000) y Chlamidia sp. (Huang et 
al., 2002). 
 El balance arginasa-iNOS también modifica muchas infecciones de protozoos; 
Se ha demostrado que la arginasa de los macrófagos durante la infección por 
Trypanosoma brucei disminuye las concentraciones de L-arginina, y de esta manera 
evita la eliminación del parásito dependiente de NO (Gobert et al., 2000); también,  en 
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la infección por Trypanosoma congolense, la arginasa y la activación alternativa de 
macrófagos juegan un papel crucial en el desarrollo de la enfermedad crónica (Noel et 
al., 2002). Durante la infección de Leishmania sp. in vitro (Iniesta et al., 2001; Iniesta et 
al., 2002) está claro que los inhibidores de la arginasa reducen la patología mediante 
reducción de la replicación del parásito dentro de los macrófagos. 
 T. cruzi desencandena la producción de citoquinas y quimioquinas en 
cardiomiocitos (Machado et al., 2000) y en macrófagos (Bergeron and Olivier, 2006) 
infectados que inducen una actividad tripanocida muy potente dependiente de óxido 
nítrico (Gazzinelli et al., 1992; Metz et al., 1993; Munoz-Fernandez et al., 1992; 
Pakianathan and Kuhn, 1994), pero los resultados en ratones infectados todavía no están 
claros (Cummings and Tarleton, 2004; Girones et al., 2006; Holscher et al., 1998). 
Además, en exceso, el NO puede tener también un efecto citotóxico en el hospedador y 
llevar a la supresión de células T (Goni et al., 2002). 
 Por otro lado, monocitos de sangre periférica mostraron niveles disminuidos de 
óxido nítrico durante la enfermedad de Chagas en ratas, debido al aumento de la 
actividad arginasa (Fabrino et al., 2004). Además, macrófagos infectados in vitro (y 
macrófagos de ratones infectados), a través de la interacción con el receptor de 
vitronectina, aumentan la liberación de TGFβ y PGE2, lo que aumenta la actividad ODC 
en macrófagos promoviendo así la proliferación de los parásitos (Freire-de-Lima et al., 
2000; Lopes et al., 2000). Así mismo, la cruzipaína, un antígenos de T. cruzi, regula a la 
alza la actividad arginasa en macrófagos y promueve el crecimiento intracelular del 
parásito (Giordanengo et al., 2002; Stempin et al., 2002; Stempin et al., 2004). Además, 
este antígeno promueve la inducción de arginasa II en cardiomiocitos actuando así como 
factor de supervivencia, porque es capaz de rescatarlos de apoptosis (Aoki et al., 2004). 
 Es importante destacar que en otros tripanosomátidos como Trypanosoma brucei 
y Leishmania donovani, la replicación es controlada por el inhibidor de la síntesis de 
poliaminas α-difluorometilornitina (DFMO) a través de la inactivación de la ODC del 
parásito. Sin embargo, T.cruzi carece de arginasa (Camargo et al., 1978) y de ODC, y el 
tratamiento con DFMO ha resultado ser inefectivo. El parásito depende de una fuente 
externa de poliaminas para su crecimiento obteniéndolas probablemente del hospedador. 
Como alternativa, T. cruzi puede sintetizar poliaminas de la L-arginina vía agmatina 
(Persson, 2007). Además, durante la infección por T. cruzi en macrófagos de ratón y 
mioblastos de rata, la inhibición farmacológica de la ODC, redujo la invasión y la 
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proliferación intracelular y su efecto era revertido por la adición exógena de agmatina o 
putrescina (Kierszenbaum et al., 1987). 
 
IV. Metabolismo de la L-arginina en células mononucleares fagocíticas. Regulación 
de la respuesta inmunológica. 
 
IV.1 Activación del monocito-macrófago: M1 & M2 
 
 Las células del linaje monocito-macrofágico son consideradas un tipo celular 
muy heterogéneo dependiendo en el estado de diferenciación y activación, lugar y 
distribución en el tejido. 
 Tradicionalmente, la activación de los macrófagos se consideraba cuando 
desarrollaban una respuesta citotóxica contra patógenos intracelulares y también cuando 
liberaban mediadores solubles de la respuesta inmunológica. Hoy en día, la capacidad 
de los macrófagos para deshacerse de los patógenos intracelulares, se conoce que está 
mediada por NO (Hibbs, 2002), RNOS y ROS (Kusmartsev et al., 2004; Xia and 
Zweier, 1997) y que está inducida por citoquinas del tipo Th1 (como IFNγ y TNF) 
solos, o junto a productos microbianos. Estos macrófagos, también muestran capacidad 
para producir altos niveles de IL-12 (en humanos también IL-23), IL-1, TNF, IL-6, y 
bajos niveles de IL-10 (revisado en (Mosser, 2003)). Este estado de activación lleva a la 
comunidad científica a llamar a estas células macrófagos activados clásicamente o 
macrófagos M1 (por analogía a Th1). 
 En oposición al tipo de macrófagos mencionados arriba, los fagocitos 
mononucleares que no muestran propiedades citotóxicas y que liberan grandes 
cantidades de IL-10 en lugar de IL-12, se denominan macrófagos activados 
altenativamente.  Esta terminología se concibe para aquellos macrófagos que son 
activados por las citoquinas IL-4/IL-13 y que expresan altos niveles de arginasa I, a los 
que algunos autores denominaron M2 , incluyendo también a aquellos que muestran un 
estado de “desactivación” en presencia de IL-10. Otros autores también distinguen entre 
la activación alternativa los que ellos llaman macrófagos activados de tipo II (Anderson 
et al., 2002), fagocitos mononucleados que están expuestos a complejos inmunológicos 
y LPS; estas células secretan niveles altos de IL-10 y bajos de IL-12 y desencadenan 
respuestas de tipo Th2 en linfocitos T (Anderson and Mosser, 2002). 
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 Debido al hecho de que se necesita un consenso para establecer una 
nomenclatura común para estas células fagocíticas mononucleadas, Mantovani y 
colaboradores (Mantovani et al., 2004) proponen lo siguiente: 
 M1 se corresponde a la activación clásica arriba descrita. El término genérico 
para M2 se utiliza para definir una activación distinta de la M1 basado en propiedades 
comunes funcionales (baja secreción de IL-12 e implicación en respuestas Th2, 
inmunoregulación y remodelación del tejido). Además, las tres formas bien definidas de 
M2 se denominarán como M2a, inducidos por IL-4/IL-13; M2b, inducidos por 
complejos inmunológicos y agonistas de receptores toll-like (TLRs), o M2c inducidos 
por IL-10 y glucocorticoides. 
 Ghassabeh y colaboradores (Ghassabeh et al., 2006) identificaron una firma de 
genes comunes para una respuesta genérica M2 desarrollada en diferentes condiciones 
patológicas analizando varios genes agrupados en grupos funcionales (anti-inflamación, 
cicatrización, angiogénesis, regulación del ciclo celular, y otros). 
 
IV. Células supresoras mieloides. 
 
 En los años 70 y principios de los 80, los investigadores describieron lo que 
llamaron células supresoras naturales; eran células no linfoides capaces de suprimir la 
respuesta de los linfocitos a inmunógenos o mitógenos de una manera independiente de 
MHC (Strober, 1984). Hoy por hoy, se conoce que estas células son un subtipo de 
células mielomonocíticas denominadas células mieloides supresoras (MSCs), las 
cuales se acumulan durante la respuesta inmunológica aguda y crónica frente a 
patógenos, estrés inmunológico (después de exposición a superantígenos y su 
consiguiente activación extensiva de células T), crecimiento de tumores y desarrollo... y 
otros casos. 
 Las MSCs están equipadas con mecanismos extremadamente eficientes para 
destruir los patógenos invasores, y además son muy eficientes a la hora de suprimir la 
activación de células T, revisado en (Bronte and Zanovello, 2005). 
 Estas células se identifican comunmente en ratones por la expresión de los 
marcadores de membrana CD11b y Gr-1; junto con estos marcadores, las MSCs, 
pueden expresar una gran variedad de marcadores diferenciadores de células mieloides 
como Ly6-C, CD31 (Bronte et al., 2000); también hay importantes diferencias en el 
fenotipo dependiendo del lugar anatómico en que se localicen o de las condiciones 
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patológicas. Una clasificación rígida para las MSCs no está disponible en la actualidad; 
se necesitaría separar el continuo que es la diferenciación mieloide a pasos muy 
definidos (Bronte and Zanovello, 2005).  
 
Supresión de las células T y el metabolismo de la L-arginina 
 
 Arginasa e iNOS, tanto en combinación como por separado, son usadas por las 
MSCs para inhibir las respuestas T (fig) 
 Arginasa: La pérdida de la cadena CD3ζ, es hasta la fecha, el único mecanismo 
que se ha descrito y demostrado que tenga un efecto en la función de la célula T. 
Cuando las MSCs se aislaron de tumores, la actividad arginasa causó la depleción del 
aminoácido L-arginina en el microambiente extracelular; ésto inhibió la re-expresión de 
la cadena ζ del CD3 despues de su internalización inducida por señalización mediada 
por el TCR y debida a la estimulación por antígeno de las células T, impidiendo de este 
modo la funcion de estas células (Baniyash, 2004; Rodriguez et al., 2004). 
 iNOS: El NO no impide los eventos de activación temprana desencadenados por 
el TCR, actúa en cambio al nivel de la señalización mediada por el receptor de la IL-2, 
bloqueando la fosforilación y la activación de las moléculas señalizadoras (Bingisser et 
al., 1998; Mazzoni et al., 2002). 
 Arginasa e iNOS: Cuando las dos enzimas están inducidas, se produce una 
depleción extracelular de la L-arginina. Esto conduce a la iNOS a cambiar su función de 
producción de NO a producir principalmente ión superóxido, y como consecuencia 
ROS y RNOS. Estas especies pueden tener múltiples efectos inhibitorios en las células 
T. Se ha demostrado que la combinación de la actividad de la arginasa y de la iNOS es 
importante en MSCs de ratones con tumores, pero también en infecciones crónicas con 
helmintos (Bronte et al., 2003; Brys et al., 2005). Esto indica que la co-expresión de 
iNOS y arginasa podría ser considerada un marcador de MSCs (Bronte and Zanovello, 
2005). Es importante considerar en este aspecto que algunos autores describen un 
mecanismo de regulación para el RNA mensajero de la iNOS cuando los niveles de L-
arginina son bajos, lo que resultaría en un descenso de la estabilidad de la iNOS (El-
Gayar et al., 2003). 
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MSCs en infecciones por parásitos 
 
 Existen varias evidencias del papel de las MSCs en enfermedades 
parasitológicas. Células T humanas estimuladas en presencia de un extracto crudo de H. 
pylori muestran proliferación reducida y este hecho se correlacionaba con una descenso 
en las expresión de CD3ζ (Zabaleta et al., 2004). Además, resultados de infecciones 
experimentales con Schistosoma spp. (Terrazas et al., 2001), Candida albicans 
(Mencacci et al., 2002), y T.cruzi (Abrahamsohn and Coffman, 1995; Goni et al., 2002) 
ilustran la existencia de un mecanismo de inmunosupresión inducido por IFNγ, 
dependiente de NO y mediado por las células MSCs que colonizan el bazo durante la 
fase aguda de la enfermedad. 
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CONCLUSIONES 
 
 
Los resultados obtenidos en este trabajo han dado lugar a las siguientes conclusiones: 
 
 
 
 
1. La arginasa I se induce en corazones de ratones infectados con T. cruzi 
correlacionándose con la carga parasitaria en este órgano. 
 
2. La inducción de arginasa I durante la infección por T. cruzi está restingida a corazón 
y a células del peritoneo. 
 
3. La inducción de arginasa I en corazones de ratones infectados con T. cruzi requiere 
de señalización por el receptor de IL-4 presumiblemente mediada por IL-13 con una 
posible cooperación con IL-4, IL-10 y PGE2. 
 
4. La iNOS se expresa en cardiomiocitos y en células CD11b+ Gr-1int Ly-6Chigh 
infiltradas en tejido cardiaco de ratones infectados, mientras que la expresión de 
arginasa I está restringida a la población CD68+ CD11b+ Gr-1int Ly-6Chigh infiltrante. 
 
5. Las células CD11b+ presentes en el infiltrado inflamatorio de corazón de ratones 
infectados con T. cruzi no presentan una polarización clara hacia un patrón de expresión 
génica M1 o M2. 
 
6. Las células CD11b+ presentes en el infiltrado inflamatorio de corazón de ratones 
infectados con T. cruzi que expresan iNOS y arginasa I, presentan un fenotipo de célula 
mieloide supresora y modulan la proliferación de células T in vitro.  
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2ABSTRACT
In Chagas disease, caused by Trypanosoma cruzi, macrophages and cardiomyocytes are 
the main targets of infection. Classical activation of macrophages during infection is 
protective while alternative activation of macrophages is involved in survival of host 
cells and parasites. We studied the expression of inducible nitric oxide synthase and 
arginase, as markers of classical and alternative activation, respectively, in heart tissue 
during in vivo infection of BALB/c and C57BL/6 mice. We found that expression of 
arginase I and II as well as ornithine decarboxylase, were much higher in BALB/c 
compared to C57BL/6 mice and related to parasite burden in heart tissue.  Inducible 
nitric oxide synthase and arginase II were expressed by cardiomyocytes. Interestingly,
heart infiltrated CD68 macrophages were the major cell type expressing arginase I. 
Th1 and Th2 cytokines were expressed in heart tissue in both infected mouse strains, 
but the Th1/Th2 balance was predominantly Th1 in C57BL/6 mice and Th2 in BALB/c 
mice at the peak of parasite infection. Our results suggest that Th2 cytokines induce 
arginase expression which may influence host and parasite cell survival, but might be 
also down-regulating the counter productive effects triggered by inducible nitric oxide 
synthase in heart during infection. 
Key words: Trypanosoma cruzi; arginase; iNOS; cardiomyocyte; alternative activation; 
macrophage; Th1/Th2 balance; heart tissue; BALB/c; C57BL/6.
Word count abstract: 195 
Word count of the text: 3500
3INTRODUCTION
Trypanosoma cruzi, a flagellated protozoan parasite, is the causative agent of 
Chagas disease, an illness affecting several million people in Latin America. During T. 
cruzi infection, macrophages are one of the most important cells to fight the parasite. 
These cells metabolize L-arginine by two main pathways. One involves inducible nitric 
oxide synthase (iNOS), responsible for nitric oxide (NO) production. This pathway is 
controlled by T helper (Th)1 cytokines known to induce iNOS expression and classical 
activation of macrophages (M1), and is essential for the early control of mouse [1], 
macrophage [2, 3] and cardiomyocyte [4] infections. However, excessive NO can also 
have cytotoxic effect in the host and lead to immune suppression of T cells [5] and 
pathology [6].
 The second pathway involves arginase, which is induced in alternative 
activation of macrophages (M2), mainly by Th2 cytokines [7] . Arginase catalyzes 
conversion of L-arginine to urea and L-ornithine, required for polyamine synthesis 
which is essential for the growth of cells and all trypanosomatidae. The limiting enzyme 
in this pathway is ornithine decarboxylase (ODC) which has a low half life [8]. Two 
arginase isoforms have been described; arginase I, located in the cytoplasm, has 
restricted expression, and is mainly induced by Th2 cytokines, but also interleukin (IL)-
10 [9] and transforming growth factor (TGF)- [10]. Arginase II, located in the 
mitochondria, is induced in many cell types by lipopolysacharide (LPS) and cyclic 
adenosine monophosphate [11]. N-Hydroxy-L-arginine, an intermediary in NO 
synthesis, inhibits arginase [12] whereas polyamines can decrease iNOS expression [13, 
14]. Moreover, arginase has been implicated in downregulating iNOS protein synthesis 
4and stability by decreasing L-arginine availability [15, 16], that depends on the cationic 
amino-acid transporter (CAT)-1 and CAT-2 [17, 18].
Helicobacter pilori [19, 20] and Chlamydia sp. [21] can modulate the metabolic 
routes mentioned above. The arginase/iNOS balance also modifies the outcome of 
several protozoan infections. Induction of macrophage arginase during Trypanosoma 
brucei infection depletes L-arginine, and may avoid NO parasite dependent killing [22]. 
Moreover, arginase and alternative activation play a crucial role in the development of a 
Trypanosoma congolense chronic infection [23]. During Leishmania sp. in vitro [24, 
25] and L. major in vivo infection [26, 27] arginase inhibitors reduce pathology by 
lowering parasite replication.
On the other hand, T. cruzi triggers the synthesis of cytokines and chemokines in 
infected cardiomyocytes [4] and macrophages [28] that induce potent NO dependent 
trypanocidal activity [3, 29-31]. However, peripheral blood monocytes showed 
decreased NO production during T. cruzi infection in rats, due to the increase of 
arginase activity [32]. Cruzipain, a major T. cruzi antigen, up-regulates arginase activity 
in macrophages promoting intracellular growth of the parasite [33-35] and induces  
arginase II in cardiomyocytes promoting their survival [36].
Taken all these previous evidences together, the aim of this work was to study 
the role of classical and alternative activation pathways during experimental T. cruzi
infection in mice with different susceptibility to the disease focusing in the most 
important and affected organ in Chagas disease: the heart. 
5MATERIALS AND METHODS
Parasites and mice
Y and Tulahuén T. cruzi strains were obtained from Dr. John David (Harvard 
Medical School Department, Boston, Massachusetts, U.S.A.). Blood trypomastigotes 
were maintained in infected mice. 6 to 8-week-old BALB/c and C57BL/6 mice (Harlan, 
Interfauna Iberica) and iNOS-/- mice (NOS2tm1 Lau, Jackson Laboratories) were 
maintained under pathogen-free conditions in compliance with normative [37]. All 
experiments were performed in groups of 3-5 mice non-infected or infected with 2x103
Y trypomastigotes, except when stated different, by intraperitoneal injection. 
Quantitative real time PCR and RT-PCR
Heart DNA was isolated with High Pure PCR Template preparation Kit (Roche), 
Heart tissue PCR reactions contained 100 ng genomic DNA and T. cruzi detection was 
performed by quantitative real time (q)PCR as described [38].
Heart RNA was extracted with TRIzol reagent (Invitrogen). Quantitative real 
time (q)RT-PCR analysis was done with High Capacity cDNA Archive Kit (Applied 
Biosystems) and amplification of different genes (arginase I, arginase II, iNOS, CAT-1, 
CAT-2, ODC, interferon (IFN)-, tumour necrosis factor (TNF)-, IL-4, IL-10, IL-13, 
TGF-, prostaglandin E2 synthase (PGE2s) and Ribosomal 18S) was performed in 
triplicate using TaqMan MGB probes and the TaqMan Universal PCR Master Mix 
(Applied Biosystems) on an ABI PRISM 7900 HT instrument (Applied Biosystems). 
Quantification of gene expression was calculated by the comparative threshold cycle 
(CT) method, normalized to the ribosomal 18S control and efficiency of the reverse 
transcription reaction (RQ 2-CT).
Protein expression and activity 
6Heart protein extracts were prepared utilizing a PT 1300 D homogenizer 
(Polytron). For western blot analyses 15 g of tissue extract were fractionated on SDS-
10% polyacrylamide gel and transferred to a nitrocellulose membrane. Primary 
antibodies were diluted as follows: anti-mouse iNOS (BD Transduction) 1:5000, goat 
anti-mouse Arginase I and Actin 1:1000 (Santa Cruz, Biotechnology, Inc.) and anti-
ODC 1:100 (Sigma-Aldrich). Membranes were incubated with horseradish peroxidase 
(HPO) rabbit anti-goat antibody (Sigma-Aldrich) 1:10000, or goat anti-mouse (Pierce) 
1:1000 as secondary antibody. Proteins were detected with Supersignal reagent (Pierce). 
Ganglia, spleen, peripheral blood mononuclear (PBMCs) and cultured cells were treated 
as above except for the mechanical disruption. Arginase activity was measured as 
previously described [39]. 
Immunohistochemistry 
Hearts from mice infected with 104 Tulahuén tripomastigotes were removed, 
fixed in 10% neutral buffered paraformaldehyde and embedded in paraffin. Four 
micrometer-thick sections were mounted on gelatine coated glass slides, deparaffinized 
and rehydrated, endogenous peroxidase activity was blocked by incubation with 3% 
hydrogen peroxide in PBS, permeabilized with 1% Triton X-100 in PBS, washed and 
non-specific binding blocked with 2% bovine serum albumine (BSA). Samples were 
incubated with anti-arginase II, anti-iNOS and isotypic antibodies (Santa Cruz 
Biotechnology, Inc.) diluted 1:100, washed with PBS and incubated with anti-rabbit 
HPO (Sigma-Aldrich) diluted 1:250, incubated with diaminobenzidine/hydrogen 
peroxide and counterstained with hematoxylin.   
Confocal immunofluorescence 
7Hearts were fixed in 4% paraformaldehyde in PBS solution, incubated in 30% 
sucrose solution, embedded in Tissue-Tek O.C.T. compound (Sakura) and frozen. 10-15 
µm thick sections were fixed in acetone. Incubation with antibodies was done at 4ºC as 
follows: 10 µg/ml goat anti-mouse arginase I, rat anti-mouse CD68 (Serotec), goat IgG 
(Jackson ImmunoResearch) and rat IgG (BD Transduction) antibodies. 1:50 F(ab´)2
Goat anti-rat IgG fluorescein isothiocyanate (Serotec), 1:50 Cy5-conjugated Donkey 
anti-goat IgG (Jackson Immunoresearch) antibodies. Pictures were taken on a LSM510 
META confocal laser coupled to an Axiovert 200 (Zeiss) microscope.
Cell cultures
BALB/c neonatal cardiomyocyte culture was obtained as described [40]. More 
than 90% of cells were cardiomyocytes as detected by immunostaining with antibody to 
mAchR M2 as described [36]. BALB/c mice peritoneal cells were collected with 0.34 
M sucrose and plated in RPMI with 5% FBS; after 4h, non-adherent cells were removed 
by washing three times with warm PBS, and fresh RPMI was restored. Trypomastigotes 
were obtained in co-cultures with Vero cells (CCL-81, ATCC), and 5 Y trypomastigotes 
were added per cardiomyocyte or macrophage. 16h later non-internalized parasites were 
removed and cells were cultured in complete RPMI medium for 48h. In addition, 
cardiomyocytes were incubated with: IL-4 (20 ng/ml, BioSource International), IFN-
(25U/ml, BioSource International), LPS (1g/ml, Escherichia coli serotype O26:B6 
Sigma-Aldrich), as indicated. 
Statistical analysis
For in vivo experiments, data reported are mean  SD of 3 individual mice. 
Significance was evaluated by Student’s two-tailed t-test. 
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Expression of L-arginine metabolic enzymes and transporters in heart tissue of 
mice infected with T. cruzi.
BALB/c and C57BL/6 mice were infected and parasites in heart tissue were 
quantified at different days post infection (d.p.i.) by qPCR. Figure 1 shows that 
maximum parasite load was detected in C57BL/6 heart at 14 d.p.i. In contrast, parasite 
burden in heart of BALB/c mice was maximal at 21 d.p.i. and decreased thereafter. 
Parasite equivalents were significantly higher (about 2 logs after parasite load peak) in 
susceptible BALB/c than in resistant C57BL/6 mice.
Quantification of arginase I and II mRNAs showed significantly higher expression in 
BALB/c than C57BL/6 mice at all d.p.i. analyzed (Fig 2a-b). In contrast, CAT-1, CAT-
2 and iNOS mRNAs expression was higher in C57BL/6 than BALB/c mice at 14 d.p.i 
(Fig. 2c-e). However, CAT-1, CAT-2 and iNOS mRNAs expression was higher in 
BALB/c mice at later times p.i. The induction of ODC mRNA expression was not 
significantly different from non-infected controls (Fig. 2f). 
Since arginase I mRNA showed major differences between C57BL/6 and 
BALB/c mice, we wanted to confirm this at the protein level. Arginase I protein 
induction in infected heart tissue was much stronger in BALB/c than C57BL/6 mice and 
spanned from 14 to 42 d.p.i, in agreement with the mRNA data (Fig. 3a). Arginase I 
expression in C57BL/6 mice was observed only between 14 and 21 d.p.i. Moreover, 
arginase enzymatic activity correlated nicely with arginase I protein expression in heart 
extracts from both mice strains (Fig. 3b), being much higher again in BALB/c mice than 
in C57BL/6 mice peaking at 21 d.p.i. In addition, iNOS protein expression was higher 
in infected BALB/c than infected C57BL/6 mice.
9Although we did not observe significant changes on ODC mRNA expression, 
ODC protein was induced in BALB/c hearts (maximum expression at 21 d.p.i) and in 
much lower extent in C57BL/6 mice (peaking at 14 d.p.i.) (Fig. 3a). This indicates that 
ODC is regulated at the post-translational level in heart tissue of mice infected with T. 
cruzi. 
We also studied the expression of arginase I and iNOS in PBMCs, spleen and 
ganglia from infected BALB/c mice at 21 d.p.i. In spleen and ganglia neither arginase I 
nor iNOS were induced (Fig 3c). There was a slight induction of arginase I expression 
in PBMCs in comparison with the induction observed in heart tissue, but no iNOS was 
detected in PBMCs, indicating that arginase I and iNOS are preferentially expressed in 
heart tissue during acute T.cruzi infection.
Cardiomyocytes express arginase II and iNOS while arginase I is expressed by 
CD68+ cells infiltrating heart tissue of T. cruzi -infected mice 
To determine the cellular source of arginase and iNOS protein detected in the 
infected hearts, we performed immunohistochemical staining. Fig 4 shows staining of a 
high percentage of cardiac fibres for both arginase II and iNOS in BALB/c infected 
mice (Fig. 4c and 4d) compared to non-infected mice (Fig. 4a and 4b). 
Arginase I expression in hearts was analyzed by confocal microscopy. Hearts 
from infected BALB/c mice at 21 d.p.i. showed an infiltrate composed by arginase I 
positive cells (Fig. 5f); no staining was observed in cardiomyocytes or endothelial cells. 
Arginase I-positive infiltrating cells showed a macrophage-like morphology. The CD68 
macrophage marker, but not the dendritic cell marker CD11c (data not shown), was 
found to co-localize with arginase I (Fig. 5e to 5h) in tissue sections of hearts from T. 
cruzi infected mice. Non infected heart tissue showed a weak staining with anti CD68 
and anti-arginase I antibodies of some infiltrated resident cells (Fig. 5a to 5d). No 
10
specific staining was observed in sections with isotypic antibodies (Fig. 5e and 5f). 
Next, we evaluated the extension of CD68+ cell infiltration in BALB/c and C57BL/6 
mice by quantification of CD68 mRNA. CD68+ cell infiltration was induced upon 
infection, being maximal at 14 d.p.i. in both mouse strains and interestingly, no 
statistically significant differences were observed between them (Fig 5k). This 
similarity in cell infiltration contrasted with the observed differences in arginase 
expression, suggesting that arginase I expression was higher in CD68+ cells from 
infected BALB/c than C57BL/6 mice.
Arginase I expression in primary cultures of cardiomyocytes and macrophages 
iNOS and arginase II induction, but no arginase I, had been reported during T. 
cruzi-infection of cardiomyocytes in vitro [4, 36]. Thus, we infected cardiomyocytes in 
vitro and analyzed arginase I and iNOS expression. iNOS but no arginase I protein was 
induced by infection in cardiomyocytes (Fig. 6a). Besides, the IL-4-dependent arginase 
I induction in non-infected cardiomyocytes was partially inhibited by T. cruzi infection. 
In contrast, the IFN-LPS-dependent iNOS induction observed in non-infected 
cardiomyocytes was strongly potentiated by T. cruzi infection of those cells. Therefore, 
iNOS expression in cardiac cells can be directly triggered by the parasite and is 
probably responsible for the inhibition of IL-4- dependent arginase I expression (Fig 
6a).
T. cruzi infection triggers NO production in IFN- activated macrophages but the 
parasite itself does not induce production of NO in this cell type [28]. We found that in 
vitro infection of BALB/c mice resident peritoneal macrophages did not increase 
arginase I expression (Fig. 6b). Therefore, arginase I induction seen in CD68 heart 
infiltrating cells is not likely triggered by the parasite but rather by the inflammatory 
environment in the heart set off during the immunological response against the parasite.
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In order to test the contribution of the iNOS gene to heart expression of arginase 
I we infected iNOS-/- mice. Parasitemia in iNOS-/- did not significantly change respect to 
wild type (W.T.) mice (figure 6c), in agreement with previous reports [41]. However, 
heart arginase I expression (Fig. 6d) and activity (Fig. 6e) were strongly increased in 
iNOS-/- compared to W.T. mice. Thus, deletion of the iNOS gene triggered the increase 
in the induction of arginase I in heart tissue of mice infected with T. cruzi.
 Both Th1 and Th2 cytokines and PGE2s are induced in heart tissue of mice 
infected with T. cruzi
We tested the levels of several cytokines in heart tissue from mice infected with 
T. cruzi by quantitative mRNA RT-PCR. The results showed that IFN- and TNF-, 
presented maximum expression at 14 and 21 d.p.i. in C57BL/6 and BALB/c mice, 
respectively (Fig. 7a-b). These cytokines were significantly higher in C57BL/6 than 
BALB/c mice at 14 d.p.i. but this situation was switched between 21 and later times., 
being higher in BALB/c than C57BL/6 mice. On the other hand, IL-4 and IL-13 showed 
maximum expression at 14 d.p.i. in both mouse strains, being higher in BALB/c than 
C57BL/6 mice through infection. Interestingly, IL-4 and, specially, IL-13 expression in 
BALB/c was maintained at 21 d.p.i. (Fig. 7c-d). IL-10 expression in the heart was 
significantly increased by infection and followed kinetics similar to TNF- (Fig. 7e). 
The induction of TGF- mRNA expression observed was not statistically different from 
non-infected controls (Fig. 7f). PGE2s mRNA was significantly increased in heart of 
both BALB/c and C57BL/6 mice upon infection being significantly higher in BALB/c 
than C57BL/6 mice at 21 d.p.i. (Fig. 7g). Thus, no pure Th1 or Th2 patterns are linked 
to strain susceptibility or infection stage. However, the Th1/Th2 balance was higher for 
C57BL/6 (resistant) than for BALB/c mice (susceptible) and Th2 cytokines and PGE2s 
were higher in BALB/c than in C57BL/6 mice.
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DISCUSSION
Heart leukocyte infiltration is thought to play an important role in the 
myocarditis associated to T. cruzi infection. However, up to date, most of the research 
in the field has focused in the characterization of T cells present in heart inflammatory 
infiltrate, while very little effort has been directed to the study of macrophages. 
Macrophages may become activated by different pathways, that play different and 
somehow opposite roles. Our results show for the first time that arginase expression and 
activity are strongly induced in heart tissue during acute T. cruzi infection in mice, 
together with an increased expression of iNOS. This was observed in both susceptible 
BALB/c and resistant C57BL/6 mice. The peak of parasite load correlated with peaks of 
arginase I and iNOS expression in heart tissue. Moreover, arginase I expression in 
BALB/c mice was higher and persisted for a longer period of time than in C57BL/6 
mice, which controlled more efficiently the infection. Besides, ODC protein expression 
was also induced during the acute phase, suggesting an increment in polyamines 
synthesis needed for mammalian cell proliferation, but more importantly, for parasite 
replication. 
We also analyzed the cellular source of these enzymes. We found that iNOS and 
arginase II were expressed in cardiomyocytes of infected BALB/c mice in agreement 
with previous reports that attributed a role for arginase II in cardiomyocyte survival [36]
and contractility [42]. Interestingly, arginase I expression was detected for the first time 
only in CD68+ infiltrating macrophages, and according to protein expression, arginase I 
was very likely responsible of arginase enzymatic activity in heart tissue. In this regard, 
previous work reported a role for cruzipain in promoting parasite replication by 
triggering arginase I expression in macrophages [35]. On the other hand, quantification 
of CD68+ cells by mRNA in heart tissue showed that their numbers were very similar in 
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BALB/c and C57BL/6 mice, indicating that the amount of infiltrating macrophages was 
not responsible for the increased arginase I expression and activity seen in BALB/c 
mice. Rather, infiltrating macrophages in infected BALB/c expressed more arginase I 
per cell than in C57BL/6.
We found that T. cruzi infection triggered iNOS expression in cardiomyocytes, 
in agreement with previous observations [4]. However, the parasite was unable to 
induce the expression of arginase I in cardiomyocytes and neither arginase I and iNOS 
in resident peritoneal macrophages.
Together, the in vitro and in vivo infection data suggest that induction of iNOS 
expression in cardiomyocytes could be triggered by the parasite, while arginase I 
expression in macrophages depends on other factors, very likely Th2 cytokines such as 
IL-4 and IL-13 which in fact were highly elevated in the heart during infection. 
Interestingly, we found that cardiomyocytes expressed arginase I upon IL-4 stimulation, 
while the parasite alone was unable to induce its expression in vitro. However, arginase 
I was not observed in cardiac cells of infected BALB/c mice even though IL-4 is found 
in cardiac tissue. Since infection partially inhibits IL-4-induced arginase I in vitro it is 
likely that a similar mechanism is operating in vivo.
It is important to note that a discrete induction of arginase I compared to the one 
detected in heart tissue was observed in circulating PBMCs but not in other lymphatic 
organs from acutely infected mice. This indicates that arginase I is preferentially 
induced in macrophages infiltrating the heart, likely by the elevated IL-4 and IL-13 
levels present in this organ. iNOS protein was not detected in PBMCs in agreement with 
previous reports [32] rather in heart tissue, suggesting a specific important role of iNOS 
in this organ. 
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 Our analysis showed that both Th1 and Th2 cytokines were induced upon 
infection in both BALB/c and C57BL/6 hearts. It is generally accepted that in many 
parasitic diseases, BALB/c susceptible mice mainly produce Th2 cytokines whereas 
C57BL/6 resistant mice Th1 cytokines [43]. However, we found that this Th1/Th2 
dichotomy is not so strict in T. cruzi infection at least in the heart. Nonetheless, heart 
Th1/Th2 balance is higher in C57BL/6 than BALB/c mice, and the levels of Th2 
cytokine expression were always higher and persisted longer in susceptible mice 
compared with resistant mice.
The induction of ODC expression could be due to the uptake of apoptotic cells 
during T. cruzi infection, which causes release of PGE2 and induction of TGF- [44]. 
Since the ODC substrate depends on arginase, its induction could be mediated by TGF-
. However, a very weak induction of TGF- mRNA was observed, as compared with 
other cytokines, suggesting that TGF- is not the main responsible of arginase I 
induction in our model. On the other hand, PGE2s expression was significantly higher 
in BALB/c respect to C57BL/6 mice at 21 d.p.i., indicating that PGE2 could partially 
contribute to the increased arginase I expression observed in BALB/c mice compared to 
C57BL/6 mice.
In the heart, NO has been described to affect cardiac vasodilation and muscle 
contractility [45]. Our experiments demonstrated elevated iNOS expression in heart 
tissue during acute T. cruzi infection likely generating high NO levels, which could 
negatively affect heart function. In contrast, arginase expressed by infiltrated 
macrophages and cardiomyocytes, could control excessive NO production. We found an 
even higher induction of arginase I upon T. cruzi infection in the hearts of iNOS-/- mice 
which presented less severe myocardial inflammation than wild type mice in previous 
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reports [46]. This suggests that arginase I could be preventing the development of 
iNOS-dependent deleterious effects. 
During acute T. cruzi infection there is also a strong suppression of T 
lymphocyte responses mediated by myeloid cells expressing NO [5]. Besides, L-
arginine depletion could cause inhibition of T cell activation by decreasing CD3
expression [47].  Since arginase is a marker of myeloid suppressor cells (MSC) 
involved in immune suppression [48], it is possible that the induction of iNOS and 
arginase seen in infected heart suppress T cell activation in the heart allowing parasite 
replication. In this direction, it is tempting to speculate that arginase expressing 
infiltrated macrophages are either M2 macrophages or MSC, although further 
characterization needs to be performed.
In summary, we have analyzed arginine metabolism enzymes in heart and 
showed for the first time that arginase I is expressed by infiltrated macrophages during 
acute experimental T. cruzi infection. This suggests that arginase I could have a role in 
regulating the immune response in heart tissue and the development of cardiac 
pathology. Arginase I may play a role in host cell and parasite growth, counteracting 
NO dependent vasodilation and cardiac muscle contractility, questions that will be 
addressed in the future. However, our immediate work will focus in the characterization 
of heart infiltrated macrophages and the elucidation of the role of IL-4 and IL-13 in the 
induction of arginase in heart tissue during acute mice infection.
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Figure legends
Figure 1. T. cruzi DNA quantification in heart tissue of BALB/c and C57BL/6 infected 
mice. DNA from heart tissue was isolated at indicated d.p.i. and qPCR was performed 
as previously described. T. cruzi DNA is expressed as pg of parasite DNA per mg of 
DNA from heart tissue sample (pg parasite DNA/mg heart tissue). Empty boxes indicate 
the values for BALB/c mice and filled rhombus the values for C57BL/6 mice. Results 
are represented as mean  SD of triplicates of pooled DNA of 5 different mice. All 
differences between BALB/c and C57BL/6 mice parasite load were statistically 
significant except at 7 d.p.i. (p  0.05). A representative experiment out of three is 
shown.
Figure 2. mRNA quantification of enzymes and transporters involved in L-arginine 
metabolism in heart tissue during T. cruzi infection. RNA from heart tissue was isolated 
at different d.p.i. and qRT-PCR was performed. Results are expressed as the logarithm 
of RQ calculated from CT values as described in material and methods. mRNAs for: a) 
Arginase I; b) Arginase II; c) CAT-1; d) CAT-2; e) iNOS f) ODC. Empty bars indicate 
the values for BALB/c mice and filled bars the values for C57BL/6 mice. Results are 
represented as mean  SD of 3 different mice. All differences observed in infected mice 
respect to non-infected mice were statistically significant except for: a) C57BL/6 at 7, 
21, 28 and 48 d.p.i.; b) C57BL/6 at 7 and 48 d.p.i.;c) C57BL/6 at 7 d.p.i.; d) BALB/c at 
7 and 42 d.p.i. and C57BL/6 at 7 d.p.i.; f) BALB/c and C57BL/6 at all d.p.i. Significant 
differences observed between BALB/c and C57BL/6 mice are indicated by an asterisk. 
(p  0.05).A representative experiment out of five is shown.
Figure 3.  iNOS and arginase I protein expression and activity during T. cruzi infection 
in heart and other tissues. Protein extracts from heart tissue were isolated from 5 
BALB/c and 5 C57BL/6 mice at different d.p.i. and pooled for western blot analysis a) 
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Arginase I, iNOS, ODC expression and Ponceau staining of the same membrane; 
numbers indicate d.p.i. b) Arginase activity of the same tissue extracts, expressed as 
mol of urea produced per hour per mg of protein sample (mol/h/mg), was assessed by 
urea colorimetric determination. Empty bars indicate the values for BALB/c mice and 
filled bars the values for C57BL/6 mice. All values for BALB/c mice were significantly 
higher compared to non infected mice except at 7 d.p.i. and in C57BL/6 were only 
significantly higher at 14 d.p.i. Asterisks indicate significant differences between 
BALB/c and C57BL/6 mice. c) BALB/c heart tissue, peripheral blood mononuclear 
cells (PBMCs), spleen and ganglia were obtained from non-infected (NI) and infected 
(I) mice at day 21 post infection. Protein extracts were isolated and analysed by western 
blot using anti-arginase I or anti-iNOS antibodies and Ponceau staining. Data are 
representative of at least two independent experiments.
Figure 4. Arginase II and iNOS expression of BALB/c mice heart tissue during acute T. 
cruzi infection. Hearts from non infected mice and infected mice at 14 d.p.i. were 
analyzed by immunohistochemistry as described. a) Non-infected tissue stained with 
anti arginase II antibody, and b) with anti iNOS antibody. c) Infected tissue stained with 
anti arginase II antibody, and d) with anti iNOS antibody. e) Isotypic antibody. Data are 
representative of several sections analyzed in at least 3 different mice. Magnification 
x1000.
Figure 5. Arginase I and CD68 expression in BALB/c mice heart tissue during acute T. 
cruzi infection. Tissue sections obtained from BALB/c mice hearts at 21 d.p.i. were 
analysed by immunofluorescence confocal microscopy as described. Non-infected 
tissue stained with a) anti CD68 antibody; b) with anti arginase I antibody; c) phase 
contrast; d) merge of a and b. Infected tissue section stained with e) anti CD68 
antibody; f) anti-arginase I antibody; g) phase contrast; h) merge of e and f. Boxed 
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regions are shown at two-fold magnification of original (x400) in insets. The scale bar is 
20m. Data are representative of several sections analyzed in at least 3 different mice. 
k) Total RNA from heart tissue was isolated at 21 d.p.i. and CD68 quantitative RT-PCR 
was performed as described. Results are represented as mean  SD of 3 different mice. 
All values for BALB/c and C57BL/6 mice were significantly higher compared to non 
infected mice. A representative experiment out of three is shown.
Figure 6. Expression of arginase I and iNOS in BALB/c cardiomyocytes, peritoneal 
macrophages and heart tissue of iNOS -/- mice. a) Western blot of neonatal 
cardiomyocyte cultures non-infected (NI) and infected (I) in vitro with T. cruzi
trypomastigotes cultured with media alone (C), IL-4, LPS+ IFN- as indicated. Arginase 
I, iNOS and actin expression is shown. b) Arginase I, iNOS and actin expression in non-
infected (NI) and infected (I) macrophage cultures; iNOS expression was not detected 
(N.D.).  e) Parasitemia of infected wild type (W.T.) (filled circles) and iNOS-/- (filled 
squares) mice. d) Arginase I expression of heart tissue extracts pooled from 3 W.T. and 
3 iNOS -/- non-infected (NI) and infected (I) mice at 21 d.p.i. and Ponceau staining of 
the same membrane. e) Arginase activity of the same extracts expressed as mol of urea 
produced per hour per mg of protein sample (mol/h/mg). Filled bars indicate the 
values for W.T. non-infected (NI) and infected (I) mice and dashed bars the values for 
NI and I iNOS-/- mice. Data are representative of at least two independent experiments.
Figure 7 Expression of cytokines and PGE2s in mouse heart tissue during T. cruzi
infection. Total RNA from heart tissue was isolated at different d.p.i. from BALB/c and 
C57BL/6 mice and qRT-PCR was performed as described. Results are expressed as the 
logarithm of RQ calculated from CT values as described in material and methods. 
mRNAs for: a) IFN-; b) TNF-; c) IL-4; d) IL-13; e) IL-10 and f) TGF- and g) 
PGE2s. Empty bars indicate the values for BALB/c mice and filled bars the values for 
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C57BL/6 mice. Results are represented as mean  SD of 3 different mice. All 
differences observed in infected mice respect to non-infected mice were statistically 
significant except for: c) and d) C57BL/6 at 7 d.p.i.; f) BALB/c and C57BL/6 at all 
d.p.i.; Significant differences observed between BALB/c and C57BL/6 mice are 
indicated by an asterisk. (p  0.05). A representative experiment out of three is shown.
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ABSTRACT: Chagas disease, caused by Trypanosoma cruzi, affects several
million people in Central and South America. About 30% of chronic pa-
tients develop cardiomyopathy probably caused by parasite persistence
and/or autoimmunity. While several cross-reactive antibodies generated
during mammal T. cruzi infection have been described, very few cross-
reactive T cells have been identified. We performed adoptive transfer ex-
periments of T cells isolated from chronically infected mice. The results
showed the generation of cardiac pathology in the absence of parasites.
We also transferred cross-reactive SAPA-specific T cells and observed
unspecific alterations in heart repolarization, cardiac inflammatory in-
filtration, and tissue damage.
KEYWORDS: T. cruzi; autoreactive T cells; autoimmunity; Chagas disease
INTRODUCTION
Chagas disease is a debilitating multisystemic disorder that affects sev-
eral million people (approximately 18 million individuals are infected with
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Trypanosoma cruzi (T. cruzi), with 120 million at risk) in Central and South
America.1–4 It is caused by the flagellated protozoan parasite Trypanosoma
cruzi, with a complex life cycle involving several stages in both vertebrates
and insect vector.2,5 Individuals residing in rural areas of Latin America are at
highest risk of infection. The World Health Organization has conducted several
programs for the elimination of the insect vector, with high impact in reduc-
ing the incidence of new infections.4 On the other hand, transfusion-acquired
Chagas disease is becoming a significant health problem in countries other
than Central and South America, especially those receiving high numbers of
immigrants from that region.6–8
Two phases, acute and chronic, can be differentiated in Chagas disease.2,3,9
In the acute phase, encompassing few weeks after infection, a local inflamma-
tory lesion appears at the site of infection where the parasite undergoes the first
rounds of replication. After parasite dissemination through the body, circulat-
ing blood trypomastigotes are easily observed in blood and a small number of
patients develop symptoms of severe myocarditis, leading, in some instances,
to heart failure responsible for the few deaths in acute Chagas disease.10,11
However, the acute phase mostly remains undiagnosed without severe clinical
symptoms. On the contrary, the severe pathology and the most common mani-
festations of this disease develop many years (10–30) after the initial infection
with T . cruzi in the so-called chronic phase, in 30–40% of the infected peo-
ple.2,3,9 During the chronic phase, circulating parasites cannot be observed by
inspection of blood but progressive tissue damage occurs involving the esopha-
gus, colon, and heart.2,3 Treatment with benznidazol or nifurtimox is effective
during the acute phase of infection, specially in newborns,12,13 but usually
no treatment is prescribed for the chronic phase.2,3 Several treatment14–18 and
vaccination19–23 trials have been conducted, but to date an effective therapy or
vaccine is still lacking.
Pathology during chronic T. cruzi infection is postulated to be caused by
parasite persistence or autoimmunity or by a combination of both mecha-
nisms.24–26 Understanding T cell responses during infection is crucial in the
development of efficient vaccines to avoid unwanted secondary effects. To
date there is no systematic assay to study immunodominant T cell responses
in infection. Some peptide candidates are being tested for protection and/or
pathology. Here we review some of the literature about T cell responses during
T. cruzi infection and study the contribution of T cells generated during T.
cruzi infection to cardiac pathology focused, in particular, in T cells specific
for the C-terminal repeats of the T. cruzi shed acute phase antigen (SAPA)
cross-reactive with the Cha autoantigen.
AUTOIMMUNITY AND T. CRUZI INFECTION
The finding of a T cell rich inflammatory mononuclear cell infiltrate and the
scarcity of parasites in heart lesions27,28 questioned the direct participation of
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T. cruzi in Chronic chagasic cardiomopathy (CCC) and suggested the possible
involvement of autoimmunity.24,29–36 Autoimmune responses can be induced
through molecular mimicry, a mechanism by which infectious agents may
trigger an antigen-specific B and/or T cell-specific immune response against
self. In addition, cytokine mediated bystander activation may directly stimulate
surrounding cytotoxic T cells in the absence of direct triggering of the T cell
receptor. Both mechanisms may contribute to tissue damage. Studies about
autoimmunity in Chagas disease were reported many years ago,37–44 and they
are supported by a large body of circumstantial evidence thereafter and had
been extensively and sequentially reviewed.24,30,31,33,45,46
On the other hand, recent evidence is challenging this view. Thus, with the
use of more sensitive techniques, parasite antigens or DNA are detected dur-
ing the chronic phase. This has led to the suggestion that damage is more
likely caused either by an inflammatory response against the parasite or to the
parasite replication itself than by autoimmunity.29,32,47 However, it should be
emphasized that to date there is no unequivocal demonstration that either au-
toimmunity or parasite-specific immunity is the actual cause of pathogenesis.
To consider that an infectious disease has an autoimmune etiology the fol-
lowing postulates have to be demonstrated: (1) association of the disease with a
particular microorganism; (2) identification of the culprit microorganism epi-
tope(s) that elicits the cross-reactive response; (3) T cell or B-cell populations
against that epitope(s) should be expanded in the infection; (4) elimination
of the cross-reactive epitope(s) from the microorganism should result in non-
pathogenic infection; (5) autoreactive T cells should be able to transfer the
disease.48 According to the literature, in Chagas disease, postulates 1–3 have
been described, the 4th is very difficult to demonstrate due to high gene copy
number for many T. cruzi genes and several putative epitopes, and the 5th is
still debated.
MOLECULAR MIMICRY
In T. cruzi infection many examples of molecular mimicry at the level of an-
tibodies have been described.49 Thus, anti-T. cruzi circulating antibodies that
cross-react with host heart and neural cells is a common finding in chagasic
humans and animal models of infection,24,33,35 but with few exceptions none
of the autoantibodies seem to be the leading cause of autoimmune pathogen-
esis. However, descriptions are scarce of cross-reactive T cells in this infec-
tion (TABLE 1). Mainly, cross-reactive T cell epitopes had been studied for a
given antigen after the B-cell epitope was identified. Parasite and self-peptide
antigen epitopes recognized by antibodies during T. cruzi infection had been
identified by different methods (affinity chromatography, peptide sequenc-
ing, cDNA library immunoscreening). Contrarily, for T cell epitopes there
is no systematic assay to identify them, so very few have been described.
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TABLE 1. T cell reactivity against host antigens: defined cross-reactive epitopes
Cross-reactive Molecular Cross-reactive
antigens Species definition epitopes Reference
Host Cardiac myosin heavy
chain
Human T cells AAALDK
::: ::
AAAGDK
(72,73)
T. cruzi B13
Host Cha Mouse T cells SLVTCPAQGSLQSSPSMEI
: . :: : :.:: .
STPSTPADSSAHSTPSTPV
(68)
T. cruzi Shed acute phase
antigen (SAPA)
Host Cardiac myosin heavy
chain
Mouse DTH (66,67)
Studies of immunodominant T cell responses during infection would be very
useful in vaccine design and also to avoid secondary effects as potentially
pathogenic epitopes. This observation can be made extensive to other infectious
diseases.
AUTOREACTIVE T CELLS
A great effort has been made in characterizing the nature of the inflam-
matory infiltrate in chronic and acute phases of T. cruzi infection both in
humans and mouse,50–57 but there are only a few reports addressing the role
of T cells in the generation of pathology (TABLE 1).49 Evidence supporting
the role for autoantigen-specific autoimmunity in disease pathogenesis de-
rives from studies on T cell-mediated immunity in mice. Ribeiro-Dos-Santos
et al. have described that CD4+ T cell line obtained from a chronic chaga-
sic mouse proliferated in response to either a crude T. cruzi Ag preparation
or heart tissue extracts from different animal species.58 In culture, this cell
line arrests the beating of fetal heart cells, and more importantly, induces my-
ocarditis in immunized mice and promotes rejection of transplanted normal
hearts in the absence of T. cruzi.58 The requirement of the parasite to cause
this rejection in mice transferred with T cells from infected mice has also been
widely debated.58–61 Thus, there are opposite results indicating that rejection
of syngeneic-transplanted hearts in chronically infected mice takes place in
the presence60 or in the absence61 of the parasite.
Cunha-Neto et al. have also proposed that myosin cross-reactive T lympho-
cytes infiltrating heart tissue lesions are involved in the generation of chronic
chagasic pathology.59,62 These T cells are activated by cardiac myosin heavy
chain cross-reactive T. cruzi antigen (Ag; TABLE 1).49,62 Moreover, T cells
from chagasic patients with overt heart disease or asymptomatic patients re-
sponded to in vitro stimulation with B13 with increased interferon (IFN)-
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and reduced interleukin (IL)-4 production suggesting a type 1 helper T cells
(Th1)-type cytokine profile.63,64 Those authors proposed that heart damage in
CCC could be due to a delayed-type hypersensitivity (DTH) process initiated
by B13 inducing the release of inflammatory cytokines.
Noteworthy, immunological tolerance to heart Ag prior to their infection
by T. cruzi resulted in less intense cardiomyopathy than control nontolerized
animals,65 which would be in favor of the autoimmune pathology hypothe-
sis. This treatment only affects CD4+ responses and not the production of
anti-myosin IgG discarding B-cell autoreactivity as the cause of pathology.
Although this suggests that the regime to make the mice tolerant was not
as effective as expected, at least regarding the humoral response (Th2 medi-
ated), it supports that the response involved in heart damage is Th1 mediated.
Leon et al. have described in the acute phase that myosin autoimmunity, while
potentially important inflammatory mechanism in acute and chronic infec-
tion, is not essential for cardiac inflammation,66 although immunization with a
T. cruzi extract induced a DTH response against myosin.67
The Cha autoantigen was isolated by immunoscreening of a human Jurkat
cDNA expression library using a pool of sera from chagasic patients, and is
expressed also in mice with a high percentage of homology. In addition, Cha
presented high homology with T. cruzi antigens (SAPA and Tenu 2845/36 kDa
antigen), being recognized by high percentage of human and mouse chagasic
sera.68 When tested in enzyme-linked immunosorbent assay (ELISA) Cha
showed high specificity and sensitivity in the diagnosis of chagasic sera.69 The
SAPA antigen is involved in evasion of the immune system and the C-terminal
repeats behaved as a strong T cell epitope during experimental infection. It
belongs to the transialidase family, the most abundantly represented in the
T. cruzi genome.70 Moreover, it is characterized for presenting several copies of
each gene. In particular the cross-reactive epitope is present in several repeats in
the C-terminal of SAPA and other members of the family as Neuraminidase. For
this reason, the demonstration of the 5th autoimmune postulate is unaffordable,
because engineering a parasite devoid of this sequence is not possible. On the
other hand, the high representation of SAPA cross-reactive repeats and the
inmunodominant response observed during infection are in agreement with a
possible pathogenic role of autoreactive T cells.
ADOPTIVE TRANSFER OF T CELLS AND AUTOIMMUNITY
Transfer of T cells from chronically infected mice to naive syngeneic mice
lead to heart infiltration, detectable 60 days later.68 These experiments were
criticized thereafter for the lack of proper controls as purity of the transferred
cells and for the detection of putative residual parasites present in the purified
T cells.29,36,49,71 We should emphasize that fluorescent staining with anti-
CD4 antibody showed that 99% of the transferred cells were positive for this
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FIGURE 1. Cardiac pathology observed after adoptive transfer of SAPA-specific
cross-reactive T cells in recipient mice. The following parameters indicative of cardiac
damage were observed: (A) a gradual decrease in electrocardiographic T wave amplitude
was observed at 30 and 60 days after adoptive transfer of SAPA-specific cross-reactive T
cells in comparison with T wave amplitude prior to transfer; (B) an increased creatine kinase
activity in serum of SAPA-transferred mice respect to control mice; (C, D) an inflammatory
infiltrate was observed in H&E stains of myocardial and endocardial tissue, respectively,
in mice transferred with SAPA-specific cross-reactive T cells in comparison with control
mice.
T cell marker, and recipient mice were devoid of T. cruzi evaluated by sensi-
tive polymerase chain reaction (PCR). No parasite DNA was detected in blood
at 10, 20, and 60 days, and neither in cardiac tissue at 60 days post-transfer,
suggesting that T cell purification got rid of any residual parasite (unpublished
440 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
results). To study in more detail the possible pathogenic role of a specific cross-
reactive T cell epitope as SAPA, we performed adoptive transfer experiments
of a CD4+ T cell clone generated from spleen cells of mice immunized with
the SAPA cross-reactive peptide. We recorded temperature, activity, heart beat,
and electrocardiographic data, by telemetry in conscious mice before transfer
and 30 and 60 days post-transfer. Mice in control and SAPA groups presented
normal basal temperature values, conscious activity, and heart beat rate (data
not shown). Interestingly, electrocardiogram results showed a significant al-
teration in heart function measured as T wave amplitude or repolarization
at 30 and 60 days post-transfer, being more severe at 60 days post-transfer
(FIG. 1A). This alteration is characteristic of inflamed and edematous hearts
and is known as unspecific alterations in heart repolarization. In addition,
cardiac damage measured by creatine kinase activity in serum was increased
at 60 days post-transfer (FIG. 1B). The hematoxylin and eosin (H&E) stain
of heart tissue showed that different structures, such as myocardium and en-
docardium, presented inflammatory infiltrate in mice transferred with SAPA
CD4+-specific T cells in comparison with recipient mice transferred with
control CD4+ cells (FIG. 1C, D, respectively). These results may explain the
unspecific repolarization alterations previously observed.
Future experiments will focus on determining the immune mechanism(s)
responsible for the pathology observed after T. cruzi-specific T cell adoptive
transfer.
CONCLUSIONS
A systematic study of the specificity of the T cell response during T. cruzi
infection is not possible to date. However, the study of the known antigens
that produce strong T cell cross-reactive responses can give some hints for
vaccine design. Our results showed that T cells purified from chronically in-
fected mice and T cells specific for the SAPA cross-reactive antigen were
able to induce alterations in heart repolarization, cardiac inflammation, and
tissue damage in recipient mice. This indicates that an autoimmune compo-
nent exists that should be considered for future preventive and therapeutical
strategies.
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Abstract Chagas’ disease, caused by Trypanosoma cruzi, has been considered
a paradigm of infection-induced autoimmune disease. Thus, the scarcity of parasites
in the chronicphaseof thedisease contrastswith the severe cardiacpathologyobserved
in approximately 30% of chronic patients and suggested a role for autoimmunity as
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the origin of the pathology. Antigen-speciﬁc and antigen-non-speciﬁc mechanisms
have been described by which T. cruzi infection might activate T and B cells, leading
to autoimmunity. Among the ﬁrst mechanisms, molecular mimicry has been claimed
as the most important mechanism leading to autoimmunity and pathology in the
chronic phase of this disease. In this regard, various T. cruzi antigens, such as B13,
cruzipain and Cha, cross-react with host antigens at the B or T cell level and their role
in pathogenesis has been widely studied. Immunization with those antigens and/or
passive transfer of autoreactive T lymphocytes in mice lead to clinical disturbances
similar to those found in Chagas’ disease patients. On the other hand, the parasite
is becoming increasingly detected in chronically infected hosts and may also be the
cause of pathology either directly or through parasite-speciﬁcmediated inﬂammatory
responses. Thus, the issue of autoimmunity versus parasite persistence as the cause
of Chagas’ disease pathology is hotly debated among many researchers in the ﬁeld.
We critically review here the evidence in favor of and against autoimmunity through
molecular mimicry as responsible for Chagas’ disease pathology from clinical, patho-
logical and immunological perspectives.
Abbreviations
Ag(s) Antigen(s)
IFN Interferon
CTL Cytotoxic T lymphocyte
IL Interleukin
TNF Tumor necrosis factor
mAb Monoclonal antibody
iNOS Inducible nitric oxide synthase
DTH Delayed-type hypersensitivity
TCR T cell receptor
ECM Extracellular matrix
MHC Major histocompatibility complex
Mhc Myosin heavy chain
CMhc Cardiac myosin heavy chain
SMhc Skeletal myosin heavy chain
APC(s) Antigen-presenting cell(s)
ICAM Intercellular adhesion molecule
CCC Chronic chagasic cardiompathy
VCAM Vascular cell adhesion molecule
1
Chagas’ Disease
1.1
General Aspects and Life Cycle
Chagas’ disease (Chagas 1909) is a debilitating multisystemic disorder which
affects several million people (approximately 18 million individuals are in-
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fectedwithTrypanosoma. cruzi, with 120million at risk) in Central and South
America (Moncayo 1999; Prata 2001; Tanowitz et al. 1992) and is considered
a paradigm of infection-mediated autoimmune disease. It is caused by the
ﬂagellated protozoan parasite Trypanosoma cruzi, with a complex life cy-
cle involving several stages in both vertebrates and insect vectors. T. cruzi
has three main different morphologies: epimastigote, which replicates in the
blood-sucking triatomine insect vector; trypomastigote, which infects the
vertebrate host’s cells; and amastigote, which replicates intracellularly in the
host’s cells (Burleigh and Andrews 1998; Tanowitz et al. 1992).
Transmission of T. cruzi to humans occurs when feces released by the bug
while it takes a blood meal, containing infective metacyclic trypomastigote
forms of the parasite penetrate, into the bloodstream, where the metacyclic
forms infect a wide variety of host phagocytic and non-phagocytic cells.
Once inside the cells, the metacyclic forms escape from endocytic vacuoles
to the cytoplasm, where they transform into amastigotes, which multiply
intracellularly (see Fig. 1 for details).
Individuals residing in rural areas of Latin America are at highest risk of
infection, because the bugs live in these dwellings and feed on the inhabitants
at night. The World Health Organisation has conducted several programs
for the elimination of the insect vector, with great results on the incidence
of new infections (Moncayo 1999). On the other hand, transfusion-acquired
Chagas’ disease is becoming a signiﬁcant health problem in countries other
than Central and South America, especially those receiving high numbers of
immigrants from that region (Kirchhoff 1989; Wendel 1998).
1.2
Clinical Findings
Twophases, acute andchronic, canbedifferentiated inChagas’ disease (Kirch-
hoff 1993; Prata 2001; Tanowitz et al. 1992). In the acute phase, encompassing
a few weeks after infection, a local inﬂammatory lesion appears at the site
of infection, where the metacyclic trypomastigotes infect and undergo their
ﬁrst rounds of multiplication. After parasite dissemination through the body,
circulating blood trypomastigotes are easily observed in blood (parasitemia)
and a small number of patients develop symptoms of cardiac insufﬁciency,
reﬂecting an underlying severe myocarditis, leading, in some instances, to
heart failure responsible for the fewdeaths in acute Chagas’ disease (Dias et al.
1956; Prata 1994).Meningoencephalitismay also occur, especially in some im-
munosuppressed patients (Hoff et al. 1978). However, the acute phase mostly
remains undiagnosed without severe clinical symptoms. In contrast, the se-
vere pathology and the most common manifestations of this disease develop
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Fig.1 Infective cycle ofTrypanosoma cruzi.Transmission ofT. cruzi to humans occurs
when feces released by the bug while it takes a blood meal and containing infective
metacyclic trypomastigote forms of the parasite (A1) penetrate into the bloodstream,
where they infect a wide variety of host phagocytic and non-phagocytic cells (A2).
Once inside the cells, the metacyclic forms escape from endocytic vacuoles to the
cytoplasm, where they transform into amastigotes, which multiply intracellularly
(A3). At some point, the amastigotes break off from the cell (A4) and differentiate into
non-replicative ﬂagellated blood trypomastigotes which in turn can penetrate and
infect adjacent susceptible cells or spread to infect cells and tissues at distant locations
of the body (A5a). Amastigotes can also directly infect phagocytic cells (A5b). Muscle
cells, including those of the heart, are amongst the most heavily infected. Circulating
trypomastigotes may be taken up by a new triatomine bug during a blood meal
(A6). Inside the vector’s intestine, ingested blood trypomastigotes differentiate into
replicative epimastigotes, which, as they move to the mid and lower gut, transform
into non-replicative but infective metacyclic trypomastigotes
many years (10 to 30) after the initial infection with T. cruzi in the so-called
chronic phase, although only in 30%–40% of the infected people (Kirchhoff
1993; Prata 2001; Tanowitz et al. 1992). During the chronic phase, circulating
parasites cannot be observed by inspection of blood but progressive tissue
damageoccurs involving theesophagus, colonandheart (Prata2001;Tanowitz
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et al. 1992). Treatment with benznidazol or nifurtimox is effective during the
acute phase of infection, but no treatment exists for the chronic phase (Prata
2001; Tanowitz et al. 1992). To date, an effective immunotherapy or vaccine is
still lacking.
1.3
Immune Response
The immune response against this parasite is complex and far from being
clearly established. Both humoral and cellular immune responses are involved
in controlling T. cruzi, which is not surprising because of the complexity of
the parasite’s life cycle. Thus, although B cell-deﬁcient mice succumb to in-
fection (Kumar and Tarleton 1998), the protective immune response seems
to depend on CD8+ T cells that produce interferon (IFN)-γ. CD8+ T cells
can control the infection through cytotoxic T lymphocyte (CTL)-induced
perforin/granzyme-mediated killing of infected cells and/or FAS-mediated
apoptosis (Kumar and Tarleton 1998). However, there are reports indicating
that CD8+ T cells cannot completely control infection because they become
unresponsive (Martin and Tarleton 2004). Cytokines play a key role in reg-
ulating both the induction and type of immune response as well as parasite
replication in infected hosts (Fresno et al. 1997). Macrophages, which can be
infected by T. cruzi, also play a crucial role in the elimination of this parasite.
Activation of monocytes by cytokines released by Th1 cells seems to be a key
process in controlling infection in vitro as well as in vivo. Thus, Interleukin
(IL)-12 produced by macrophages in response to infection mediates resis-
tance to T. cruzi (Aliberti et al. 1996). Tumor necrosis factor (TNF)-α and IFN
have been identiﬁed as themost important cytokines involved in the killing of
intracellular T. cruzi through an NO-mediated-l-arginine dependent killing
mechanism (Gazzinelli et al. 1992; Muñoz-Fernandez et al. 1992). This was
corroborated in vivo, because anti-IFN-γ monoclonal antibody (mAb) ad-
ministration results in a drastic increase in parasitemia and mortality (Silva
et al. 1992; Torrico et al. 1991). Moreover, mice deﬁcient for IFN-γ receptor
and inducible nitric oxide synthase (iNOS) had an increased susceptibility to
infection and parasitemia (Holscher et al. 1998; Goni et al. 2002), although the
role of NO has been recently disputed because some iNOS-deﬁcient mice do
not seem to be more susceptible to infection (Laucella et al. 2004). TNF-R1-
FcIgG3 transgenic mice are also more susceptible to T. cruzi infection, clearly
indicating a protective role for TNF-α (Castanos-Velez et al. 1998).
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2
Chronic Chagasic Cardiopathy
2.1
Pathological Findings
The most important pathology of Chagas’ disease develops 10–30 years after
primary infectionandaffects several internalorgans,mainly,heart, esophagus
and colon, as well as the peripheral nervous system. The heart is the organ
most commonly involved; cardiopathy frequently develops, congestive heart
failure being a common cause of death in these patients. Megaesophagus
and/or megacolon may also develop in chronic chagasic patients, which in
the most severe form can cause life-threatening malnutrition and intractable
constipation.Chronic chagasic cardiopathy (CCC) is thus themostdevastating
manifestation of Chagas’ disease. However, despite affecting about a third of
the infected people the pathogenesis of CCC is still poorly understood.
CCC may be considered a progressive disease, in which myocardial in-
ﬂammation and ﬁbrosis plays a pivotal role (Carrasco Guerra et al. 1987;
Higuchi et al. 1987; Pereira Barretto et al. 1986). Higher percentages of severe
myocarditis, ﬁbrosis and myocardial hypertrophy are found in CCC patients
with heart failure compared to patients in the indeterminate phase and with
cardiac arrhythmia. Examination of the hearts of CCC patients who have
died of heart failure shows biventricular enlargement with occasional apical
aneurysms. In addition, individuals with CCC often develop mural thrombi,
which may cause cerebrovascular accidents. Histological examination of the
heart reveals diffuse interstitial ﬁbrosis, lymphoid inﬁltration and damaged
myocytes, all occurring in the apparent absence of parasites. Fibrosis and
chronic inﬂammation are also detected in the conduction system of the heart,
which may account for the high incidence of arrhythmias.
2.2
Mechanisms of Pathogenesis
Despite intensive research, the etiology of Chagas’ heart disease, both in
humans and in experimental animal models of the disease, is not clearly
understood. Although the acute and chronic phases of the disease share some
similar pathological ﬁndings, it is still unclear whether similar pathogenic
mechanisms operate. In this regard, inﬁltration by CD4+ T cells seems to take
place in the acute phase of the disease, whereas CD8+ T cells predominate in
the chronic phase (Henriques-Pons et al. 2002). Moreover, it is plausible that
the pathology of the acute phase may affect the ﬁnal outcome of the chronic
phase.
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To date,many pathogenicmechanisms have been described to explain how
cardiac pathology develops. They can be mediated directly by the parasite or
caused by an inﬂammatory/immune/autoimmune mechanism or a combina-
tion of these. These mechanisms are summarized below:
– Primary neuronal damage resulting in denervation of the parasympathetic
autonomous system in theheart. Thiswas oneof theﬁrst pathogenicmech-
anisms described during the acute phase (Koberle 1961, 1970). However,
subsequent studies only show slight neuronal damage in the heart, sug-
gesting that neuronal lesions are an epiphenomenon, secondary to inﬂam-
mation and ﬁbrosis (Davila et al. 1991, 2002; Rossi 1996).
– T. cruzi-induced damage to cardiomyocytes, due to the cytopathic effect
caused by intracellular infection with amastigotes or by the release of se-
creted T. cruzi product(s), which can be toxic for host cells and tissues
(Koberle and Nador 1955). This is an obvious mechanism, but may have
only some relevance in the acute phase and in heavily parasitized or im-
munosuppressed patients.
– Parasite-inducedmicrovascular changesmay lead to cardiac hypoperfusion
and ﬁnally to myocyte degeneration and chronic inﬂammation (Factor et
al. 1985; Morris et al. 1990; Petkova et al. 2001).
– Persisting T. cruzi antigensmay act as trigger for speciﬁc CD4+ or CD8+ T-
cell mediated responses of either the delayed-hypersensitivity (DTH) type
or cytotoxic CD8+ cells that lead to damage to infected cells or to bystander
cells in the host tissues (Ben Younes-Chennouﬁ et al. 1988; Tarleton 2001;
Tarleton and Zhang 1999). This mechanism may take place in both the
acute and the chronic phase.
– Autoimmunity may occur by a variety of mechanisms (listed in Table 1).
Those could be due to T. cruzi antigen (Ag)-speciﬁc mechanisms (molec-
ular mimicry) or non-parasite Ag-speciﬁc effector mechanisms and are
discussed in detail below.
An important point which is often ignored in this debated ﬁeld is that
none of themechanisms listed above ismutually exclusive.Moreover, it seems
unlikely that heart damage can be attributed to only one of thesemechanisms.
2.3
Immunological Findings
In CCC, 50% macrophages, 40% T cells with a predominance of CD8+
over CD4+ T cells and 10% B cells comprise the inﬂammatory inﬁltrate
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Table 1 Mechanisms for activation of T and B cells in autoimmune diseases
a. Microbial antigen speciﬁc:
– Molecular mimicry between parasite and host antigens triggers autoimmunity
– Bystander activation (TCR dependent)
b. Microbial antigen non-speciﬁc:
– Release of autoantigen(s) during an infection
– Bystander activation (TCR independent)
– Cryptic epitopes
– Superantigens
(Cunha-Neto et al. 2004). T cell receptor (TCR) Vβ transcripts are heteroge-
neous in heart biopsies from CCC patients (Cunha-Neto et al. 1994) which
is a characteristic of other well-deﬁned autoimmune diseases. The number
of CD4+ T cells increased in parallel to the number of CD8+ T cells in
acute-phase but not in chronic-phase patients with heart failure, suggesting
an immunological imbalance.
Cytokines and chemokines produced in response to the parasite may up-
regulate vascular cell adhesionmolecule (VCAM)-1 and intercellular adhesion
molecule (ICAM)-1, increased on endothelial cells of patients, which recruit
VLA-4+LFA-1+CD8+ T lymphocytes (dos Santos et al. 2001). In this regard,
a role for cell adhesion molecules and integrin receptors, extracellular matrix
(ECM) components , matrix metalloproteinases and chemokines has been
proposed in the differential recruitment and migration in infected hosts of T.
cruzi-elicited CD8+ and inﬂammatory cells into the heart and other suscep-
tible host tissues (Marino et al. 2003a, 2003b). It is worth noting that ECM
components may absorb parasite Ags and cytokines which could contribute
to the establishment and perpetuation of inﬂammation. Moreover, we have
found that T. cruzi requires β1 integrins to gain access to the cell (Fernandez
et al. 1993). The inﬂammatory response, which is probably recurrent, under-
going periods of more accentuated exacerbation, is most likely responsible
for progressive neuronal damage, microcirculation alterations, heart matrix
deformations and consequent organ failure.
CCC patients have increased expression of major histocompatibility com-
plex (MHC)molecules. Thus, class I MHC are upregulated in the sarcolemma
of myocytes in the myocardium (Higuchi Mde et al. 2003) and there is also
evidence for an over-expression of class II MHC in endothelial cells (Ben-
venuti et al. 2000; Laucella et al. 1999; Reis et al. 1993). This may favor the
presentation of cryptic epitopes to inﬁltrating T cells.
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3
Autoimmunity and Infection
Two main classes of mechanisms have been described by which infectious
agents might activate T and B cells, leading to autoimmunity: Ag-speciﬁc
and Ag-non-speciﬁc (Table 1). The Ag-speciﬁc mechanisms mostly state that
sequence similarity between infectious agents and self-proteins (molecular
mimicry or epitope mimicry) is responsible for the triggering of the autoim-
mune response (Oldstone 1989; Penninger and Bachmaier 2000; Rose 2001;
Rose andMackay 2000;Wucherpfennig 2001).AutoreactiveBand/orT cells, in
response to foreignAgs originated bymolecularmimicry, can arise fromaT/B
cell cooperation mechanism, but experimental direct evidence is still scarce
(Oldstone 1989; Rose andMackay 2000). However, there are as yet no absolute
formal proofs demonstrating that molecular mimicry is the initiating event
of human autoimmune disease and responsible for the pathology, as noted
recently (Benoist and Mathis 2001; Fourneau et al. 2004). Probably, Chagas’
disease is close to that paradigm. There is some consensus that in order to
prove the involvement of epitope mimicry in a disease of suspected autoim-
mune etiology ﬁve criteria must be demonstrated experimentally (Benoist
and Mathis 2001; Kierszenbaum 1986) (see Table 2).
Themicrobial Ag-non-speciﬁc theory has several variations. The common
characteristic is that no particular microbial determinant is implicated, al-
though the infection may be the initial event which triggers the autoimmune
reaction. For example, infection might cause host cell destruction, which re-
sults in the release of large quantities of normally sequestered Ags. Those
cryptic epitopes found in intracellular proteins are not normally presented in
the context of Class I MHC and are therefore not normally encountered by
host lymphocytes. These Ags could then be captured by dendritic cells that
migrate toT cell areas of the lymphoid organs,where they trigger naïveT cells,
or presented at the invasion site, leading to activation of autoreactive cells (but
Table 2 Criteria required for demonstration of the involvement of molecular mimicry
in a disease of suspected autoimmune etiology
1. Association of the disease with a particular microorganism
2. Identiﬁcation of the culprit microorganism epitope that elicits
the cross-reactive response
3. T or B cell populations against that epitope should be expanded in the infection
4. Elimination of the cross-reactive epitope from the microorganism should result
in non-pathogenic infection
5. Autoreactive T cells should be able to transfer the disease
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not against the infecting microorganism). In addition, cryptic epitopes may
initiate and maintain autoimmunity through various non-mutually exclusive
mechanisms (Lanzavecchia 1995). Those cryptic epitopes can be presented
by non-professional Ag-presenting cells (APCs, such as B cells) and induce T
cell activation. Autoreactive B cells initiate autoimmunity in the absence of
T cells speciﬁc for the self-Ag. Alternatively, autoreactive B cells may take up
a foreign Ag that cross-reacts with a self-Ag at the B cell level but contains
different T cell epitopes. Finally, activated B cells, which efﬁciently take up
and present self-Ag, may prime autoreactive T cells. All these mechanisms
may result in a self-sustained autoimmune response.
Microbial infection may result in bystander activation, which may take
place in the setting of a proinﬂammatory milieu. Thus microbial infection in-
duces the release of proinﬂammatory cytokines such as TNF and chemokines
which could be able to activate autoreactive T cells by lowering the threshold
of activation (Kim and Teh 2001; Vakkila et al. 2001). These T cells may then
proliferate in response to self-Ags presented on host APCs. Inﬂammation
could also alter lymphocyte migration patterns and activate APCs, render-
ing them more effective as APCs by enhancing Ag uptake and processing,
cell surface expression of major MHCmolecules, or costimulatorymolecules.
Finally, infection might provoke polyclonal lymphocyte activation via either
a mitogen or a super-Ag effect (Stauffer et al. 2001).
4
Autoimmunity in T. cruzi Infection
The ﬁnding of a T cell-rich inﬂammatory mononuclear cell inﬁltrate and the
scarcity of parasites in heart lesions questioned the direct participation of
T. cruzi in CCC and suggested the possible involvement of autoimmunity,
although this remains a hotly debated issue (Engman and Leon 2002; Kier-
szenbaum 1986, 1999; Levin 1996; Soares et al. 2001; Tarleton 2001, 2003).
Several early studies on Chagas’ disease already emphasized the scarcity of
parasites in histological sections in the chronic phase of the disease (An-
drade and Andrade 1955; Mazza 1949). Since then, much research in the ﬁeld
has focused on the possibility that autoimmune responses set off by molecu-
lar mimicry and/or bystander activation contribute to tissue damage. Those
mechanisms were initially reported many years ago (Acosta and Santos-Buch
1985; Cossio et al. 1984, 1974a, 1974b;McCormick and Rowland 1989; Santos-
Buch and Teixeira 1974; Takle and Hudson 1989; Wood et al. 1982) and they
were supported by a large body of circumstantial evidence thereafter and have
been extensively and sequentially reviewed (Eisen and Kahn 1991; Engman
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and Leon 2002; Kierszenbaum 1986, 1999; Leon and Engman 2001; Soares et
al. 2001). Although the presence of “anti-self” immune responses in T. cruzi
infections has been unquestionably demonstrated, the case of the mediation
of cross-reactive antibodies or T cells in pathology is still far from settled.
Taking into account the variety of the mechanisms of induction of autoim-
munity shown in Table 1 the relevant question is, Which mechanisms can be
applied to T. cruzi infection?
On the other hand, mounting evidence is challenging this view. Thus, with
the use of more sensitive techniques, parasite Ags or parasite DNA has been
detected during the chronic phase, attributing all the damage either to an
inﬂammatory response against the parasite or to the parasite replication itself
(reviewed in Tarleton 2001, 2003; Tarleton and Zhang 1999). It should be
emphasized that to date there is no unequivocal demonstration that either
autoimmunity or parasite-speciﬁc immunity is pathogenic.
5
Molecular Mimicry
The detection of circulating anti-T. cruzi antibodies that cross-react with host
heart and neural Ags is a common ﬁnding in chagasic humans and animal
models of infection (reviewed in Engman and Leon 2002; Kierszenbaum
1999, 2003) but, with few exceptions, none of the autoantibodies seems to be
the leading cause of autoimmune pathogenesis. In T. cruzi infection many
examples of molecular mimicry at the level of T cells or antibodies have been
described (recently reviewed in Cunha-Neto et al. 2004). However, few of
these have been extensively studied and/or deﬁned at the molecular level (see
Table 3). We will focus our review only on those examples.
5.1
Mimetic B Cell Epitopes
5.1.1
Myosin
Probably the most studied cross-reactive autoantigen in Chagas’ disease is
myosin. Several T. cruzi Ags have been shown to cross-react with myosin
(cardiac or skeletalmuscle) andhavebeen implicated inpathogenesis through
molecular mimicry. Cunha-Neto and collaborators have described cardiac
myosin heavy chain (CMhc) as a major Ag of heart-speciﬁc autoimmunity
and suggested the possible relevance of myosin recognition in human CCC
(Cunha-Neto et al. 1995; Kalil and Cunha-Neto 1996). Antibodies to CMhc
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Table 3 Molecular mimicry described during T. cruzi infection. Deﬁned and partially
deﬁned cross-reactive epitopes
Cross-reactive
antigens
Cross-reactive
epitopes
Molecular
deﬁnition
Reference
Host
T. cruzi
Cardiac myosin heavy
chain (CMhc)
B13
AAALDK
::: ::
AAAGDK
Ab
T cells
Abel
et al.
1997
Host
T. cruzi
23-kDa ribosomal
protein
Ribosomal
protein (R13)
EESD(D/E)DMGFGLFD
:: : : ::::::::
EEED D DMGFGLFD
Ab Levitus
et al.
1991
Host
T. cruzi
β1 Adrenergic receptor
Ribosomal protein PO
AESDE
::: :
AESEE
Ab Ferrari
et al.
1995
Host
T. cruzi
β1 Adrenergic receptora
M2 muscarinic receptora
Ribosomal protein (R13)
--ED-D-GF-LFDa
--EDDDMGF-LFDa
EEEDDDMGFGLFD
Ab Mahler
et al.
2004
Host
T. cruzi
47-kDa neuron protein
FL-160
TPQRKTTEDRPQ Ab Van
Voorhis
et al.
1991
Host
T. cruzi
Cha antigen
Shed acute-phase
antigen (SAPA)
SLVTCPAQGSLQSSPSMEI
: . :: : :.:: .
STPSTPADSSAHSTPSTPV
T cells Girones
et al.
2001b
Host
T. cruzi
Cha antigen
TENU2845/36 kDa
MRQLDTNVER
.:::: ::.
LRQLDF-VEE
Ab Girones
et al.
2001a,
2001b
aResidues of the R13 epitope that when interacting with puriﬁed antibodies trigger
stimulation of the denoted receptor.
were found insymptomaticaswell asasymptomaticpatients.Afﬁnity-puriﬁed
anti-CMhc antibodies speciﬁcally recognized twopolypeptides of 140,000 and
116,000Da inT. cruzi trypomastigotes. At themolecular level, cross-reactivity
was shown to exist between the amino acid sequence AAALDK of CMhc and
the AAAGDK sequence from a recombinant T. cruzi peptide named B13
(Table 3). All sera from patients with CCC disease, but only 14% of sera from
asymptomatic chagasic patients, recognized B13 (Gruber and Zingales 1993).
These results have been often disputed, although no contradictory results
have been published (see Kierszenbaum 2003). However, there were some
discrepancies between the 100% reactivity of the sera from chronic patients
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with overt heart disease with CMhc and only 61% reactivity in those with T.
cruzi, a ﬁnding difﬁcult to reconcile with molecular mimicry.
Cruzipain, a well-deﬁned and highly abundant T. cruzi Ag, is involved
in CCC pathogenesis by various direct and indirect mechanisms. The latter
are also related to cross-reactivity with myosin, although not with CMhc but
with skeletalmusclemyosinheavy chain (SMhc). Thuspuriﬁed anti-cruzipain
antibodies raised in cruzipain-immunizedmice cross-react with SMhc (Gior-
danengoet al. 2000a, 2000b) and,more importantlywere associatedwithheart
conduction disturbances in those animals. Moreover, ultrastructural ﬁndings
revealed severe alterations of cardiomyocytes and IgG deposit on heart tissue
of immunized mice. Giordanengo et al. investigated whether antibodies in-
duced by cruzipain transferred from immunized mothers to their offspring
could alter the heart function in the pups. All IgG isotypes against cruzipain
derived from transplacental crossing were detected in pups’ sera. Electrocar-
diographic studies performed in the offspring born to immunized mothers
revealed conduction abnormalities (Giordanengo et al. 2000b). These results
provide strong evidence for a pathogenic role of the humoral autoimmune
response induced by a puriﬁed T. cruzi Ag in the development of experi-
mental Chagas’ disease. More recently, Sterin-Borda et al. have reported that
immunization with cruzipain also induces autoantibodies againstmuscarinic
acetylcholine receptorswhich can be implicated in pathology (Sterin-Borda et
al. 2003). However, in both cases described above themolecular identiﬁcation
of cross-reactive epitopes of cruzipain and host proteins is still lacking.
On the other hand, T. cruzi- infected A/J mice (a strain of mice highly
susceptible to T. cruzi infection) generated anti-myosin IgG, both in the acute
phase and the chronic phase of infection (Leon et al. 2001). Moreover, heart
lesions resembling those seen in T. cruzi-infected mice can be induced by im-
munization with puriﬁed myosin. However, not all mouse strains are equally
susceptible to myocytolysis after T. cruzi infection (Leon and Engman 2001).
Interestingly, in C57BL/6 mice, the levels of anti-myosin IgG found after T.
cruzi infection were small or undetectable and no myocarditis was observed
in the acute phase (Leon et al. 2001). Moreover, the C57BL/6 mouse strain has
been claimed not to develop cardiac autoimmunity after immunization with
myosin (Neu et al. 1987). These results suggest that generation of anti-myosin
antibodies by T. cruzi infection or myosin immunization depends on the ge-
netic background of the host and that there is a clear relationship between
anti-myosin IgG and heart damage. However, from these results it is unclear
whether anti-myosin IgG is the cause or the effect of heart damage. Accord-
ingly, we have seen that C57BL/6 mice infected with T. cruzi did not develop
clinically relevant myocarditis in the acute phase. However, at 120 days after
infection, C57BL/6 mice developed a milder myocarditis compared to mice
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deﬁcient for iNOS gene with the same genetic background (Girones et al.
2004). Because C57BL/6 developed lower parasitemias than iNOS knockout
mice in the acute phase, this may be taken as an indication that the presence
or absence ofmyocarditismay depend on the initial level of control of parasite
replication rather than on the genetic background of the host.
In contrast to the above, other reports suggested that anti-myosin anti-
bodies are not involved in the pathogenesis. For example, immunization with
myosin in immunosuppressed mice did not induce autoantibodies but still
caused myocarditis (Neu et al. 1990). How myosin can trigger myocarditis
in these immunosuppressed mice is difﬁcult to envisage. Moreover, passive
transfer of a high-titer anti-myosin antibody preparation failed to induce
myocarditis (Neu et al. 1990). Because the ﬁne speciﬁcity of the different anti-
myosin Igs has not been addressed in most of those studies, they are difﬁcult
to compare. Myosin is a very large molecule and it is possible that the myosin
determinant(s) recognized by the different sera are not identical.
Some authors believe that other mechanisms than molecular mimicry can
explainmyosinautoreactivity (seeBenoist andMathis2001;EngmanandLeon
2002; Kierszenbaum2003). They feel thatmimicry is less likely to be occurring
than Ag release due to myocardial damage leading to expansion of normally
tolerantmyosin-reactiveT cells, particularly becausemyosin autoimmunity is
seen in myocarditis associated with other insults. Thus anti-myosin antibod-
ies are induced in patients with heart disease unrelated to T. cruzi infection
such as viral myocarditis, myocardial infarction, coronary artery bypass and
heart valve surgery, among others (de Scheerder et al. 1989; Fedoseyeva et al.
1999; Nomura et al. 1994). B cell anti-myosin response seems to be mainly
responsible for pathology in other heart infections, induced by Coxsackie B3
viral infection (Rose andHill 1996) or by bacteria (Cunningham 2004). In this
regard, it is worth mentioning that peptides of CMhc, a cytoplasmic protein,
are associated with MHC class II molecules on APCs even in normal mouse
myocardium(SmithandAllen1992) andMHCclass IImolecules are increased
in the heart of T. cruzi-infected patients and animals. Cardiomyocyte damage
caused either by parasite replication in the heart or by inﬂammation may
release self-Ags, leading to the induction of anti-heart antibodies rather than
anti-cross-reactiveT. cruziAgs. Thus it could be likely that the initial heart tis-
sue destruction resulting from infection could induce anti-myosin immunity
in Chagas’ heart disease, being thus the effect and not the cause of the pathol-
ogy. Alternatively, is possible that although several pathogens may share the
ability to destroy the heart they may have different cross-reactive epitopes
with heart proteins (myosin). Thus it is possible that the trigger is the combi-
nation of pathogen and damage together, although the ﬁne speciﬁcity of the
autoreactive responseagainstmyosinwill bedifferent for eachheartpathogen.
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In summary, before suggesting a possible role for anti-myosin immunity
in Chagas’ heart disease, some questions need to be fully addressed: (1) Is the
damage during T. cruzi infection different from heart tissue injury of a dif-
ferent etiology? (2) Do anti-myosin antibodies truly contribute to chagasic
pathology? (3) If anti-myosin antibodies appeared after the occurrence of tis-
sue damage,would they aggravate the pathology bymediating the destruction
of intact cardiomyocytes?
5.1.2
Ribosomal Proteins
Another set of autoantigens which have been involved in CCC pathology are
ribosomal proteins. Anti-ribosomal P protein antibodies were detected in
the serum of chagasic patients and their titer associated with the degree of
myocarditis, suggesting a correlation between the appearance of these an-
tibodies and heart pathology (Levin et al. 1990, 1989; Skeiky et al. 1992).
By screening a T. cruzi expression cDNA library with such sera, some DNA
clones were identiﬁed. One of the clones, termed JL5, codiﬁed for a T. cruzi
ribosomal protein, TcP2L, and showed sequence homology with human P
ribosomal proteins. The homology was between the EDDDMGFGLFD region
of Tc2PL and the SD(D/E)DMGFGLFD sequence present in the C-terminal
region of human P ribosomal protein (R13 epitope) which was responsible
for the cross-reactivity in chagasic serum (Table 3). However, reactivity with
ribosomal proteins is also found in some patients with systemic lupus ery-
thematosus (SLE); approximately 15% of SLE patients have autoantibodies to
a shared epitope (H13) located in the C-terminal regions of the ribosomal
proteins, P0, P1, and P2 (Elkon et al. 1986). However, antibodies against ri-
bosomal proteins from CCC and SLE patients show differential recognition.
Thus sera from patients with chronic Chagas’ heart disease have been shown
to contain relatively high levels of anti-R13 but low levels of anti-H13 antibody
(Lopez Bergami et al. 1997), whereas both titers are comparable in SLE sera
(Kaplan et al. 1997, 1993). Despite this positive correlation between molecu-
lar mimicry and pathology, some discrepancies exist. First, attempts to link
anti-R13 reactivity by ELISA in the sera with the symptomatology in chronic
or asymptomatic patients failed to ﬁnd a signiﬁcant correlation. Thus 60%
and 49%, of chronic and asymptomatic sera, respectively, displayed reactiv-
ity with R13 but varied signiﬁcantly depending on the geographical origin
of the patients (Aznar et al. 1995). Moreover, no correlation between anti-
R13 reactivity and cardiomyopathy was found in a group of 14 patients from
whom endomyocardial biopsies and blood samples were taken at the same
time. Furthermore,mice immunizedwithTcP2Ldeveloped antibodies against
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the cross-reactive epitope, as well as many others, in contrast with the ﬁne
speciﬁcity of antibodies obtained from infected mice (Sepulveda et al. 2000).
On theotherhand, someevidence indicates that those anti-P ribosomal an-
tibodies could be pathogenic. Thus puriﬁed IgG, reactive with the C-terminus
epitope of T. cruzi ribosomal P protein, caused a chronotropic alteration in
primary rat cardiomyocytes through selective stimulation of β1-adrenergic
receptors (Elies et al. 1996; Ferrari et al. 1995). However, in this case, the rel-
evant cross-reactive epitope included the AESDE amino acid sequence from
the second extracellular loop of the human β1-adrenergic receptor, which is
homologous to the internal AESEE sequence of TcP0 (Table 3) (Ferrari et al.
1995). Moreover, passive transfer of a mAb against R13, which cross-reacts
with the human β1-adrenergic receptor, had a chronotropic effect on cul-
tured rat cardiomyocytes (Mahler et al. 2001). Mice immunized with P0 T.
cruzi ribosomal protein develop electrocardiographic alterations late after
immunization, when the titer of antibodies is extremely high, similar to those
in chagasic animals but not identical to the complex response of chronic T.
cruzi infection (Lopez Bergami et al. 2001). In contrast, those hyperimmu-
nizedwith TcP2L died at an earlier time and did not showheart inﬂammation.
Sera from chagasic patients also contain IgG antibodies which immuno-
precipitated humanM2muscarinic cholinergic receptormolecules andwhich
were able to activate them, having an agonist effect on cardiomyocytes and
causing partial desensitization (Leiros et al. 1997). The original stimulus for
the formation of these antibodies was not ascertained andwhether they could
cause heart dysfunctions of the types seen in chagasic patients remains an
open question.
5.1.3
Cha
We have described an autoantigen, Cha, a mammalian transcription factor
which is recognized by almost all chagasic sera and by sera from T. cruzi-
infected mice (Girones et al. 2001b). This Ag was isolated by screening of
a library with seven CCC sera and has two regions of homology with T. cruzi,
one with in an expressed sequence tag of the parasite (TENU2845) and an-
other with SAPA, the Ag shed in the acute phase ofT. cruzi infections (Table 3)
(Cazzulo and Frasch 1992; Pollevick et al. 1993). Interestingly, we found that
the two epitopes, named R1 and R3, are recognized by T and B cells, respec-
tively, both having signiﬁcant sequence homology. Very interestingly, there is
a strong association of anti-Cha (R3) antibodies and pathology. Thus the titer
of the sera from chagasic patients against R3 increases with symptomatology
and decreases with treatment (Girones et al. 2001a). However, we have not
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determined yet whether anti-R3 antibodies have any effect on pathology of
the disease. Future experimentswill focus on this. Our hypothesis is that these
antibodies arise during infection by cooperation of Cha-speciﬁc B cells with
T cells of different speciﬁcity (Fig. 2).
Fig. 2 Generation of anti Cha T/B cell responses. T. cruzi infection causes the secre-
tion of parasite Ags to the medium and lyses host’s cells, triggering release of self
Ags. In particular, during T. cruzi infection SAPA Ag is released to the extracellular
environment and is taken up by macrophages (1). There SAPA is processed intracel-
lularly and presented to naïve T cells through MHC Class II molecules (2). These T
cells undergo maturation and develop into primed effector T cells speciﬁc for SAPA
and the cross-reactive epitope R1 of Cha (3). Interaction of SAPA/R1 T cells with B
cells of the same speciﬁcity (4) triggers anti-SAPA antibody production (5), which
is observed during infection. However, the Cha Ag epitopes can be presented on the
surface of B cells byMHCClass II molecules by two possible mechanisms: (a) The Cha
epitopes can be naturally presented on B cells and (b) the Cha epitopes can be released
during infection due to lysis of infected cells. Then, SAPA/R1 T cells can interact with
B cells that present the R1 cross-reactive epitope of Cha (6) and trigger anti-Cha(R3)
antibodies of different speciﬁcity (7). On the other hand, SAPA/R1 T cells are able
to induce inﬂammatory inﬁltrates and damage in hearts of recipient mice through
cytokines and/or activation of CD8 T cells (8)
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5.2
Autoreactive T Cells
Perhaps the best evidence supporting a role for autoantigen-speciﬁc autoim-
munity in disease pathogenesis derives from studies on T cell-mediated im-
munity in mice. Ribeiro-Dos-Santos et al. have reported that a CD4+ T cell
line obtained froma chronic chagasicmouse consisting of approximately 95%
CD4+ T cells proliferated in response to either a crude T. cruzi Ag preparation
or heart tissue extracts from different animal species (Ribeiro-Dos-Santos et
al. 2001). In culture, this cell line arrests the beating of fetal heart cells and,
more importantly, induces myocarditis in immunized mice and promotes
rejection of transplanted normal hearts in the absence of T. cruzi (Ribeiro-
Dos-Santos et al. 2001). The requirement of the parasite to cause rejection
in mice transplanted with T cells from infected mice has been also widely
debated (Cunha-Neto et al. 1995; dos Santos et al. 1992; Ribeiro-Dos-Santos
et al. 2001; Tarleton et al. 1997). Thus rejection of syngeneic transplanted
hearts in chronically infected mice has been shown to take place either in the
absence (dos Santos et al. 1992) or in the presence (Tarleton et al., 1997) of
the parasite. These differences may be due to the different mice and parasite
strain combinations used, and when the presence of the parasite is required
for rejection, inﬂammation and not T. cruzi replication may be necessary to
provide the necessary adjuvant effect to trigger autoreactivity and could be
the rejection-inducing agent in the implanted hearts.
Besides proposing that B cell cross-reactivity against myosin is involved
in pathogenesis, Cunha-Neto et al. have also proposed that myosin cross-
reactive T lymphocytes inﬁltrating heart tissue lesions are also involved in
chronic chagasic heart tissue lesions (Cunha-Neto et al. 1996, 1995). These T
cells are also activated by CMhc cross-reactive T. cruzi Ag B13 as in B cells
(Cuhna-Neto 2000; Cunha-Neto et al. 1996) (Table 3). Thus T cells from cha-
gasic patients with overt heart disease or asymptomatic patients responded
to in vitro stimulation with B13 with increased IFN-γ and reduced IL-4 pro-
duction, suggesting a Th1-type cytokine proﬁle (Cunha-Neto and Kalil 2001;
Cunha-Neto et al. 1998). Those authors proposed that heart damage in CCC
could be secondary to the release of inﬂammatory cytokines and a DTH pro-
cess initiated by B13. However, the assumption that pathology arises from
molecular mimicry between B13 T. cruzi and CMhc has been challenged by
other authors because T cell autoreactivity against B13 was shown to exist
not only in CCC but also in asymptomatic patients and in other cardiopathies
(Kierszenbaum 2003). Moreover, both the level of the response to B13 and
the cytokine production proﬁle of lymphocytes from asymptomatic chagasic
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patients were similar to those of T cells from patients with overt heart disease
(Cunha-Neto and Kalil 2001).
It is noteworthy that immunological tolerance to heart Ags induced inmice
by heart Ag administration and anti-CD4 antibody before their infection
by T. cruzi resulted in less intense cardiopathy than that in control non-
tolerized animals (Pontes-de-Carvalho et al. 2002), which is in favor of an
autoimmune pathology. This treatment affects CD4+ responses and not the
production of anti-myosin IgG. Although this suggests that the regime to
make the mice tolerant was not as effective as expected, at least regarding the
humoral response (Th2 mediated), it is becoming increasingly evident that
the response involved in heart damage is Th1 mediated. Recently, Leon et
al. have described (although in the acute phase) that myosin autoimmunity,
while a potentially important inﬂammatory mechanism in acute and chronic
infection, is not essential for cardiac inﬂammation (Leon et al. 2003), although
immunization with a T. cruzi extract induced a DTH response against myosin
(Leon et al. 2004).
We also studied the T cell response to Cha autoantigen during T. cruzi in-
fection. T lymphocytes fromT. cruzi-infectedmice also proliferated to recom-
binant Cha. More interestingly, transfer of T cells from chronically infected
mice to naïve syngeneic mice led to heart inﬁltration and to production of
anti-Cha antibodies, detectable 60 days later (when chronic pathology arises
inmice after T. cruzi infection) (Girones et al. 2001b). Transferred T cells were
almost pure CD3 cells (99%). Consistently, transfer of T cell clones speciﬁc for
SAPA/R1 cross-reactive epitopes results in heart inﬁltration in the absence of
anti-Cha antibody production (Girones et al., in preparation). Therefore, in
some cases the presence of the parasite is not necessary to produce pathol-
ogy if one transfers activated autoreactive T cells. How this takes place and
whether the Cha autoantigen (normally an intracytoplasmic protein) comes
to be presented to T cells are under investigation in our laboratory (see Fig. 2
for a hypothetical model). The observed anti-Cha response is likely due to
a cooperation of R1-Cha-speciﬁc T cells with naïve anti-R3 autoreactive B
cells. We believe that Cha autoreactive T cells are responsible for the heart
damage, and that Cha autoantibodies are an epiphenomenon secondary to
heart tissue destruction. Our results suggest that T cells cooperate with naïve
B cells in the animal after heart damage because transfer of T cell clones
induces heart inﬁltration but no anti-Cha antibodies. Although our results
suggest that Cha may be involved in pathology, this by no means indicates
that Cha would be the only autoantigen involved in the pathology of Chagas’
disease.
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6
Bystander Activation
As reviewed recently by von Herrath et al. (2003), bystander activation is
deﬁned as the activation of autoreactive lymphocytes that do not recognize
microbial Ags. This can be mediated through cytokines and/or APCs (TCR-
independent bystander activation). However, bystander activation might also
require concurrent exposure to the cognate Ag. Ag-speciﬁc cells induced by
molecular mimicry can be activated by a non-speciﬁc stimulus such as other
Fig.3 Diagramof thedifferentmechanismsof inductionofpathogenicity byT. cruzi.T.
cruzi induces T and B cell anti-parasite responses which, through molecular mimicry
with extracellular Ags or epitopes in Ags normally presented by APCs, can lead to
autoimmune disease. T. cruzi can lead to secretion of cytokines which mediate some
cardiac damage, liberating autoantigens reconized by autoreactive T cells and au-
toantibodies that further damage the cardiac tissue via bystander activation. Simulta-
neously parasite replication can induce release of self-antigens, usually intracellular,
which contain cryptic epitopes that can be presented by APCs. Also, over-expression
of intracellular Ags induced by T. cruzi can result in presentation of cryptic epitopes
by APCs. If cryptic epitopes are cross-reactive with T. cruzi epitopes, then autoim-
mune disease can arise. T. cruzi contains several molecules capable of stimulating the
immune system in a non-Ag-speciﬁc manner, known as the adjuvant effect, which to-
gether with the release of self-antigens and exposure of cryptic epitopes can contribute
to sustain a local immune activation known as bystander activation
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infections or heart damage, or by adjuvants in experimental settings, to in-
duce autoimmune disease. Regarding T. cruzi Ags, both types of bystander
activation have been described. T. cruzi parasitization of host tissue induces
the release of autoantigens (Talvani et al. 2000) and a proinﬂammatory envi-
ronment rich in cytokines, nitric oxide and chemokines sufﬁcient to activate
autoreactive T cells by lowering the threshold of activation (Fedoseyeva et al.
1999) (see Fig. 3). These cells may then proliferate in response to self-Ag pre-
sented on host APC. If this were the case formyosin, aberrant Ag presentation
per se would not be necessary, because peptides of cardiacmyosin, a cytoplas-
mic protein, are found complexed with class II MHCmolecules on APCs even
in normal mouse myocardium (Smith and Allen 1992) and are increased in
the heart of infected patients and animals. The anti-self response is initiated
and tissue damage may ensue if the response is of sufﬁcient intensity.
7
Parasite Persistence
Despite all the facts mentioned above, several researchers in this ﬁeld defend
the idea that T. cruzi persistence in the infected host is solely responsible for
the damage in the chronic phase. Tarleton has reviewed all the arguments
in favor of the parasite persistence hypothesis to explain the pathogenesis of
chronic Chagas’ disease in general and of CCC in particular (Tarleton 2001,
2003; Tarleton and Zhang, 1999). Arguments in favor of the idea that disease
is linked to parasite presence are supported by the fact that treatments which
decrease the parasite burden in the acute phase are associated with a de-
crease in clinical symptoms (Viotti et al. 1994). Enhancing the efﬁciency of
the anti-parasite response by immunotherapy, gene deletion, or vaccination
results in decreased severity of the chronic phase, not exacerbation of disease
as predicted by the autoimmune hypothesis (Tarleton 2003). However, this
argument cannot be used against autoimmunity because the ﬁne speciﬁcity
(cross-reactivity?) of those anti-parasite responses was not studied. Effective
chemotherapy could also enhance anti-T. cruzi immunity in mice (Olivieri et
al. 2002). In humans, the link between persistence of T. cruzi and clinical dis-
ease is also supported by the tissue-speciﬁc detection of parasite DNA in the
hearts, but not in the esophageal tissue, of individuals with cardiac disease,
and vice versa (Jones et al. 1993; Vago et al. 1996). Very recent data in humans
show a higher frequency of parasite-speciﬁc IFN-γ-producing CD8+ T cells
among chronic Chagas’ disease patients with mild clinical disease than in
those with the most severe form of the disease, supporting a link between the
strength and nature of the anti-parasite response and the severity of chronic-
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stage disease (Laucella et al. 2004). Apparently this supports the parasite
persistence hypothesis in opposition to autoimmunity, arguing strongly in
favor of the participation of an effective anti-parasite response in preventing
disease (Tarleton 2003). Conversely, it has been observed that immunosup-
pressive treatments correlate with exacerbation of the infection and disease
(Ferreira andBorges 2002) although this is not always the case. Thus the use of
cyclosporin A has been shown to reactivate parasitemia in several but not all
of the heart-transplanted patients. In general, chagasic heart transplants are
not rejected or suffer frommyocarditis despite the use of immunosuppressive
drugs (see Kierszenbaum 2003). These data have been taken as an argument
against an autoimmune-based pathology in CCC because transplanted hearts
given to patients with themost severe cases of Chagas’ heart disease remained
essentially undamaged for so many years. However, we need to be cautious
because few studies have gone more than 10 years when in a normal in-
fection the pathology of CCC sometimes appears 15–30 years after primary
infection. Moreover, if proven true, this mostly discards autoantibodies as
the main pathological cause of CCC, but not autoreactive T cells. The same
treatment that suppressed alloantigen T cell reactivity may have suppressed
autoreactive T cells. So a role for T cells cannot be discarded.
In addition, we have found that autoreactivity in the chronic phase is also
linked toparasitemia because the antibody titer andnumber of reactiveT cells
against the Cha autoantigen are lower in C57BL/6 (non-susceptible) than
in BALB/c (susceptible) mice (Girones et al. 2001b). Moreover, potentially
pathogenic anti-Cha autoantibodies also decreased with chemotherapeutic
treatment of Chagas’ patients. The titer of anti-Cha antibodies, as well as anti-
T. cruzi antibodies, decreased in parallel with treatment and increased with
symptomatology (Girones et al. 2001a) (Table 4). Thus anti-parasite response,
someanti-self responses andpathology seem to go together. This poses aword
Table 4 Myocarditis and antibody responses in chagasic patients increase with symp-
tomatology and decrease with treatment
Chagasic patients Anti-Cha
antibodies
Anti-T. cruzi
antibodies
Myocarditis
Symptomatic +++ +++ +++
Asymptomatic untreated ++ ++ −
Asymptomatic treated + + −
The presence or absence of myocarditis was given by clinical histories of patients.
Antibody response was taken from Girones et al. 2001a (OD 450 nm<0.3, +; OD
450 nm between 0.3 and 1.0, ++; OD 450 nm<1.0, +++).
Trypanosoma cruzi-Induced Molecular Mimicry and Chagas’ Disease 111
of caution in interpreting some clinical data when not all aspects of the
problem are measured. Those results may be interpreted in very different
ways: (a) theparasite is theonly causeof thedisease andanti-parasite andanti-
self responses are direct consequences of parasite replication, (b) pathology
may be caused by the anti-T. cruzi response or (c) the parasite is the trigger
of autoimmune response which is the effector mechanism.
The presence of T. cruzi in the chronic phase of the disease was already
observed in early descriptions (Vianna 1911) and was documented subse-
quently by other authors (Almeida et al. 1984; Teixeira Vde et al. 1993). With
more sensitive techniques such as polymerase chain reaction (PCR), the par-
asite (more properly parasite DNA) is commonly detected in chronic patients
(reviewed in Higuchi Mde et al. 2003). Recent immunohistochemistry stud-
ies have demonstrated higher frequencies of T. cruzi Ags, reaching 100% of
hearts from chronic chagasic patients who died due to heart failure when
several samples of the myocardium were analyzed (Higuchi 1993; Palomino
2000). Many previous failures to detect parasite Ags in biopsy material from
patients in the chronic phase have been attributed to the fact that it seems
necessary to examine several different sections of the heart to detect the par-
asite in this phase of the disease (Higuchi Mde et al. 2003). Using a mouse
strain which develops chagasic cardiomyopathy when infected with a highly
virulent T. cruzi strain, amastigotes were detected in myocytes through the
chronic phase, although their numbers were low and much lower than in the
acute phase (Guarner et al. 2001). A general ﬁnding not always acknowledged
by the supporters of the parasite persistence hypothesis is that there is no
direct correlation between the sites of parasite detection and heart damage,
and also no correlation between the levels of parasites (for example, as de-
tected by PCR) and clinical ﬁndings (Monteon-Padilla et al. 2001). However,
a signiﬁcant association between the presence of T. cruzi Ags in the heart
and severe ormoderate inﬂammation was observed both in humans (Higuchi
Mde et al., 2003) and in animal models of the disease (Buckner et al. 1999).
However, the number of parasites was low in relation to the intensity of the
myocarditis and whole myocardial ﬁbers containing parasites did not elicit
inﬂammation (Higuchi Mde et al. 2003). This suggests two possibilities: exu-
berant host reactions to the few remaining parasites, either immunemediated
or not, or autoimmune-induced inﬂammation. Parasite Ags probably work as
a trigger response against themyocardial ﬁbers. In addition, it is plausible that
some lesions lack parasites or parasite Ags because of the effective clearance
of parasites from the site by an effective anti-parasite immune response, thus
preventing observation of an exact correlation. However, this is difﬁcult to
reconcile with the fact that a strong anti-parasite immune response results in
decreased symptoms (Laucella et al. 2004).
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Thus parasites are somehow present in the chronic phase, but what one
ought to know is whether relevant parasite Ags persist and are presented
by APCs to T cells. No matter the Ag recognized, Ag-speciﬁc T cells must
be stimulated to become effector cells (helper, cytotoxic or other). For this,
the Ag needs to be presented. Although some APCs could be very efﬁcient
in presenting Ags, it is rather unlikely that there are enough parasite Ags to
continuously support chronic T cell stimulation.
Recently, it has been shown thatT. cruzikinetoplastDNA is able to integrate
into human and other mammalian cell genomes and was transmitted to the
descendants (Nitz et al. 2004). This has important implications not only for
the detection of parasite mentioned above (some based in kinetoplast DNA)
but also for pathology, because T. cruzi kinetoplast Ag could be continuously
presentedandmaycontinuously triggera response to thoseAgsof theparasite,
thus killing normal cells.
8
Coexistence of Parasite Persistence and Autoimmunity
We think that because cardiac myosin autoimmunity develops in the acute
phase, when there is lysis of cardiac myocytes and easily detectable para-
sites, it is very likely that the two processes, bystander damage and molecular
mimicry, co-exist until the chronic phase, where damage is produced via ef-
fector cells recognizing cross-reactiveT. cruzi/autoantigen throughmolecular
mimicry.
Thus we propose that the parasite is the trigger which activates some T
cells (autoantigen/cross-reactive parasite Ag). Once they are activated, they
secrete inﬂammatory cytokines which mediate some cardiac damage. This
liberates autoantigen which is also recognized by some other autoreactive
T cells and autoantibodies which further damage the cardiac tissue via by-
stander activation. This is like a vicious cycle triggered by parasite Ags but
fueled by cross-reactive autoantigens and implies that purely parasite-speciﬁc
T cells may cause very little cardiac damage. This also involves two of the pro-
posed pathogenicmechanisms: bystander damage andmolecularmimicry.T.
cruzimight also function as an adjuvant for an immunological cross-reaction
between common parasitic andmyocardial ﬁber Ags, resulting in severe lym-
phocytic myocarditis (see Fig. 3).
Thus parasites are necessary to trigger autoantibodies and autoreactive T
cells andmay be necessary tomaintain them in the chronic phase. Altogether,
we believe that activeT. cruzi infection is necessary to trigger the autoimmune
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process, most likely through autoreactive T cells, which once induced can
produce the cardiac pathology.
Obviously, the elucidation of the mechanisms of pathogenesis in Chagas’
disease may have implications for vaccination and therapy. If autoimmunity
by molecular mimicry is responsible, anti-T. cruzi chemotherapy would not
necessarily suppress pathogenic autoimmune responses initially elicited by
parasite Ags and subsequently boosted by host tissue Ags. Also, in the search
for protective vaccine we should discard T. cruzi Ags that elicit pathogenic
anti-self responses.
9
Final Remarks
Asmentionedabove, several criteria, put originally forth in theT. cruziﬁeldby
Kierszenbaum 1986 and more broadly by Benoist et al. (Benoist and Mathis,
2001) must be met to consider a disease as caused by molecular mimicry
(see Table 2). In T. cruzi infection, the ﬁrst three conditions have been clearly
demonstrated, and this has allowed the identiﬁcation of several candidate
autoantigens. If there were a unique cross-reactive Ag, infection with genet-
ically deﬁcient parasites lacking the inducing Ag, or infection of knockout
mice lacking the cross-reactive autoantigen, would prevent the disease. How-
ever, asmultiple autoantigens seem to be involved in the pathology of Chagas’
disease, such experiments are very difﬁcult to perform, and therefore the
fourth criterion has not been demonstrated yet.
The ﬁfth criterion is considered to be the decisive test of the concept of
autoimmunity.
In most publications about autoimmunity in Chagas’ disease the putative
causes are either autoantibodies or autoreactive T cells originated by molec-
ular mimicry between parasite and host Ags. Nevertheless, evidence for the
mediation of cross-reactive antibodies or T cells in pathology is still far from
settled.Moreover, most of the data come from experimentalT. cruzi infection,
and an additional problem is the extrapolation of the results to the human
model which is more difﬁcult to study.
One way to determine the pathological effect of autoreactive T or B cells
wouldbe to immunizemicewith cross-reactiveAgs to seewhether this induces
pathology. However, immunization with an autoantigen (injected together
with adjuvants and via different routes than natural infection) may not reﬂect
the way the autoantigen is presented during natural infection and may elicit
hyperimmune responses, tolerance or regulatory T cells which may suppress
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autoimmunity. An alternative approach is the transfer of putative autoreactive
T cells from chronically infected mice speciﬁc for a given autoantigen. Either
immunization with or transfer of T cells speciﬁc for autoantigens may answer
some of these questions and determinewhich of the candidates are really rele-
vant for pathology. In this respect, the presence of autoreactive T cells against
Cha proteins shown in our experiment with Cha autoantigen is the closest
to this. Recently, an interesting observation was made by von Herrath et al.
(2003), proposed that autoimmunediseases couldbe induced and exacerbated
bymany differentmicrobial infections. Their hypothesis is that after infection
there is exposure to self, foreign and environmental agents. After clearance
of infection, the inﬂammatory response drops, but when there are additional
infections the threshold for autoimmunity is reached and autoaggressive T
cells expand and develop.
On the other hand, the parasite persistence hypothesis is based on the
fact that T. cruzi persists in the chronic phase of Chagas’ disease and that
treatment against the parasite results in a decrease of the severity of the
disease. There are also some questions that need to be fully addressed: (1)
Whydo lesions develop primarily in the heart andnot at other sites of parasite
persistence? (2) Why does parasite burden not always correlate with disease
severity? A demonstration of these hypotheses is also difﬁcult to perform,
because one ought to separate the components of the immune response, self
and anti-self during infection. However, we think that things are not so easy,
because co-existence of self and non-self Ags would enhance the immune
response against both, being always triggered by the parasite.
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